<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Ogivri, INN-trastuzumab</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Ogivri, INN-trastuzumab"/>
<meta name="date" content="2022-09-20T11:48:39+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:ArialMT;color:#000000;}
	.ft11{font-size:17px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
	.ft12{font-size:17px;font-family:JOFRRA+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft10">1&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:534px;left:412px;white-space:nowrap" class="ft12"><b>ANNEX&#160;I&#160;</b></p>
<p style="position:absolute;top:553px;left:446px;white-space:nowrap" class="ft12"><b>&#160;</b></p>
<p style="position:absolute;top:572px;left:264px;white-space:nowrap" class="ft12"><b>SUMMARY&#160;OF PRODUCT&#160;CHARACTERISTICS&#160;</b></p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft23{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft24{font-size:17px;font-family:ArialMT;color:#000000;}
	.ft25{font-size:17px;line-height:24px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft20">2&#160;</p>
<p style="position:absolute;top:109px;left:130px;white-space:nowrap" class="ft21">This&#160;medicinal&#160;product&#160;is subject&#160;to additional&#160;monitoring. This will&#160;allow&#160;quick&#160;identification of&#160;</p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft21">new safety&#160;information. Healthcare professionals&#160;are&#160;asked&#160;to report&#160;any&#160;suspected adverse&#160;reactions.&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft21">See section 4.8 for&#160;how&#160;to report&#160;adverse reactions&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft22"><b>1.&#160;</b></p>
<p style="position:absolute;top:204px;left:160px;white-space:nowrap" class="ft22"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft21">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft21">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft22"><b>2.&#160;</b></p>
<p style="position:absolute;top:318px;left:160px;white-space:nowrap" class="ft22"><b>QUALITATIVE&#160;AND&#160;QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft21">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft21">One vial&#160;contains&#160;150&#160;mg of&#160;trastuzumab, a humanised&#160;IgG1 monoclonal&#160;antibody&#160;produced by&#160;</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft21">mammalian&#160;(Chinese&#160;hamster&#160;ovary)&#160;cell&#160;suspension culture and purified by affinity and ion exchange&#160;</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft21">chromatography&#160;including&#160;specific viral&#160;inactivation&#160;and removal&#160;procedures.&#160;</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft21">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft21">One vial&#160;contains&#160;420&#160;mg of&#160;trastuzumab, a humanised&#160;IgG1&#160;monoclonal&#160;antibody&#160;produced by&#160;</p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft21">mammalian&#160;(Chinese&#160;hamster&#160;ovary)&#160;cell&#160;suspension culture and purified by affinity and ion exchange&#160;</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft21">chromatography&#160;including&#160;specific viral&#160;inactivation&#160;and removal&#160;procedures.&#160;</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft21">The reconstituted&#160;Ogivri&#160;solution contains 21&#160;mg/mL of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft21">Excipient&#160;with known&#160;effect&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft21">Each&#160;150&#160;mg&#160;vial&#160;contains&#160;115.2&#160;mg sorbitol&#160;(E420).&#160;&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft21">Each&#160;420&#160;mg&#160;vial&#160;contains&#160;322.6&#160;mg sorbitol&#160;(E420).&#160;&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft21">For the full&#160;list&#160;of&#160;excipients, see&#160;section 6.1.&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft22"><b>3.&#160;</b></p>
<p style="position:absolute;top:773px;left:160px;white-space:nowrap" class="ft22"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft21">Powder&#160;for&#160;concentrate for&#160;solution for&#160;infusion&#160;(powder&#160;for&#160;concentrate).&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft21">White&#160;to pale yellow&#160;lyophilised powder.&#160;</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft22"><b>4.&#160;</b></p>
<p style="position:absolute;top:906px;left:160px;white-space:nowrap" class="ft22"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft22"><b>4.1&#160;</b></p>
<p style="position:absolute;top:944px;left:160px;white-space:nowrap" class="ft22"><b>Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft21">Breast&#160;cancer&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft25">&#160;<br/><i>Metastatic breast&#160;cancer&#160;</i></p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft21">Ogivri&#160;is indicated for&#160;the&#160;treatment&#160;of&#160;adult&#160;patients with HER2 positive&#160;metastatic breast&#160;cancer&#160;</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft21">(MBC):&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft21">-&#160;</p>
<p style="position:absolute;top:1115px;left:149px;white-space:nowrap" class="ft21">as&#160;monotherapy&#160;for&#160;the&#160;treatment&#160;of&#160;those patients&#160;who&#160;have&#160;received at&#160;least&#160;two&#160;chemotherapy&#160;</p>
<p style="position:absolute;top:1134px;left:149px;white-space:nowrap" class="ft21">regimens&#160;for&#160;their&#160;metastatic disease. Prior&#160;chemotherapy must&#160;have&#160;included at&#160;least&#160;an&#160;</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft36{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft30">3&#160;</p>
<p style="position:absolute;top:104px;left:149px;white-space:nowrap" class="ft31">anthracycline&#160;and a&#160;taxane&#160;unless patients are unsuitable for&#160;these treatments. Hormone&#160;receptor&#160;</p>
<p style="position:absolute;top:123px;left:149px;white-space:nowrap" class="ft31">positive patients must&#160;also&#160;have&#160;failed&#160;hormonal&#160;therapy, unless&#160;patients&#160;are&#160;unsuitable&#160;for&#160;these&#160;</p>
<p style="position:absolute;top:142px;left:149px;white-space:nowrap" class="ft31">treatments&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:180px;left:149px;white-space:nowrap" class="ft31">in combination&#160;with paclitaxel&#160;for&#160;the&#160;treatment&#160;of&#160;those patients who&#160;have&#160;not&#160;received&#160;</p>
<p style="position:absolute;top:199px;left:149px;white-space:nowrap" class="ft31">chemotherapy for&#160;their&#160;metastatic disease&#160;and for&#160;whom&#160;an&#160;anthracycline is not&#160;suitable&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:237px;left:149px;white-space:nowrap" class="ft31">in combination&#160;with docetaxel&#160;for&#160;the&#160;treatment&#160;of&#160;those patients who&#160;have&#160;not&#160;received&#160;</p>
<p style="position:absolute;top:256px;left:149px;white-space:nowrap" class="ft31">chemotherapy for&#160;their&#160;metastatic disease&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:294px;left:149px;white-space:nowrap" class="ft31">in combination&#160;with an&#160;aromatase&#160;inhibitor&#160;for&#160;the&#160;treatment&#160;of&#160;postmenopausal&#160;patients with&#160;</p>
<p style="position:absolute;top:313px;left:149px;white-space:nowrap" class="ft31">hormone-receptor&#160;positive&#160;MBC, not&#160;previously&#160;treated with&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft36"><i>&#160;<br/>Early&#160;breast&#160;cancer&#160;</i></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft31">Ogivri&#160;is indicated for&#160;the&#160;treatment&#160;of&#160;adult&#160;patients with HER2 positive early breast&#160;cancer&#160;(EBC):&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:427px;left:149px;white-space:nowrap" class="ft31">following surgery, chemotherapy&#160;(neoadjuvant&#160;or&#160;adjuvant)&#160;and&#160;radiotherapy&#160;(if&#160;applicable)&#160;(see&#160;</p>
<p style="position:absolute;top:446px;left:149px;white-space:nowrap" class="ft31">section&#160;5.1)&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:484px;left:149px;white-space:nowrap" class="ft31">following adjuvant&#160;chemotherapy with doxorubicin and&#160;cyclophosphamide,&#160;in combination with&#160;</p>
<p style="position:absolute;top:503px;left:149px;white-space:nowrap" class="ft31">paclitaxel&#160;or&#160;docetaxel&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:541px;left:149px;white-space:nowrap" class="ft31">in combination&#160;with adjuvant&#160;chemotherapy consisting&#160;of&#160;docetaxel&#160;and&#160;carboplatin.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft31">-&#160;</p>
<p style="position:absolute;top:579px;left:149px;white-space:nowrap" class="ft31">in combination&#160;with neoadjuvant&#160;chemotherapy&#160;followed by adjuvant&#160;Ogivri&#160;therapy, for&#160;locally&#160;</p>
<p style="position:absolute;top:598px;left:149px;white-space:nowrap" class="ft31">advanced (including&#160;inflammatory)&#160;disease or&#160;tumours&#160;&gt;&#160;2 cm&#160;in&#160;diameter&#160;(see&#160;sections 4.4&#160;and&#160;</p>
<p style="position:absolute;top:617px;left:149px;white-space:nowrap" class="ft31">5.1).&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft31">Ogivri&#160;should only&#160;be used&#160;in patients with&#160;metastatic&#160;or&#160;EBC&#160;whose&#160;tumours have either&#160;HER2&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft31">overexpression or&#160;HER2 gene amplification as determined by an accurate&#160;and validated&#160;assay&#160;(see&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft31">sections 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft31">Metastatic gastric cancer&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft31">Ogivri&#160;in&#160;combination with&#160;capecitabine or&#160;5-fluorouracil&#160;and cisplatin is&#160;indicated&#160;for&#160;the&#160;treatment&#160;of&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft31">adult&#160;patients with HER2 positive metastatic adenocarcinoma of&#160;the stomach or&#160;gastroesophageal&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft31">junction who have not&#160;received prior&#160;anti-cancer&#160;treatment&#160;for&#160;their&#160;metastatic disease.&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft31">Ogivri&#160;should only&#160;be used&#160;in patients with&#160;metastatic&#160;gastric cancer&#160;(MGC)&#160;whose tumours have&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft31">HER2 overexpression as defined by IHC2+ and&#160;a confirmatory SISH&#160;or&#160;FISH&#160;result, or&#160;by&#160;an IHC&#160;3+&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft31">result. Accurate and&#160;validated assay&#160;methods&#160;should be&#160;used&#160;(see sections&#160;4.4 and&#160;5.1).<i>&#160;</i></p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft32"><b>4.2&#160;</b></p>
<p style="position:absolute;top:920px;left:160px;white-space:nowrap" class="ft32"><b>Posology and&#160;method of&#160;administration&#160;</b></p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft31">HER2 testing&#160;is&#160;mandatory&#160;prior&#160;to initiation of&#160;therapy&#160;(see&#160;sections 4.4 and&#160;5.1).&#160;Trastuzumab&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft31">treatment&#160;should&#160;only be&#160;initiated by&#160;a physician&#160;experienced in the administration&#160;of&#160;cytotoxic&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft31">chemotherapy (see&#160;section&#160;4.4),&#160;and should&#160;be administered by&#160;a healthcare professional&#160;only.&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft31">Ogivri&#160;intravenous&#160;formulation&#160;is&#160;not&#160;intended for&#160;subcutaneous&#160;administration and should be&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft31">administered via an&#160;intravenous infusion&#160;only.&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft31">If&#160;an alternate&#160;route of&#160;administration&#160;is&#160;required,&#160;other&#160;trastuzumab products&#160;offering such an&#160;option&#160;</p>
<p style="position:absolute;top:1110px;left:106px;white-space:nowrap" class="ft31">should be used.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft47{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft40">4&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft41">In order&#160;to prevent&#160;medication errors it&#160;is important&#160;to&#160;check&#160;the vial&#160;labels&#160;to ensure that&#160;the&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft41">medicinal&#160;product&#160;being prepared and&#160;administered&#160;is&#160;Ogivri&#160;(trastuzumab)&#160;and&#160;not&#160;another&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft41">trastuzumab-containing&#160;product&#160;(e.g.&#160;trastuzumab&#160;emtansine&#160;or&#160;trastuzumab&#160;deruxtecan).&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft41">Posology&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft46">&#160;<br/><i>Metastatic breast&#160;cancer&#160;<br/>&#160;<br/>Three-weekly&#160;schedule&#160;</i></p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft41">The recommended&#160;initial&#160;loading&#160;dose&#160;is&#160;8&#160;mg/kg&#160;body&#160;weight. The&#160;recommended&#160;maintenance&#160;dose&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft47">at&#160;three-weekly&#160;intervals is&#160;6&#160;mg/kg body weight,&#160;beginning&#160;three&#160;weeks&#160;after&#160;the&#160;loading dose.&#160;<br/><i>&#160;<br/>Weekly&#160;schedule&#160;</i></p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft41">The recommended&#160;initial&#160;loading&#160;dose&#160;of&#160;trastuzumab&#160;is 4&#160;mg/kg&#160;body weight. The recommended&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft41">weekly&#160;maintenance&#160;dose&#160;of&#160;trastuzumab&#160;is&#160;2&#160;mg/kg&#160;body weight, beginning one&#160;week after&#160;the&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft41">loading dose.&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft45">&#160;<br/><i>Administration&#160;in combination with paclitaxel&#160;or docetaxel&#160;</i></p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft41">In the pivotal&#160;trials&#160;(H0648g, M77001), paclitaxel&#160;or&#160;docetaxel&#160;was&#160;administered the day&#160;following the&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft41">first&#160;dose&#160;of&#160;trastuzumab&#160;(for&#160;dose, see the Summary&#160;of&#160;Product&#160;Characteristics (SmPC)&#160;for&#160;paclitaxel&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft41">or&#160;docetaxel)&#160;and immediately after&#160;the&#160;subsequent&#160;doses&#160;of&#160;trastuzumab&#160;if&#160;the preceding dose of&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft46">trastuzumab was&#160;well&#160;tolerated.&#160;<br/><i>&#160;<br/>Administration&#160;in combination with an&#160;aromatase&#160;inhibitor&#160;</i></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft41">In the pivotal&#160;trial&#160;(BO16216)&#160;trastuzumab and&#160;anastrozole were&#160;administered from&#160;day&#160;1. There were&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft41">no restrictions on&#160;the relative timing of&#160;trastuzumab and&#160;anastrozole at&#160;administration (for&#160;dose,&#160;see&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft46">the SmPC&#160;for&#160;anastrozole or&#160;other&#160;aromatase inhibitors).&#160;<br/><i>&#160;<br/>Early&#160;breast&#160;cancer&#160;<br/>&#160;<br/>Three-weekly and weekly schedule&#160;</i></p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft41">As a&#160;three-weekly&#160;regimen&#160;the&#160;recommended initial&#160;loading&#160;dose&#160;of&#160;trastuzumab&#160;is 8&#160;mg/kg&#160;body&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft41">weight. The&#160;recommended&#160;maintenance dose&#160;of&#160;trastuzumab&#160;at&#160;three-weekly intervals&#160;is&#160;6&#160;mg/kg&#160;body&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft41">weight, beginning&#160;three&#160;weeks&#160;after&#160;the&#160;loading dose.&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft41">As a&#160;weekly regimen (initial&#160;loading dose of&#160;4&#160;mg/kg&#160;followed by 2&#160;mg/kg every&#160;week)&#160;concomitantly&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft41">with paclitaxel&#160;following&#160;chemotherapy&#160;with doxorubicin and cyclophosphamide.&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft47">See section 5.1 for&#160;chemotherapy&#160;combination dosing.&#160;<br/><i>&#160;<br/>Metastatic gastric&#160;cancer&#160;<br/>&#160;<br/>Three-weekly&#160;schedule&#160;</i></p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft41">The recommended&#160;initial&#160;loading&#160;dose&#160;is&#160;8&#160;mg/kg&#160;body&#160;weight. The&#160;recommended&#160;maintenance&#160;dose&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft41">at&#160;three-weekly&#160;intervals is&#160;6&#160;mg/kg body weight,&#160;beginning&#160;three&#160;weeks&#160;after&#160;the&#160;loading dose.&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft46">Breast&#160;cancer&#160;and&#160;gastric&#160;cancer&#160;<br/><i>&#160;<br/>Duration of&#160;treatment&#160;</i></p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft41">Patients with MBC&#160;or&#160;MGC&#160;should&#160;be&#160;treated with&#160;trastuzumab&#160;until&#160;progression&#160;of&#160;disease.&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft41">Patients with EBC&#160;should be treated with&#160;trastuzumab&#160;for&#160;1 year&#160;or&#160;until&#160;disease&#160;recurrence, whichever&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft46">occurs first;&#160;extending&#160;treatment&#160;in&#160;EBC&#160;beyond&#160;one year&#160;is not&#160;recommended (see section 5.1).&#160;<br/><i>&#160;<br/>Dose&#160;reduction&#160;</i></p>
<p style="position:absolute;top:1110px;left:106px;white-space:nowrap" class="ft41">No reductions&#160;in&#160;the dose&#160;of&#160;trastuzumab were&#160;made&#160;during&#160;clinical&#160;trials. Patients may continue&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft41">therapy during periods of&#160;reversible, chemotherapy-induced&#160;myelosuppression but&#160;they&#160;should be&#160;</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft58{font-size:17px;font-family:LREDTW+Symbol;color:#000000;}
-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft50">5&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft51">monitored&#160;carefully for&#160;complications of&#160;neutropenia&#160;during this&#160;time. Refer&#160;to the SmPC&#160;for&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft51">paclitaxel, docetaxel&#160;or&#160;aromatase&#160;inhibitor&#160;for&#160;information on dose&#160;reduction or&#160;delays.&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft51">If&#160;left&#160;ventricular&#160;ejection fraction&#160;(LVEF)&#160;percentage&#160;drops&#160;≥&#160;10&#160;points&#160;from&#160;baseline AND&#160;to below&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft51">50&#160;%,&#160;treatment&#160;should be&#160;suspended and&#160;a repeat&#160;LVEF assessment&#160;performed within&#160;approximately&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft51">3 weeks. If&#160;LVEF&#160;has&#160;not&#160;improved, or&#160;has declined&#160;further, or&#160;if&#160;symptomatic&#160;congestive heart&#160;failure&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft51">(CHF) has&#160;developed, discontinuation of&#160;trastuzumab&#160;should be strongly&#160;considered, unless&#160;the&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft51">benefits for&#160;the&#160;individual&#160;patient&#160;are deemed to&#160;outweigh the&#160;risks. All&#160;such&#160;patients should be&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft51">referred&#160;for&#160;assessment&#160;by&#160;a cardiologist&#160;and&#160;followed&#160;up.</p>
<p style="position:absolute;top:256px;left:489px;white-space:nowrap" class="ft52"><b>&#160;</b></p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft57"><i>&#160;<br/>Missed&#160;doses&#160;</i></p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft51">If&#160;the patient&#160;has missed a&#160;dose&#160;of&#160;trastuzumab&#160;by one&#160;week or&#160;less,&#160;then&#160;the&#160;usual&#160;maintenance&#160;dose&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft51">(weekly regimen:&#160;2&#160;mg/kg;&#160;three-weekly regimen:&#160;6&#160;mg/kg)&#160;should be administered as&#160;soon as&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft51">possible. Do not&#160;wait&#160;until&#160;the next&#160;planned cycle. Subsequent&#160;maintenance doses&#160;should be&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft51">administered 7 days or&#160;21 days&#160;later&#160;according to&#160;the weekly&#160;or&#160;three-weekly schedules, respectively.&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft51">If&#160;the patient&#160;has missed a&#160;dose&#160;of&#160;trastuzumab&#160;by&#160;more&#160;than one week, a&#160;re-loading dose&#160;of&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft51">trastuzumab&#160;should be&#160;administered&#160;over&#160;approximately 90 minutes&#160;(weekly&#160;regimen:&#160;4&#160;mg/kg;&#160;three-</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft51">weekly&#160;regimen:&#160;8&#160;mg/kg)&#160;as&#160;soon as&#160;possible. Subsequent&#160;trastuzumab&#160;maintenance&#160;doses&#160;(weekly&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft51">regimen:&#160;2&#160;mg/kg;&#160;three-weekly&#160;regimen 6&#160;mg/kg respectively)&#160;should be&#160;administered&#160;7 days or&#160;21&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft51">days&#160;later&#160;according to the&#160;weekly&#160;or&#160;three-weekly schedules respectively.</p>
<p style="position:absolute;top:484px;left:597px;white-space:nowrap" class="ft52"><b>&#160;</b></p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft57"><i>&#160;<br/>Special&#160;populations&#160;</i></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft51">Dedicated&#160;pharmacokinetic&#160;studies&#160;in&#160;the&#160;elderly and those&#160;with&#160;renal&#160;or&#160;hepatic&#160;impairment&#160;have not&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft51">been carried out. In a population&#160;pharmacokinetic analysis,&#160;age&#160;and&#160;renal&#160;impairment&#160;were not&#160;shown&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft57">to affect&#160;trastuzumab disposition.&#160;<br/><i>&#160;<br/>Paediatric population&#160;</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft51">There&#160;is no relevant&#160;use&#160;of&#160;trastuzumab&#160;in&#160;the&#160;paediatric population.&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft51">Method of&#160;administration&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft51">Trastuzumab&#160;loading dose&#160;should be&#160;administered as&#160;a&#160;90-minute&#160;intravenous infusion. Do&#160;not&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft51">administer&#160;as an&#160;intravenous push or&#160;bolus.&#160;Trastuzumab&#160;intravenous infusion&#160;should be&#160;administered&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft51">by a healthcare provider&#160;prepared to manage anaphylaxis and an&#160;emergency&#160;kit&#160;should be available.&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft51">Patients should&#160;be observed&#160;for&#160;at&#160;least&#160;six&#160;hours after&#160;the start&#160;of&#160;the first&#160;infusion&#160;and for&#160;two&#160;hours&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft51">after&#160;the&#160;start&#160;of&#160;the&#160;subsequent&#160;infusions&#160;for&#160;symptoms like fever&#160;and&#160;chills or&#160;other&#160;infusion-related&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft51">symptoms&#160;(see sections&#160;4.4&#160;and 4.8). Interruption or&#160;slowing the rate of&#160;the&#160;infusion may help control&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft51">such symptoms. The infusion may be&#160;resumed when&#160;symptoms abate.&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft51">If&#160;the&#160;initial&#160;loading&#160;dose&#160;was&#160;well&#160;tolerated,&#160;the&#160;subsequent&#160;doses can be&#160;administered as a&#160;30-minute&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft51">infusion.&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft51">For instructions on&#160;reconstitution of&#160;the&#160;medicinal&#160;product&#160;before administration, see&#160;section 6.6.&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft52"><b>4.3&#160;</b></p>
<p style="position:absolute;top:958px;left:160px;white-space:nowrap" class="ft52"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft58">•&#160;</p>
<p style="position:absolute;top:997px;left:149px;white-space:nowrap" class="ft51">Hypersensitivity&#160;to the active substance,&#160;murine proteins, or&#160;to any of&#160;the excipients listed&#160;</p>
<p style="position:absolute;top:1015px;left:149px;white-space:nowrap" class="ft51">in section 6.1.&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft58">•&#160;</p>
<p style="position:absolute;top:1034px;left:149px;white-space:nowrap" class="ft51">Severe dyspnoea&#160;at&#160;rest&#160;due&#160;to&#160;complications of&#160;advanced malignancy or&#160;requiring&#160;</p>
<p style="position:absolute;top:1052px;left:149px;white-space:nowrap" class="ft51">supplementary&#160;oxygen therapy.&#160;</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft69{font-size:17px;line-height:25px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft60">6&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft62"><b>4.4&#160;</b></p>
<p style="position:absolute;top:104px;left:160px;white-space:nowrap" class="ft62"><b>Special&#160;warnings&#160;and&#160;precautions&#160;for use&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft61">Traceability&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft61">In order&#160;to&#160;improve&#160;the&#160;traceability of&#160;biological&#160;medicinal&#160;products,&#160;the name and&#160;the batch number&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft61">of&#160;the administered&#160;product&#160;should be&#160;clearly recorded.&#160;</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft61">HER2 testing&#160;must&#160;be performed in a specialised laboratory which&#160;can ensure adequate validation&#160;of&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft61">the&#160;testing procedures (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft61">Currently no data&#160;from&#160;clinical&#160;trials&#160;are available on&#160;re-treatment&#160;of&#160;patients with&#160;previous&#160;exposure&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft61">to trastuzumab in the adjuvant&#160;setting</p>
<p style="position:absolute;top:319px;left:354px;white-space:nowrap" class="ft62"><b>.&#160;</b></p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft61">Cardiac&#160;dysfunction&#160;</p>
<p style="position:absolute;top:377px;left:106px;white-space:nowrap" class="ft66">&#160;<br/><i>General&#160;considerations&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft61">Patients treated&#160;with trastuzumab&#160;are at&#160;increased&#160;risk&#160;for&#160;developing CHF&#160;(New&#160;York Heart&#160;</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft61">Association&#160;[NYHA]&#160;Class&#160;II-IV)&#160;or&#160;asymptomatic cardiac&#160;dysfunction. These&#160;events have&#160;been&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft61">observed&#160;in patients receiving trastuzumab&#160;therapy alone or&#160;in combination with paclitaxel&#160;or&#160;</p>
<p style="position:absolute;top:494px;left:106px;white-space:nowrap" class="ft61">docetaxel, particularly&#160;following anthracycline&#160;(doxorubicin or&#160;epirubicin)&#160;containing chemotherapy.&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft61">These&#160;may&#160;be&#160;moderate&#160;to&#160;severe and have been associated with death (see&#160;section 4.8). In addition,&#160;</p>
<p style="position:absolute;top:533px;left:106px;white-space:nowrap" class="ft61">caution&#160;should be&#160;exercised&#160;in treating patients with&#160;increased&#160;cardiac risk,&#160;e.g. hypertension,&#160;</p>
<p style="position:absolute;top:553px;left:106px;white-space:nowrap" class="ft61">documented coronary&#160;artery disease, CHF, LVEF&#160;of&#160;&lt;&#160;55%, older&#160;age.&#160;</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:592px;left:106px;white-space:nowrap" class="ft61">All&#160;candidates&#160;for&#160;treatment&#160;with trastuzumab, but&#160;especially those&#160;with&#160;prior&#160;anthracycline&#160;and&#160;</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft61">cyclophosphamide (AC)&#160;exposure, should&#160;undergo baseline cardiac&#160;assessment&#160;including history&#160;and&#160;</p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft61">physical&#160;examination, electrocardiogram&#160;(ECG), echocardiogram,&#160;and/or&#160;multigated acquisition&#160;</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft61">(MUGA)&#160;scan or&#160;magnetic&#160;resonance imaging.&#160;Monitoring&#160;may help to identify patients who develop&#160;</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft61">cardiac&#160;dysfunction. Cardiac assessments,&#160;as&#160;performed at&#160;baseline, should&#160;be&#160;repeated every 3&#160;months&#160;</p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft61">during treatment&#160;and&#160;every&#160;6 months&#160;following discontinuation of&#160;treatment&#160;until&#160;24 months&#160;from&#160;the&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft61">last&#160;administration of&#160;trastuzumab. A&#160;careful&#160;risk-benefit&#160;assessment&#160;should be&#160;made&#160;before deciding&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft61">to treat&#160;with&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft61">Trastuzumab&#160;may persist&#160;in&#160;the circulation&#160;for&#160;up to 7&#160;months after&#160;stopping&#160;Ogivri&#160;treatment&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft61">population pharmacokinetic analysis of&#160;all&#160;available&#160;data&#160;(see section 5.2).&#160;Patients who&#160;receive&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft61">anthracyclines after&#160;stopping&#160;trastuzumab&#160;may&#160;possibly be at&#160;increased risk of&#160;cardiac&#160;dysfunction. If&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft61">possible, physicians should&#160;avoid&#160;anthracycline-based&#160;therapy&#160;for&#160;up to&#160;7&#160;months&#160;after&#160;stopping&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft61">trastuzumab. If&#160;anthracyclines&#160;are&#160;used,&#160;the patient’s cardiac&#160;function should&#160;be&#160;monitored&#160;carefully.&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft61">Formal&#160;cardiological&#160;assessment&#160;should&#160;be considered&#160;in patients in whom&#160;there&#160;are cardiovascular&#160;</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft61">concerns&#160;following baseline screening. In all&#160;patients&#160;cardiac&#160;function should&#160;be&#160;monitored&#160;during&#160;</p>
<p style="position:absolute;top:923px;left:106px;white-space:nowrap" class="ft61">treatment&#160;(e.g. every 12 weeks).&#160;Monitoring&#160;may help&#160;to identify patients who develop&#160;cardiac&#160;</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft61">dysfunction. Patients who develop asymptomatic&#160;cardiac&#160;dysfunction&#160;may benefit&#160;from&#160;more frequent&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft61">monitoring (e.g. every&#160;6&#160;-&#160;8 weeks). If&#160;patients have a&#160;continued decrease in left&#160;ventricular&#160;function,&#160;</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft61">but&#160;remain&#160;asymptomatic,&#160;the physician&#160;should consider&#160;discontinuing therapy&#160;if&#160;no clinical&#160;benefit&#160;of&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft61">trastuzumab&#160;therapy has&#160;been seen.&#160;</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft61">The safety of&#160;continuation&#160;or&#160;resumption of&#160;trastuzumab&#160;in patients who&#160;experience&#160;cardiac&#160;</p>
<p style="position:absolute;top:1060px;left:106px;white-space:nowrap" class="ft61">dysfunction has&#160;not&#160;been prospectively&#160;studied. If&#160;LVEF percentage&#160;drops ≥&#160;10 points from&#160;baseline&#160;</p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft61">AND&#160;to below&#160;50%,&#160;treatment&#160;should be&#160;suspended&#160;and a repeat&#160;LVEF&#160;assessment&#160;performed within&#160;</p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft61">approximately 3 weeks. If&#160;LVEF&#160;has&#160;not&#160;improved,&#160;or&#160;declined further,&#160;or&#160;symptomatic CHF has&#160;</p>
<p style="position:absolute;top:1118px;left:106px;white-space:nowrap" class="ft61">developed,&#160;discontinuation&#160;of&#160;trastuzumab&#160;should&#160;be strongly considered, unless the benefits&#160;for&#160;the&#160;</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft70">7&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft71">individual&#160;patient&#160;are deemed to outweigh&#160;the&#160;risks. All&#160;such patients should be referred&#160;for&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft71">assessment&#160;by a&#160;cardiologist&#160;and&#160;followed&#160;up.&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft71">If&#160;symptomatic&#160;cardiac&#160;failure develops during&#160;trastuzumab&#160;therapy, it&#160;should&#160;be&#160;treated with&#160;standard&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft71">medicinal&#160;products for&#160;CHF. Most&#160;patients who developed CHF or&#160;asymptomatic&#160;cardiac&#160;dysfunction&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft71">in pivotal&#160;trials&#160;improved with&#160;standard CHF treatment&#160;consisting of&#160;an&#160;angiotensin-converting&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft71">enzyme&#160;(ACE) inhibitor&#160;or&#160;angiotensin&#160;receptor&#160;blocker&#160;(ARB)&#160;and a beta-blocker. The majority of&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft71">patients with cardiac&#160;symptoms&#160;and evidence&#160;of&#160;a&#160;clinical&#160;benefit&#160;of&#160;trastuzumab&#160;treatment&#160;continued&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft76">on therapy without&#160;additional&#160;clinical&#160;cardiac events.&#160;<br/><i>&#160;<br/>Metastatic breast&#160;cancer&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft71">Trastuzumab&#160;and&#160;anthracyclines&#160;should&#160;not&#160;be given&#160;concurrently&#160;in&#160;combination&#160;in the MBC&#160;setting.&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft71">Patients with MBC&#160;who&#160;have previously received&#160;anthracyclines&#160;are also at&#160;risk of&#160;cardiac&#160;dysfunction&#160;</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft71">with&#160;trastuzumab&#160;treatment, although&#160;the&#160;risk&#160;is&#160;lower&#160;than with&#160;concurrent&#160;use&#160;of&#160;trastuzumab&#160;and&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft71">anthracyclines.&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft76">&#160;<br/><i>Early&#160;breast&#160;cancer&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft71">For patients with EBC, cardiac&#160;assessments,&#160;as&#160;performed&#160;at&#160;baseline, should&#160;be&#160;repeated every 3&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft71">months during treatment&#160;and every&#160;6&#160;months&#160;following&#160;discontinuation of&#160;treatment&#160;until&#160;24&#160;months&#160;</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft71">from&#160;the last&#160;administration&#160;of&#160;trastuzumab. In patients&#160;who receive anthracycline-containing&#160;</p>
<p style="position:absolute;top:553px;left:106px;white-space:nowrap" class="ft71">chemotherapy further&#160;monitoring&#160;is&#160;recommended, and&#160;should occur&#160;yearly up to&#160;5&#160;years from&#160;the last&#160;</p>
<p style="position:absolute;top:573px;left:106px;white-space:nowrap" class="ft71">administration&#160;of&#160;trastuzumab, or&#160;longer&#160;if&#160;a continuous decrease&#160;of&#160;LVEF&#160;is&#160;observed.&#160;</p>
<p style="position:absolute;top:592px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft71">Patients with history of&#160;myocardial&#160;infarction (MI), angina pectoris&#160;requiring&#160;medical&#160;treatment,&#160;</p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft71">history&#160;of&#160;or&#160;existing CHF (NYHA&#160;Class II&#160;–IV), LVEF&#160;of&#160;&lt;&#160;55%, other&#160;cardiomyopathy, cardiac&#160;</p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft71">arrhythmia requiring&#160;medical&#160;treatment, clinically significant&#160;cardiac valvular&#160;disease, poorly&#160;</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft71">controlled&#160;hypertension (hypertension&#160;controlled by standard&#160;medical&#160;treatment&#160;eligible),&#160;and&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft71">hemodynamic effective pericardial&#160;effusion were excluded from&#160;adjuvant&#160;and neoadjuvant&#160;EBC&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft71">pivotal&#160;trials with&#160;trastuzumab&#160;and therefore&#160;treatment&#160;cannot&#160;be recommended in such patients.&#160;</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft76">&#160;<br/><i>Adjuvant&#160;treatment&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft71">Trastuzumab&#160;and&#160;anthracyclines&#160;should&#160;not&#160;be given&#160;concurrently&#160;in&#160;combination&#160;in the adjuvant&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft71">treatment&#160;setting.&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft71">In patients with EBC&#160;an&#160;increase in the incidence&#160;of&#160;symptomatic and asymptomatic cardiac&#160;events&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft71">was&#160;observed when&#160;trastuzumab was&#160;administered&#160;after&#160;anthracycline-containing&#160;chemotherapy&#160;</p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft71">compared to&#160;administration&#160;with a&#160;non-anthracycline regimen of&#160;docetaxel&#160;and&#160;carboplatin and was&#160;</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft71">more marked when&#160;trastuzumab was administered&#160;concurrently with&#160;taxanes&#160;than&#160;when administered&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft71">sequentially&#160;to taxanes. Regardless of&#160;the&#160;regimen used, most&#160;symptomatic cardiac events occurred&#160;</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft71">within&#160;the first&#160;18 months.&#160;In one of&#160;the 3&#160;pivotal&#160;studies&#160;conducted&#160;in which a&#160;median&#160;follow-up of&#160;</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft71">5.5 years was available (BCIRG006)&#160;a continuous&#160;increase in the cumulative&#160;rate&#160;of&#160;symptomatic&#160;</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft71">cardiac&#160;or&#160;LVEF&#160;events was observed&#160;in patients who&#160;were administered&#160;trastuzumab&#160;concurrently&#160;</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft71">with a&#160;taxane&#160;following anthracycline&#160;therapy&#160;up to 2.37&#160;%&#160;compared to&#160;approximately 1&#160;%&#160;in&#160;the&#160;two&#160;</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft71">comparator&#160;arms&#160;(anthracycline plus cyclophosphamide followed&#160;by&#160;taxane and taxane, carboplatin&#160;</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft71">and trastuzumab).&#160;</p>
<p style="position:absolute;top:1060px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft71">Risk factors for&#160;a&#160;cardiac event&#160;identified&#160;in four&#160;large&#160;adjuvant&#160;studies&#160;included&#160;advanced age&#160;</p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft71">(&gt;&#160;50&#160;years),&#160;low&#160;LVEF&#160;(&lt;&#160;55&#160;%)&#160;at&#160;baseline, prior&#160;to or&#160;following&#160;the&#160;initiation of&#160;paclitaxel&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft810{font-size:10px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft80">8&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft81">treatment, decline&#160;in LVEF&#160;by 10-15 points, and&#160;prior&#160;or&#160;concurrent&#160;use of&#160;anti-hypertensive&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft81">medicinal&#160;products.&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft81">In patients receiving trastuzumab&#160;after&#160;completion of&#160;adjuvant&#160;chemotherapy,&#160;the&#160;risk&#160;of&#160;cardiac&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft81">dysfunction was associated&#160;with a&#160;higher&#160;cumulative dose of&#160;anthracycline given&#160;prior&#160;to initiation of&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft81">trastuzumab&#160;and a body&#160;mass&#160;index&#160;(BMI)&#160;&gt;&#160;25&#160;kg/m2.&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft86">&#160;<br/><i>Neoadjuvant-adjuvant&#160;treatment&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft81">In patients with EBC&#160;eligible for&#160;neoadjuvant-adjuvant&#160;treatment,&#160;trastuzumab&#160;should be&#160;used&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft81">concurrently with anthracyclines&#160;only&#160;in chemotherapy-naive patients and only with&#160;low-dose&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft81">anthracycline&#160;regimens&#160;i.e.&#160;maximum&#160;cumulative doses of&#160;doxorubicin 180&#160;mg/m2&#160;or&#160;epirubicin&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft81">360&#160;mg/m2.&#160;</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft81">If&#160;patients have been&#160;treated concurrently with a&#160;full&#160;course&#160;of&#160;low-dose&#160;anthracyclines&#160;and&#160;</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft81">trastuzumab&#160;in the neoadjuvant&#160;setting, no&#160;additional&#160;cytotoxic chemotherapy&#160;should be&#160;given after&#160;</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft81">surgery. In other&#160;situations,&#160;the decision on&#160;the need&#160;for&#160;additional&#160;cytotoxic chemotherapy&#160;is&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft81">determined based on&#160;individual&#160;factors.&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft81">Experience of&#160;concurrent&#160;administration of&#160;trastuzumab with&#160;low&#160;dose&#160;anthracycline regimens is&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft81">currently&#160;limited&#160;to&#160;the&#160;trial&#160;MO16432.&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft81">In the pivotal&#160;trial&#160;MO16432, trastuzumab was administered concurrently with neoadjuvant&#160;</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft81">chemotherapy containing three&#160;cycles&#160;of&#160;doxorubicin (cumulative&#160;dose&#160;180&#160;mg/m2).&#160;</p>
<p style="position:absolute;top:553px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:573px;left:106px;white-space:nowrap" class="ft81">The incidence&#160;of&#160;symptomatic&#160;cardiac&#160;dysfunction was&#160;1.7&#160;%&#160;in&#160;the&#160;trastuzumab arm.&#160;</p>
<p style="position:absolute;top:592px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft81">Clinical&#160;experience&#160;is limited in patients&#160;above&#160;65 years of&#160;age.&#160;</p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft81">Infusion-related reactions (IRRs)&#160;and hypersensitivity&#160;</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft81">Serious IRRs to&#160;trastuzumab infusion including dyspnoea, hypotension, wheezing, hypertension,&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft81">bronchospasm,&#160;supraventricular&#160;tachyarrhythmia,&#160;reduced oxygen saturation, anaphylaxis,&#160;respiratory&#160;</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft81">distress, urticaria and&#160;angioedema have been reported (see section&#160;4.8). Pre-medication may&#160;be used to&#160;</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft81">reduce risk&#160;of&#160;occurrence&#160;of&#160;these&#160;events. The majority&#160;of&#160;these&#160;events&#160;occur&#160;during or&#160;within 2.5&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft81">hours&#160;of&#160;the start&#160;of&#160;the&#160;first&#160;infusion. Should an infusion reaction occur&#160;the infusion should be&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft81">discontinued or&#160;the&#160;rate of&#160;infusion slowed&#160;and&#160;the patient&#160;should be&#160;monitored&#160;until&#160;resolution of&#160;all&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft81">observed symptoms&#160;(see section 4.2). These&#160;symptoms&#160;can be&#160;treated with&#160;an analgesic/antipyretic&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft81">such as meperidine&#160;or&#160;paracetamol, or&#160;an antihistamine&#160;such as diphenhydramine.&#160;The majority of&#160;</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft81">patients experienced&#160;resolution of&#160;symptoms and&#160;subsequently&#160;received further&#160;infusions of&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft81">trastuzumab. Serious&#160;reactions have been treated&#160;successfully with supportive therapy such as&#160;oxygen,&#160;</p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft81">beta&#160;agonists, and corticosteroids. In rare&#160;cases,&#160;these&#160;reactions are associated with&#160;a clinical&#160;course&#160;</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft81">culminating&#160;in a&#160;fatal&#160;outcome. Patients experiencing dyspnoea at&#160;rest&#160;due&#160;to complications&#160;of&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft81">advanced&#160;malignancy&#160;and comorbidities may be&#160;at&#160;increased&#160;risk of&#160;a&#160;fatal&#160;infusion reaction.&#160;</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft81">Therefore, these&#160;patients&#160;should not&#160;be treated with&#160;trastuzumab&#160;(see&#160;section 4.3).&#160;</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft81">Initial&#160;improvement&#160;followed by clinical&#160;deterioration&#160;and delayed reactions with&#160;rapid clinical&#160;</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft81">deterioration have also been reported. Fatalities&#160;have occurred within hours&#160;and up to one week&#160;</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft81">following&#160;infusion. On very rare occasions, patients have&#160;experienced&#160;the onset&#160;of&#160;infusion symptoms&#160;</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft81">and pulmonary symptoms&#160;more than six hours&#160;after&#160;the start&#160;of&#160;the&#160;trastuzumab&#160;infusion. Patients&#160;</p>
<p style="position:absolute;top:1060px;left:106px;white-space:nowrap" class="ft81">should be warned&#160;of&#160;the possibility of&#160;such&#160;a late onset&#160;and should&#160;be instructed&#160;to&#160;contact&#160;their&#160;</p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft81">physician if&#160;these&#160;symptoms occur.&#160;</p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft911{font-size:17px;font-family:BCDEEE+MS Mincho;color:#000000;}
-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:439px;white-space:nowrap" class="ft90">9&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft91">Pulmonary events&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft91">Severe pulmonary&#160;events&#160;have&#160;been reported&#160;with the&#160;use&#160;of&#160;trastuzumab in&#160;the&#160;post-marketing setting&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft91">(see&#160;section 4.8). These&#160;events have&#160;occasionally been&#160;fatal. In addition, cases&#160;of&#160;interstitial&#160;lung&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft91">disease&#160;including&#160;lung&#160;infiltrates, acute respiratory&#160;distress syndrome, pneumonia,&#160;pneumonitis,&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft91">pleural&#160;effusion,&#160;respiratory&#160;distress,&#160;acute pulmonary&#160;oedema and respiratory insufficiency&#160;have&#160;been&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft91">reported. Risk factors&#160;associated with&#160;interstitial&#160;lung&#160;disease&#160;include&#160;prior&#160;or&#160;concomitant&#160;therapy&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft91">with other&#160;anti-neoplastic&#160;therapies known&#160;to be&#160;associated with&#160;it&#160;such&#160;as&#160;taxanes, gemcitabine,&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft91">vinorelbine&#160;and&#160;radiation&#160;therapy. These events may occur&#160;as part&#160;of&#160;an&#160;infusion-related reaction or&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft91">with a&#160;delayed&#160;onset. Patients experiencing dyspnoea&#160;at&#160;rest&#160;due&#160;to complications&#160;of&#160;advanced&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft91">malignancy&#160;and comorbidities&#160;may&#160;be at&#160;increased risk&#160;of&#160;pulmonary events. Therefore, these patients&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft91">should not&#160;be&#160;treated with&#160;trastuzumab&#160;(see&#160;section&#160;4.3). Caution&#160;should be&#160;exercised for&#160;pneumonitis,&#160;</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft91">especially&#160;in&#160;patients&#160;being&#160;treated concomitantly with&#160;taxanes.&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft99">Excipients&#160;<br/><i>Sorbitol&#160;content&#160;</i></p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft91">Ogivri&#160;150&#160;mg&#160;contains&#160;115.2&#160;mg&#160;sorbitol&#160;in each vial.&#160;&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft91">Ogivri&#160;420&#160;mg&#160;contains&#160;322.6&#160;mg&#160;sorbitol&#160;in each vial.&#160;</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft91">Patients with hereditary&#160;fructose intolerance&#160;(HFI)&#160;must&#160;not&#160;be&#160;given&#160;this&#160;medicine&#160;unless&#160;strictly&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft91">necessary.&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft91">A&#160;detailed history with&#160;regards&#160;to HFI&#160;symptoms has&#160;to&#160;be taken of&#160;each patient&#160;prior&#160;to&#160;being given&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft91">this medicinal&#160;product.&#160;</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft99">&#160;<br/><i>Sodium&#160;</i></p>
<p style="position:absolute;top:573px;left:106px;white-space:nowrap" class="ft91">This&#160;medicinal&#160;product&#160;contains less&#160;than 1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;dose,&#160;that&#160;is to&#160;say, essentially&#160;</p>
<p style="position:absolute;top:592px;left:106px;white-space:nowrap" class="ft91">‘sodium-free’.&#160;</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft92"><b>4.5&#160;</b></p>
<p style="position:absolute;top:631px;left:160px;white-space:nowrap" class="ft92"><b>Interaction&#160;with other&#160;medicinal&#160;products and other forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:669px;left:106px;white-space:nowrap" class="ft91">No interaction studies&#160;have&#160;been performed. Clinically&#160;significant&#160;interactions&#160;between&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:688px;left:106px;white-space:nowrap" class="ft91">and the concomitant&#160;medicinal&#160;products&#160;used&#160;in&#160;clinical&#160;trials&#160;have&#160;not&#160;been&#160;observed.&#160;</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft95">Effect&#160;of&#160;trastuzumab on&#160;the pharmacokinetics&#160;of&#160;other&#160;antineoplastic agents&#160;<br/><i>&#160;</i></p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft91">Pharmacokinetic data&#160;from&#160;studies&#160;BO15935 and&#160;M77004 in women&#160;with HER2-positive MBC&#160;</p>
<p style="position:absolute;top:784px;left:106px;white-space:nowrap" class="ft91">suggested&#160;that&#160;exposure&#160;to&#160;paclitaxel&#160;and&#160;doxorubicin&#160;(and&#160;their&#160;major&#160;metabolites 6-α&#160;hydroxyl-</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft91">paclitaxel, POH, and&#160;doxorubicinol, DOL) was&#160;not&#160;altered&#160;in&#160;the presence of&#160;trastuzumab (8&#160;mg/kg&#160;or&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft91">4&#160;mg/kg&#160;intravenous&#160;loading dose&#160;followed&#160;by 6&#160;mg/kg q3w&#160;or&#160;2&#160;mg/kg q1w&#160;intravenous,&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft91">respectively).&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft91">However,&#160;trastuzumab&#160;may&#160;elevate the overall&#160;exposure of&#160;one doxorubicin&#160;metabolite,&#160;(7-deoxy-13&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft91">dihydro-doxorubicinone, D7D). The bioactivity of&#160;D7D&#160;and the clinical&#160;impact&#160;of&#160;the elevation of&#160;this&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft91">metabolite were&#160;unclear.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft91">Data&#160;from&#160;study&#160;JP16003, a&#160;single-arm&#160;study&#160;of&#160;trastuzumab&#160;(4&#160;mg/kg&#160;intravenous&#160;loading dose&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft91">2&#160;mg/kg&#160;intravenous&#160;weekly)&#160;and&#160;docetaxel&#160;(60&#160;mg/m2&#160;intravenous)&#160;in Japanese&#160;women with&#160;HER2-&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft91">positive MBC, suggested that&#160;concomitant&#160;administration of&#160;trastuzumab had no&#160;effect&#160;on the single&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft91">dose&#160;pharmacokinetics&#160;of&#160;docetaxel. Study JP19959 was&#160;a sub&#160;study of&#160;BO18255&#160;(ToGA)&#160;performed&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft91">in male and&#160;female Japanese patients with&#160;advanced&#160;gastric&#160;cancer&#160;(AGC)&#160;to&#160;study&#160;the&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft91">pharmacokinetics&#160;of&#160;capecitabine and cisplatin when used with or&#160;without&#160;trastuzumab. The&#160;results of&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft91">this sub&#160;study suggested&#160;that&#160;the exposure&#160;to the bioactive metabolites&#160;(e.g. 5-FU)&#160;of&#160;capecitabine was&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft91">not&#160;affected by&#160;concurrent&#160;use&#160;of&#160;cisplatin or&#160;by&#160;concurrent&#160;use&#160;of&#160;cisplatin plus&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft91">However, capecitabine&#160;itself&#160;showed&#160;higher&#160;concentrations and&#160;a longer&#160;half-life when combined with&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft91">trastuzumab. The data also&#160;suggested&#160;that&#160;the pharmacokinetics&#160;of&#160;cisplatin were&#160;not&#160;affected by&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft91">concurrent&#160;use&#160;of&#160;capecitabine or&#160;by&#160;concurrent&#160;use&#160;of&#160;capecitabine plus&#160;trastuzumab.&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft100">10&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft101">Pharmacokinetic data&#160;from&#160;Study H4613g/GO01305 in&#160;patients with&#160;metastatic or&#160;locally advanced&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft101">inoperable HER2-positive&#160;cancer&#160;suggested&#160;that&#160;trastuzumab&#160;had no&#160;impact&#160;on&#160;the&#160;PK&#160;of&#160;carboplatin.&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft101">Effect&#160;of&#160;antineoplastic agents on&#160;trastuzumab&#160;pharmacokinetics&#160;&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft101">By comparison&#160;of&#160;simulated serum&#160;trastuzumab&#160;concentrations&#160;after&#160;trastuzumab&#160;monotherapy&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft101">(4&#160;mg/kg&#160;loading/2&#160;mg/kg&#160;q1w&#160;intravenous)&#160;and observed serum&#160;concentrations&#160;in Japanese&#160;women&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft101">with HER2-&#160;positive&#160;MBC&#160;(study JP16003)&#160;no evidence of&#160;a&#160;PK&#160;effect&#160;of&#160;concurrent&#160;administration of&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft101">docetaxel&#160;on&#160;the&#160;pharmacokinetics&#160;of&#160;trastuzumab was&#160;found.&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft101">Comparison of&#160;PK&#160;results&#160;from&#160;two&#160;phase II&#160;studies (BO15935 and&#160;M77004)&#160;and&#160;one&#160;phase&#160;III&#160;study&#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft101">(H0648g)&#160;in which&#160;patients&#160;were&#160;treated concomitantly&#160;with&#160;trastuzumab&#160;and paclitaxel&#160;and two&#160;phase&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft101">II&#160;studies&#160;in which&#160;trastuzumab was administered&#160;as&#160;monotherapy (W016229 and&#160;MO16982), in&#160;</p>
<p style="position:absolute;top:371px;left:106px;white-space:nowrap" class="ft101">women with HER2-positive MBC&#160;indicates&#160;that&#160;individual&#160;and&#160;mean&#160;trastuzumab&#160;trough serum&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft101">concentrations&#160;varied&#160;within and across&#160;studies&#160;but&#160;there was&#160;no clear&#160;effect&#160;of&#160;the&#160;concomitant&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft101">administration&#160;of&#160;paclitaxel&#160;on the&#160;pharmacokinetics&#160;of&#160;trastuzumab. Comparison&#160;of&#160;trastuzumab PK&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft101">data&#160;from&#160;Study&#160;M77004 in&#160;which women with HER2-positive MBC&#160;were&#160;treated&#160;concomitantly with&#160;</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft101">trastuzumab, paclitaxel&#160;and&#160;doxorubicin&#160;to trastuzumab PK&#160;data&#160;in&#160;studies where&#160;trastuzumab was&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft101">administered as&#160;monotherapy (H0649g)&#160;or&#160;in&#160;combination with&#160;anthracycline plus&#160;cyclophosphamide&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft101">or&#160;paclitaxel&#160;(Study H0648g), suggested no effect&#160;of&#160;doxorubicin and paclitaxel&#160;on the&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft101">pharmacokinetics&#160;of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft101">Pharmacokinetic data&#160;from&#160;Study H4613g/GO01305 suggested&#160;that&#160;carboplatin&#160;had no impact&#160;on&#160;the&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft101">PK&#160;of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft101">The administration of&#160;concomitant&#160;anastrozole did not&#160;appear&#160;to influence the pharmacokinetics&#160;of&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft101">trastuzumab.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft102"><b>4.6&#160;</b></p>
<p style="position:absolute;top:655px;left:160px;white-space:nowrap" class="ft102"><b>Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft101">Women of&#160;childbearing&#160;potential&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft101">Women of&#160;childbearing&#160;potential&#160;should be advised to&#160;use&#160;effective&#160;contraception&#160;during treatment&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft101">with&#160;trastuzumab&#160;and for&#160;7&#160;months after&#160;treatment&#160;has&#160;concluded&#160;(see section 5.2).&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft101">Pregnancy&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft101">Reproduction studies&#160;have&#160;been conducted&#160;in Cynomolgus&#160;monkeys&#160;at&#160;doses up&#160;to 25 times&#160;that&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft101">weekly&#160;human&#160;maintenance&#160;dose&#160;of&#160;2&#160;mg/kg trastuzumab intravenous formulation&#160;and have revealed&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft101">no evidence of&#160;impaired fertility or&#160;harm&#160;to&#160;the&#160;foetus.&#160;Placental&#160;transfer&#160;of&#160;trastuzumab&#160;during&#160;the&#160;</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft101">early (days&#160;20–50 of&#160;gestation)&#160;and late&#160;(days 120–150&#160;of&#160;gestation)&#160;foetal&#160;development&#160;period was&#160;</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft101">observed. It&#160;is not&#160;known whether&#160;trastuzumab can affect&#160;reproductive capacity.&#160;As animal&#160;</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft101">reproduction studies&#160;are not&#160;always predictive of&#160;human response, trastuzumab should be avoided&#160;</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft101">during pregnancy unless&#160;the potential&#160;benefit&#160;for&#160;the&#160;mother&#160;outweighs the potential&#160;risk&#160;to&#160;the&#160;foetus.&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft101">In the post-marketing setting, cases&#160;of&#160;foetal&#160;renal&#160;growth and/or&#160;function&#160;impairment&#160;in&#160;association&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft101">with oligohydramnios, some associated with&#160;fatal&#160;pulmonary&#160;hypoplasia of&#160;the&#160;foetus, have&#160;been&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft101">reported in&#160;pregnant&#160;women receiving&#160;trastuzumab.&#160;Women who become pregnant&#160;should be advised&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft101">of&#160;the possibility of&#160;harm&#160;to&#160;the&#160;foetus. If&#160;a pregnant&#160;woman&#160;is&#160;treated with&#160;trastuzumab,&#160;or&#160;if&#160;a patient&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft101">becomes&#160;pregnant&#160;while&#160;receiving&#160;trastuzumab&#160;or&#160;within 7&#160;months&#160;following the&#160;last&#160;dose of&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft105">trastuzumab, close&#160;monitoring by a&#160;multidisciplinary team&#160;is desirable.&#160;<br/><i>&#160;</i></p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1112{font-size:15px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
	.ft1113{font-size:18px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft110">11&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft111">Breast-feeding&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft111">A&#160;study&#160;conducted in Cynomolgus&#160;monkeys&#160;at&#160;doses&#160;25 times that&#160;of&#160;the&#160;weekly&#160;human&#160;maintenance&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft111">dose&#160;of&#160;2&#160;mg/kg trastuzumab intravenous formulation&#160;from&#160;days&#160;120&#160;to 150&#160;of&#160;pregnancy&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft111">demonstrated&#160;that&#160;trastuzumab&#160;is&#160;secreted&#160;in the&#160;milk&#160;postpartum. The&#160;exposure&#160;to trastuzumab&#160;in&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft111">utero and&#160;presence of&#160;trastuzumab in&#160;the serum&#160;of&#160;infant&#160;monkeys was&#160;not&#160;associated with any adverse&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft111">effects on&#160;their&#160;growth or&#160;development&#160;from&#160;birth&#160;to 1&#160;month of&#160;age. It&#160;is&#160;not&#160;known whether&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft111">trastuzumab&#160;is secreted in&#160;human&#160;milk. As human IgG1 is&#160;secreted&#160;into&#160;human&#160;milk, and&#160;the potential&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft111">for&#160;harm&#160;to the infant&#160;is unknown, women should&#160;not&#160;breast-feed during trastuzumab&#160;therapy&#160;and&#160;for&#160;7&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft115">months after&#160;the&#160;last&#160;dose.&#160;<br/><i>&#160;</i></p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft111">Fertility&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft115">There&#160;is no fertility data&#160;available.&#160;<br/><i>&#160;</i></p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft112"><b>4.7&#160;</b></p>
<p style="position:absolute;top:389px;left:160px;white-space:nowrap" class="ft112"><b>Effects on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines&#160;</b></p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft111">Ogivri&#160;has&#160;a&#160;minor&#160;influence on the ability to&#160;drive&#160;and&#160;use&#160;machines&#160;(see&#160;section&#160;4.8).&#160;Dizziness and&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft111">somnolence&#160;may&#160;occur&#160;during treatment&#160;with&#160;Ogivri&#160;(see&#160;section&#160;4.8).&#160;Patients experiencing&#160;infusion-</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft111">related symptoms (see&#160;section&#160;4.4)&#160;should be&#160;advised&#160;not&#160;to&#160;drive&#160;and use&#160;machines until&#160;symptoms&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft111">abate.&#160;&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft112"><b>4.8&#160;</b></p>
<p style="position:absolute;top:522px;left:160px;white-space:nowrap" class="ft112"><b>Undesirable&#160;effects&#160;</b></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft111">Summary of&#160;the&#160;safety profile&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft111">Amongst&#160;the&#160;most&#160;serious and/or&#160;common adverse&#160;reactions reported&#160;in&#160;trastuzumab usage&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft111">(intravenous and&#160;subcutaneous formulations)&#160;to&#160;date are cardiac dysfunction,&#160;infusion-related&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft111">reactions, haematotoxicity (in particular&#160;neutropenia),&#160;infections and pulmonary adverse reactions.&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft111">Tabulated&#160;list&#160;of&#160;adverse&#160;reactions&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft111">In this&#160;section, the following categories of&#160;frequency have&#160;been used:&#160;very common&#160;(≥&#160;1/10), common&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft111">(≥&#160;1/100&#160;to&#160;&lt;&#160;1/10), uncommon&#160;(≥&#160;1/1,000 to &lt;&#160;1/100),&#160;rare (≥&#160;1/10,000 to&#160;&lt;&#160;1/1,000), very&#160;rare&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft111">(&lt;&#160;1/10,000), not&#160;known (cannot&#160;be estimated from&#160;the&#160;available data).&#160;Within each frequency&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft111">grouping, adverse&#160;reactions&#160;are presented&#160;in order&#160;of&#160;decreasing seriousness.&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft111">Presented in Table 1 are&#160;adverse reactions that&#160;have&#160;been reported&#160;in association&#160;with&#160;the use&#160;of&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft111">intravenous&#160;trastuzumab&#160;alone or&#160;in&#160;combination with&#160;chemotherapy in pivotal&#160;clinical&#160;trials and&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft111">post-marketing setting.&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft111">All&#160;the&#160;terms&#160;included are based on the highest&#160;percentage&#160;seen&#160;in pivotal&#160;clinical&#160;trials.&#160;In&#160;addition,&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft111">terms&#160;reported&#160;in the post&#160;marketing&#160;setting are&#160;included in Table 1.&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft111">Table&#160;1 Undesirable effects&#160;reported with intravenous&#160;trastuzumab&#160;monotherapy or&#160;in&#160;combination&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft111">with chemotherapy in pivotal&#160;clinical&#160;trials (N&#160;=&#160;8386)&#160;and in&#160;post-marketing&#160;</p>
<p style="position:absolute;top:978px;left:121px;white-space:nowrap" class="ft1112">&#160;</p>
<p style="position:absolute;top:996px;left:123px;white-space:nowrap" class="ft112"><b>System&#160;organ&#160;class</b></p>
<p style="position:absolute;top:994px;left:255px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:996px;left:317px;white-space:nowrap" class="ft112"><b>Adverse&#160;reaction</b></p>
<p style="position:absolute;top:994px;left:436px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:996px;left:617px;white-space:nowrap" class="ft112"><b>Frequency</b></p>
<p style="position:absolute;top:994px;left:692px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1016px;left:123px;white-space:nowrap" class="ft111">Infections&#160;and&#160;infestations</p>
<p style="position:absolute;top:1014px;left:296px;white-space:nowrap" class="ft1113">&#160;&#160;Infection&#160;</p>
<p style="position:absolute;top:1016px;left:617px;white-space:nowrap" class="ft111">Very&#160;common</p>
<p style="position:absolute;top:1014px;left:712px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1035px;left:317px;white-space:nowrap" class="ft111">Nasopharyngitis</p>
<p style="position:absolute;top:1034px;left:426px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1035px;left:617px;white-space:nowrap" class="ft111">Very&#160;common</p>
<p style="position:absolute;top:1034px;left:712px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1055px;left:317px;white-space:nowrap" class="ft111">Neutropenic&#160;sepsis</p>
<p style="position:absolute;top:1054px;left:441px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1055px;left:617px;white-space:nowrap" class="ft111">Common</p>
<p style="position:absolute;top:1054px;left:679px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1075px;left:317px;white-space:nowrap" class="ft111">Cystitis</p>
<p style="position:absolute;top:1073px;left:368px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1075px;left:617px;white-space:nowrap" class="ft111">Common</p>
<p style="position:absolute;top:1073px;left:679px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1095px;left:317px;white-space:nowrap" class="ft111">Influenza</p>
<p style="position:absolute;top:1093px;left:380px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1095px;left:617px;white-space:nowrap" class="ft111">Common</p>
<p style="position:absolute;top:1093px;left:679px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1114px;left:317px;white-space:nowrap" class="ft111">Sinusitis</p>
<p style="position:absolute;top:1113px;left:374px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1114px;left:617px;white-space:nowrap" class="ft111">Common</p>
<p style="position:absolute;top:1113px;left:679px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1134px;left:317px;white-space:nowrap" class="ft111">Skin&#160;infection</p>
<p style="position:absolute;top:1133px;left:410px;white-space:nowrap" class="ft1113">&#160;</p>
<p style="position:absolute;top:1134px;left:617px;white-space:nowrap" class="ft111">Common</p>
<p style="position:absolute;top:1133px;left:679px;white-space:nowrap" class="ft1113">&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft120">12&#160;</p>
<p style="position:absolute;top:105px;left:123px;white-space:nowrap" class="ft122"><b>System&#160;organ&#160;class</b></p>
<p style="position:absolute;top:103px;left:255px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:105px;left:317px;white-space:nowrap" class="ft122"><b>Adverse&#160;reaction</b></p>
<p style="position:absolute;top:103px;left:436px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:105px;left:617px;white-space:nowrap" class="ft122"><b>Frequency</b></p>
<p style="position:absolute;top:103px;left:692px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:124px;left:317px;white-space:nowrap" class="ft121">Rhinitis</p>
<p style="position:absolute;top:123px;left:369px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:124px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:123px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:144px;left:317px;white-space:nowrap" class="ft121">Upper&#160;respiratory&#160;tract&#160;infection</p>
<p style="position:absolute;top:143px;left:529px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:144px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:143px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:164px;left:317px;white-space:nowrap" class="ft121">Urinary&#160;tract&#160;infection</p>
<p style="position:absolute;top:162px;left:464px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:164px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:162px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:184px;left:317px;white-space:nowrap" class="ft121">Pharyngitis</p>
<p style="position:absolute;top:182px;left:392px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:184px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:182px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft121">Neoplasms&#160;benign,&#160;</p>
<p style="position:absolute;top:222px;left:123px;white-space:nowrap" class="ft121">malignant&#160;and&#160;unspecified&#160;</p>
<p style="position:absolute;top:241px;left:123px;white-space:nowrap" class="ft121">(incl.&#160;cysts&#160;and&#160;polyps)</p>
<p style="position:absolute;top:240px;left:275px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:203px;left:317px;white-space:nowrap" class="ft121">Malignant&#160;neoplasm&#160;progression</p>
<p style="position:absolute;top:202px;left:532px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:203px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:202px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:223px;left:317px;white-space:nowrap" class="ft121">Neoplasm&#160;progression</p>
<p style="position:absolute;top:222px;left:465px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:223px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:222px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:261px;left:123px;white-space:nowrap" class="ft121">Blood&#160;and&#160;lymphatic&#160;</p>
<p style="position:absolute;top:280px;left:123px;white-space:nowrap" class="ft121">system&#160;disorders</p>
<p style="position:absolute;top:278px;left:233px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:261px;left:317px;white-space:nowrap" class="ft121">Febrile&#160;neutropenia</p>
<p style="position:absolute;top:259px;left:446px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:261px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:259px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:286px;left:317px;white-space:nowrap" class="ft121">Anaemia</p>
<p style="position:absolute;top:284px;left:377px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:286px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:284px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:310px;left:317px;white-space:nowrap" class="ft121">Neutropenia</p>
<p style="position:absolute;top:309px;left:399px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:310px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:309px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:330px;left:317px;white-space:nowrap" class="ft121">White&#160;blood&#160;cell&#160;count&#160;</p>
<p style="position:absolute;top:349px;left:317px;white-space:nowrap" class="ft121">decreased/leukopenia</p>
<p style="position:absolute;top:348px;left:459px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:330px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:329px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:369px;left:317px;white-space:nowrap" class="ft121">Thrombocytopenia</p>
<p style="position:absolute;top:368px;left:443px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:369px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:368px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:389px;left:317px;white-space:nowrap" class="ft121">Hypoprothrombinaemia</p>
<p style="position:absolute;top:387px;left:475px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:389px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:387px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:409px;left:317px;white-space:nowrap" class="ft121">Immune&#160;thrombocytopenia</p>
<p style="position:absolute;top:408px;left:496px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:409px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:408px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:429px;left:123px;white-space:nowrap" class="ft121">Immune&#160;system&#160;disorders</p>
<p style="position:absolute;top:428px;left:291px;white-space:nowrap" class="ft1213">&#160;&#160;Hypersensitivity&#160;</p>
<p style="position:absolute;top:429px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:428px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:448px;left:317px;white-space:nowrap" class="ft1210">+Anaphylactic&#160;reaction</p>
<p style="position:absolute;top:448px;left:468px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:449px;left:617px;white-space:nowrap" class="ft121">Rare</p>
<p style="position:absolute;top:448px;left:648px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:468px;left:317px;white-space:nowrap" class="ft1210">+Anaphylactic&#160;shock</p>
<p style="position:absolute;top:467px;left:453px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:469px;left:617px;white-space:nowrap" class="ft121">Rare</p>
<p style="position:absolute;top:467px;left:648px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:489px;left:123px;white-space:nowrap" class="ft121">Metabolism&#160;and&#160;nutrition&#160;</p>
<p style="position:absolute;top:508px;left:123px;white-space:nowrap" class="ft121">disorders</p>
<p style="position:absolute;top:506px;left:183px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:489px;left:317px;white-space:nowrap" class="ft121">Weight&#160;decreased/Weight&#160;loss</p>
<p style="position:absolute;top:487px;left:516px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:489px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:487px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:508px;left:317px;white-space:nowrap" class="ft121">Anorexia</p>
<p style="position:absolute;top:507px;left:379px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:508px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:507px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:528px;left:317px;white-space:nowrap" class="ft121">Tumour&#160;lysis syndrome&#160;</p>
<p style="position:absolute;top:528px;left:617px;white-space:nowrap" class="ft121">Not&#160;known&#160;</p>
<p style="position:absolute;top:548px;left:317px;white-space:nowrap" class="ft121">Hyperkalaemia</p>
<p style="position:absolute;top:546px;left:418px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:548px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:546px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:568px;left:123px;white-space:nowrap" class="ft121">Psychiatric&#160;disorders</p>
<p style="position:absolute;top:566px;left:260px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:568px;left:317px;white-space:nowrap" class="ft121">Insomnia</p>
<p style="position:absolute;top:566px;left:379px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:568px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:566px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:587px;left:317px;white-space:nowrap" class="ft121">Anxiety</p>
<p style="position:absolute;top:586px;left:370px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:587px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:586px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:607px;left:317px;white-space:nowrap" class="ft121">Depression</p>
<p style="position:absolute;top:606px;left:391px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:607px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:606px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:627px;left:123px;white-space:nowrap" class="ft121">Nervous&#160;system&#160;disorders</p>
<p style="position:absolute;top:625px;left:292px;white-space:nowrap" class="ft1213">&#160;&#160;1Tremor&#160;</p>
<p style="position:absolute;top:627px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:625px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:647px;left:317px;white-space:nowrap" class="ft121">Dizziness</p>
<p style="position:absolute;top:645px;left:381px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:647px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:645px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:668px;left:317px;white-space:nowrap" class="ft121">Headache</p>
<p style="position:absolute;top:667px;left:382px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:668px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:667px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:688px;left:317px;white-space:nowrap" class="ft121">Paraesthesia</p>
<p style="position:absolute;top:686px;left:399px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:688px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:686px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:708px;left:317px;white-space:nowrap" class="ft121">Dysgeusia</p>
<p style="position:absolute;top:706px;left:386px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:708px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:706px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:728px;left:317px;white-space:nowrap" class="ft121">Peripheral&#160;neuropathy</p>
<p style="position:absolute;top:726px;left:463px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:728px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:726px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:747px;left:317px;white-space:nowrap" class="ft121">Hypertonia</p>
<p style="position:absolute;top:746px;left:392px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:747px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:746px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:767px;left:317px;white-space:nowrap" class="ft121">Somnolence</p>
<p style="position:absolute;top:765px;left:399px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:767px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:765px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:787px;left:123px;white-space:nowrap" class="ft121">Eye&#160;disorders</p>
<p style="position:absolute;top:785px;left:213px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:787px;left:317px;white-space:nowrap" class="ft121">Conjunctivitis</p>
<p style="position:absolute;top:785px;left:411px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:787px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:785px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:806px;left:317px;white-space:nowrap" class="ft121">Lacrimation&#160;increased</p>
<p style="position:absolute;top:805px;left:464px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:806px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:805px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:826px;left:317px;white-space:nowrap" class="ft121">Dry&#160;eye</p>
<p style="position:absolute;top:825px;left:370px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:826px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:825px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:846px;left:317px;white-space:nowrap" class="ft121">Papilloedema</p>
<p style="position:absolute;top:844px;left:407px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:846px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:844px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:866px;left:317px;white-space:nowrap" class="ft121">Retinal&#160;haemorrhage</p>
<p style="position:absolute;top:865px;left:455px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:866px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:865px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:886px;left:123px;white-space:nowrap" class="ft121">Ear&#160;and&#160;labyrinth&#160;disorders</p>
<p style="position:absolute;top:885px;left:301px;white-space:nowrap" class="ft1213">&#160;&#160;Deafness&#160;</p>
<p style="position:absolute;top:886px;left:617px;white-space:nowrap" class="ft121">Uncommon</p>
<p style="position:absolute;top:885px;left:695px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:906px;left:123px;white-space:nowrap" class="ft121">Cardiac&#160;disorders</p>
<p style="position:absolute;top:905px;left:238px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:905px;left:317px;white-space:nowrap" class="ft1210">1&#160;&#160;Blood&#160;pressure&#160;decreased</p>
<p style="position:absolute;top:905px;left:495px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:906px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:905px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:925px;left:317px;white-space:nowrap" class="ft1210">1&#160;&#160;Blood&#160;pressure&#160;increased</p>
<p style="position:absolute;top:925px;left:492px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:926px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:925px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:946px;left:317px;white-space:nowrap" class="ft1210">1&#160;&#160;Heart&#160;beat&#160;irregular</p>
<p style="position:absolute;top:945px;left:455px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:947px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:945px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:966px;left:317px;white-space:nowrap" class="ft1210">1Cardiac&#160;flutter</p>
<p style="position:absolute;top:966px;left:418px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:967px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:966px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:987px;left:317px;white-space:nowrap" class="ft121">Ejection&#160;fraction&#160;decreased*</p>
<p style="position:absolute;top:986px;left:504px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:987px;left:617px;white-space:nowrap" class="ft121">Very&#160;common</p>
<p style="position:absolute;top:986px;left:712px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1006px;left:317px;white-space:nowrap" class="ft1210">+Cardiac&#160;failure&#160;(congestive)</p>
<p style="position:absolute;top:1005px;left:507px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1007px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:1005px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1026px;left:317px;white-space:nowrap" class="ft1210">+1Supraventricular&#160;tachyarrhythmia</p>
<p style="position:absolute;top:1025px;left:550px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1027px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:1025px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1047px;left:317px;white-space:nowrap" class="ft121">Cardiomyopathy</p>
<p style="position:absolute;top:1045px;left:428px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1047px;left:617px;white-space:nowrap" class="ft121">Common</p>
<p style="position:absolute;top:1045px;left:679px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1065px;left:317px;white-space:nowrap" class="ft1210">1Palpitation&#160;</p>
<p style="position:absolute;top:1066px;left:617px;white-space:nowrap" class="ft121">Common&#160;</p>
<p style="position:absolute;top:1086px;left:317px;white-space:nowrap" class="ft121">Pericardial&#160;effusion</p>
<p style="position:absolute;top:1084px;left:446px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1086px;left:617px;white-space:nowrap" class="ft121">Uncommon</p>
<p style="position:absolute;top:1084px;left:695px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1106px;left:317px;white-space:nowrap" class="ft121">Cardiogenic&#160;shock</p>
<p style="position:absolute;top:1104px;left:440px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1106px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:1104px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1125px;left:317px;white-space:nowrap" class="ft121">Gallop&#160;rhythm&#160;present</p>
<p style="position:absolute;top:1124px;left:465px;white-space:nowrap" class="ft1213">&#160;</p>
<p style="position:absolute;top:1125px;left:617px;white-space:nowrap" class="ft121">Not&#160;known</p>
<p style="position:absolute;top:1124px;left:691px;white-space:nowrap" class="ft1213">&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft130">13&#160;</p>
<p style="position:absolute;top:105px;left:123px;white-space:nowrap" class="ft132"><b>System&#160;organ&#160;class</b></p>
<p style="position:absolute;top:103px;left:255px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:105px;left:317px;white-space:nowrap" class="ft132"><b>Adverse&#160;reaction</b></p>
<p style="position:absolute;top:103px;left:436px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:105px;left:617px;white-space:nowrap" class="ft132"><b>Frequency</b></p>
<p style="position:absolute;top:103px;left:692px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:124px;left:123px;white-space:nowrap" class="ft131">Vascular&#160;disorders</p>
<p style="position:absolute;top:123px;left:245px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:124px;left:317px;white-space:nowrap" class="ft131">Hot&#160;flush</p>
<p style="position:absolute;top:123px;left:379px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:124px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:123px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:143px;left:317px;white-space:nowrap" class="ft1310">+1&#160;Hypotension</p>
<p style="position:absolute;top:143px;left:415px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:144px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:143px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:164px;left:317px;white-space:nowrap" class="ft131">Vasodilatation</p>
<p style="position:absolute;top:162px;left:414px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:164px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:162px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:184px;left:123px;white-space:nowrap" class="ft131">Respiratory,&#160;thoracic&#160;and&#160;</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft131">mediastinal&#160;disorders</p>
<p style="position:absolute;top:201px;left:263px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:182px;left:317px;white-space:nowrap" class="ft1310">+Dyspnoea</p>
<p style="position:absolute;top:182px;left:389px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:184px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:182px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:204px;left:317px;white-space:nowrap" class="ft131">Cough</p>
<p style="position:absolute;top:203px;left:361px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:204px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:203px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:224px;left:317px;white-space:nowrap" class="ft131">Epistaxis</p>
<p style="position:absolute;top:223px;left:378px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:224px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:223px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:243px;left:317px;white-space:nowrap" class="ft131">Rhinorrhoea</p>
<p style="position:absolute;top:241px;left:400px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:243px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:241px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:261px;left:317px;white-space:nowrap" class="ft1310">+Pneumonia</p>
<p style="position:absolute;top:261px;left:397px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:263px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:261px;left:678px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:282px;left:317px;white-space:nowrap" class="ft131">Asthma</p>
<p style="position:absolute;top:281px;left:369px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:282px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:281px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:302px;left:317px;white-space:nowrap" class="ft131">Lung&#160;disorder</p>
<p style="position:absolute;top:301px;left:410px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:302px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:301px;left:678px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:321px;left:317px;white-space:nowrap" class="ft1310">+Pleural&#160;effusion</p>
<p style="position:absolute;top:320px;left:428px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:322px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:320px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:341px;left:317px;white-space:nowrap" class="ft1310">+1Wheezing&#160;</p>
<p style="position:absolute;top:343px;left:617px;white-space:nowrap" class="ft131">Uncommon&#160;</p>
<p style="position:absolute;top:363px;left:317px;white-space:nowrap" class="ft131">Pneumonitis</p>
<p style="position:absolute;top:362px;left:400px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:363px;left:617px;white-space:nowrap" class="ft131">Uncommon</p>
<p style="position:absolute;top:362px;left:695px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:383px;left:317px;white-space:nowrap" class="ft1310">+Pulmonary&#160;fibrosis</p>
<p style="position:absolute;top:383px;left:448px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:384px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:383px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:403px;left:317px;white-space:nowrap" class="ft1310">+Respiratory&#160;distress</p>
<p style="position:absolute;top:403px;left:453px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:404px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:403px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:423px;left:317px;white-space:nowrap" class="ft1310">+Respiratory&#160;failure</p>
<p style="position:absolute;top:423px;left:447px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:424px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:423px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:444px;left:317px;white-space:nowrap" class="ft1310">+Lung&#160;infiltration</p>
<p style="position:absolute;top:444px;left:432px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:445px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:444px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:464px;left:317px;white-space:nowrap" class="ft1310">+Acute&#160;pulmonary&#160;oedema</p>
<p style="position:absolute;top:464px;left:493px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:465px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:464px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:484px;left:317px;white-space:nowrap" class="ft1310">+Acute&#160;respiratory&#160;distress&#160;syndrome</p>
<p style="position:absolute;top:484px;left:560px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:485px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:484px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:503px;left:317px;white-space:nowrap" class="ft1310">+Bronchospasm</p>
<p style="position:absolute;top:503px;left:421px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:505px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:503px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:523px;left:317px;white-space:nowrap" class="ft1310">+Hypoxia</p>
<p style="position:absolute;top:523px;left:380px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:524px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:523px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:543px;left:317px;white-space:nowrap" class="ft1310">+Oxygen&#160;saturation&#160;decreased</p>
<p style="position:absolute;top:543px;left:513px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:544px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:543px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:564px;left:317px;white-space:nowrap" class="ft131">Laryngeal&#160;oedema</p>
<p style="position:absolute;top:562px;left:439px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:564px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:562px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:584px;left:317px;white-space:nowrap" class="ft131">Orthopnoea</p>
<p style="position:absolute;top:582px;left:395px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:584px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:582px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:603px;left:317px;white-space:nowrap" class="ft131">Pulmonary&#160;oedema</p>
<p style="position:absolute;top:602px;left:444px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:603px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:602px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:623px;left:317px;white-space:nowrap" class="ft131">Interstitial&#160;lung&#160;disease</p>
<p style="position:absolute;top:622px;left:469px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:623px;left:617px;white-space:nowrap" class="ft131">Not&#160;known</p>
<p style="position:absolute;top:622px;left:691px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:643px;left:123px;white-space:nowrap" class="ft131">Gastrointestinal&#160;disorders</p>
<p style="position:absolute;top:641px;left:291px;white-space:nowrap" class="ft1313">&#160;&#160;Diarrhoea&#160;</p>
<p style="position:absolute;top:643px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:641px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:663px;left:317px;white-space:nowrap" class="ft131">Vomiting</p>
<p style="position:absolute;top:661px;left:380px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:663px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:661px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:682px;left:317px;white-space:nowrap" class="ft131">Nausea</p>
<p style="position:absolute;top:681px;left:366px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:682px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:681px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:701px;left:317px;white-space:nowrap" class="ft1310">1&#160;Lip&#160;swelling</p>
<p style="position:absolute;top:701px;left:408px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:702px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:701px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:723px;left:317px;white-space:nowrap" class="ft131">Abdominal&#160;pain</p>
<p style="position:absolute;top:721px;left:423px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:723px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:721px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:745px;left:317px;white-space:nowrap" class="ft131">Dyspepsia</p>
<p style="position:absolute;top:744px;left:386px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:745px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:744px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:765px;left:317px;white-space:nowrap" class="ft131">Constipation</p>
<p style="position:absolute;top:764px;left:402px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:765px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:764px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:785px;left:317px;white-space:nowrap" class="ft131">Stomatitis</p>
<p style="position:absolute;top:783px;left:384px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:785px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:783px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:805px;left:317px;white-space:nowrap" class="ft131">Haemorrhoids</p>
<p style="position:absolute;top:803px;left:412px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:805px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:803px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:824px;left:317px;white-space:nowrap" class="ft131">Dry&#160;mouth</p>
<p style="position:absolute;top:823px;left:389px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:824px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:823px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:844px;left:123px;white-space:nowrap" class="ft131">Hepatobiliary&#160;disorders</p>
<p style="position:absolute;top:843px;left:277px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:844px;left:317px;white-space:nowrap" class="ft131">Hepatocellular&#160;injury</p>
<p style="position:absolute;top:843px;left:457px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:844px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:843px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:867px;left:317px;white-space:nowrap" class="ft131">Hepatitis</p>
<p style="position:absolute;top:865px;left:377px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:867px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:865px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:889px;left:317px;white-space:nowrap" class="ft131">Liver&#160;tenderness</p>
<p style="position:absolute;top:888px;left:426px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:889px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:888px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:909px;left:317px;white-space:nowrap" class="ft131">Jaundice</p>
<p style="position:absolute;top:908px;left:375px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:909px;left:617px;white-space:nowrap" class="ft131">Rare</p>
<p style="position:absolute;top:908px;left:648px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:929px;left:123px;white-space:nowrap" class="ft131">Skin&#160;and&#160;subcutaneous&#160;</p>
<p style="position:absolute;top:948px;left:123px;white-space:nowrap" class="ft131">tissue&#160;disorders</p>
<p style="position:absolute;top:947px;left:224px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:929px;left:317px;white-space:nowrap" class="ft131">Erythema</p>
<p style="position:absolute;top:928px;left:381px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:929px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:928px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:949px;left:317px;white-space:nowrap" class="ft131">Rash</p>
<p style="position:absolute;top:947px;left:350px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:949px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:947px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:967px;left:317px;white-space:nowrap" class="ft1310">1&#160;Swelling&#160;face</p>
<p style="position:absolute;top:967px;left:415px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:969px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:967px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:988px;left:317px;white-space:nowrap" class="ft131">Alopecia</p>
<p style="position:absolute;top:987px;left:377px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:988px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:987px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1008px;left:317px;white-space:nowrap" class="ft131">Nail&#160;disorder</p>
<p style="position:absolute;top:1007px;left:403px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1008px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:1007px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1028px;left:317px;white-space:nowrap" class="ft131">Palmar-plantar&#160;erythrodysaesthesia&#160;</p>
<p style="position:absolute;top:1047px;left:317px;white-space:nowrap" class="ft131">syndrome&#160;</p>
<p style="position:absolute;top:1028px;left:617px;white-space:nowrap" class="ft131">Very&#160;common</p>
<p style="position:absolute;top:1026px;left:712px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1067px;left:317px;white-space:nowrap" class="ft131">Acne</p>
<p style="position:absolute;top:1065px;left:352px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1067px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:1065px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1086px;left:317px;white-space:nowrap" class="ft131">Dry&#160;skin</p>
<p style="position:absolute;top:1085px;left:374px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1086px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:1085px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1106px;left:317px;white-space:nowrap" class="ft131">Ecchymosis</p>
<p style="position:absolute;top:1104px;left:397px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1106px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:1104px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1126px;left:317px;white-space:nowrap" class="ft131">Hyperhydrosis</p>
<p style="position:absolute;top:1124px;left:414px;white-space:nowrap" class="ft1313">&#160;</p>
<p style="position:absolute;top:1126px;left:617px;white-space:nowrap" class="ft131">Common</p>
<p style="position:absolute;top:1124px;left:679px;white-space:nowrap" class="ft1313">&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft140">14&#160;</p>
<p style="position:absolute;top:105px;left:123px;white-space:nowrap" class="ft142"><b>System&#160;organ&#160;class</b></p>
<p style="position:absolute;top:103px;left:255px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:105px;left:317px;white-space:nowrap" class="ft142"><b>Adverse&#160;reaction</b></p>
<p style="position:absolute;top:103px;left:436px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:105px;left:617px;white-space:nowrap" class="ft142"><b>Frequency</b></p>
<p style="position:absolute;top:103px;left:692px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:124px;left:317px;white-space:nowrap" class="ft141">Maculopapular&#160;rash</p>
<p style="position:absolute;top:123px;left:448px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:124px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:123px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:144px;left:317px;white-space:nowrap" class="ft141">Pruritus</p>
<p style="position:absolute;top:143px;left:369px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:144px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:143px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:164px;left:317px;white-space:nowrap" class="ft141">Onychoclasis</p>
<p style="position:absolute;top:162px;left:406px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:164px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:162px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:184px;left:317px;white-space:nowrap" class="ft141">Dermatitis</p>
<p style="position:absolute;top:182px;left:387px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:184px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:182px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:203px;left:317px;white-space:nowrap" class="ft141">Urticaria</p>
<p style="position:absolute;top:202px;left:376px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:203px;left:617px;white-space:nowrap" class="ft141">Uncommon</p>
<p style="position:absolute;top:202px;left:695px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:223px;left:317px;white-space:nowrap" class="ft141">Angioedema</p>
<p style="position:absolute;top:222px;left:401px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:223px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:222px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:243px;left:123px;white-space:nowrap" class="ft141">Musculoskeletal&#160;and&#160;</p>
<p style="position:absolute;top:262px;left:123px;white-space:nowrap" class="ft141">connective&#160;tissue&#160;disorders</p>
<p style="position:absolute;top:260px;left:299px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:243px;left:317px;white-space:nowrap" class="ft141">Arthralgia</p>
<p style="position:absolute;top:241px;left:385px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:243px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:241px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:261px;left:317px;white-space:nowrap" class="ft1410">1Muscle&#160;tightness</p>
<p style="position:absolute;top:261px;left:434px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:263px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:261px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:282px;left:317px;white-space:nowrap" class="ft141">Myalgia</p>
<p style="position:absolute;top:281px;left:372px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:282px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:281px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:302px;left:317px;white-space:nowrap" class="ft141">Arthritis</p>
<p style="position:absolute;top:301px;left:373px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:302px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:301px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:322px;left:317px;white-space:nowrap" class="ft141">Back&#160;pain</p>
<p style="position:absolute;top:320px;left:383px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:322px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:320px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:344px;left:317px;white-space:nowrap" class="ft141">Bone&#160;pain</p>
<p style="position:absolute;top:342px;left:384px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:344px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:342px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:366px;left:317px;white-space:nowrap" class="ft141">Muscle&#160;spasms</p>
<p style="position:absolute;top:365px;left:417px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:366px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:365px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:388px;left:317px;white-space:nowrap" class="ft141">Neck&#160;Pain</p>
<p style="position:absolute;top:387px;left:385px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:388px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:387px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:410px;left:317px;white-space:nowrap" class="ft141">Pain&#160;in&#160;extremity</p>
<p style="position:absolute;top:409px;left:430px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:410px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:409px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:432px;left:123px;white-space:nowrap" class="ft141">Renal&#160;and&#160;urinary&#160;disorders</p>
<p style="position:absolute;top:431px;left:304px;white-space:nowrap" class="ft1413">&#160;&#160;Renal&#160;disorder&#160;</p>
<p style="position:absolute;top:432px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:431px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:456px;left:317px;white-space:nowrap" class="ft141">Glomerulonephritis&#160;membranous</p>
<p style="position:absolute;top:454px;left:535px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:456px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:454px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:476px;left:317px;white-space:nowrap" class="ft141">Glomerulonephropathy</p>
<p style="position:absolute;top:474px;left:471px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:476px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:474px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:498px;left:317px;white-space:nowrap" class="ft141">Renal&#160;failure</p>
<p style="position:absolute;top:496px;left:403px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:498px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:496px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:520px;left:123px;white-space:nowrap" class="ft141">Pregnancy,&#160;puerperium&#160;and&#160;</p>
<p style="position:absolute;top:539px;left:123px;white-space:nowrap" class="ft141">perinatal&#160;conditions</p>
<p style="position:absolute;top:537px;left:253px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:520px;left:317px;white-space:nowrap" class="ft141">Oligohydramnios</p>
<p style="position:absolute;top:518px;left:433px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:520px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:518px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:542px;left:317px;white-space:nowrap" class="ft141">Renal&#160;hypoplasia</p>
<p style="position:absolute;top:540px;left:431px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:542px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:540px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:564px;left:317px;white-space:nowrap" class="ft141">Pulmonary&#160;hypoplasia</p>
<p style="position:absolute;top:563px;left:464px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:564px;left:617px;white-space:nowrap" class="ft141">Not&#160;known</p>
<p style="position:absolute;top:563px;left:691px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:586px;left:123px;white-space:nowrap" class="ft141">Reproductive&#160;system&#160;and&#160;</p>
<p style="position:absolute;top:605px;left:123px;white-space:nowrap" class="ft141">breast&#160;disorders</p>
<p style="position:absolute;top:604px;left:226px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:586px;left:317px;white-space:nowrap" class="ft141">Breast&#160;inflammation/mastitis</p>
<p style="position:absolute;top:585px;left:508px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:586px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:585px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:625px;left:123px;white-space:nowrap" class="ft141">General&#160;disorders&#160;and&#160;</p>
<p style="position:absolute;top:644px;left:123px;white-space:nowrap" class="ft141">administration&#160;site&#160;</p>
<p style="position:absolute;top:663px;left:123px;white-space:nowrap" class="ft141">conditions</p>
<p style="position:absolute;top:661px;left:191px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:625px;left:317px;white-space:nowrap" class="ft141">Asthenia</p>
<p style="position:absolute;top:623px;left:376px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:625px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:623px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:645px;left:317px;white-space:nowrap" class="ft141">Chest&#160;pain</p>
<p style="position:absolute;top:644px;left:387px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:645px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:644px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:665px;left:317px;white-space:nowrap" class="ft141">Chills</p>
<p style="position:absolute;top:664px;left:357px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:665px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:664px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:686px;left:317px;white-space:nowrap" class="ft141">Fatigue</p>
<p style="position:absolute;top:684px;left:367px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:686px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:684px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:706px;left:317px;white-space:nowrap" class="ft141">Influenza-like&#160;symptoms</p>
<p style="position:absolute;top:704px;left:481px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:706px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:704px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:726px;left:317px;white-space:nowrap" class="ft141">Infusion&#160;related&#160;reaction</p>
<p style="position:absolute;top:724px;left:478px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:726px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:724px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:745px;left:317px;white-space:nowrap" class="ft141">Pain</p>
<p style="position:absolute;top:744px;left:347px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:745px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:744px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:765px;left:317px;white-space:nowrap" class="ft141">Pyrexia</p>
<p style="position:absolute;top:763px;left:368px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:765px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:763px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:785px;left:317px;white-space:nowrap" class="ft141">Mucosal&#160;inflammation</p>
<p style="position:absolute;top:783px;left:466px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:785px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:783px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:804px;left:317px;white-space:nowrap" class="ft141">Peripheral&#160;oedema</p>
<p style="position:absolute;top:803px;left:440px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:804px;left:617px;white-space:nowrap" class="ft141">Very&#160;common</p>
<p style="position:absolute;top:803px;left:712px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:824px;left:317px;white-space:nowrap" class="ft141">Malaise</p>
<p style="position:absolute;top:823px;left:369px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:824px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:823px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:844px;left:317px;white-space:nowrap" class="ft141">Oedema</p>
<p style="position:absolute;top:843px;left:372px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:844px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:843px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:865px;left:123px;white-space:nowrap" class="ft141">Injury,&#160;poisoning&#160;and&#160;</p>
<p style="position:absolute;top:885px;left:123px;white-space:nowrap" class="ft141">procedural&#160;complications</p>
<p style="position:absolute;top:883px;left:289px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:865px;left:317px;white-space:nowrap" class="ft141">Contusion</p>
<p style="position:absolute;top:864px;left:385px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:865px;left:617px;white-space:nowrap" class="ft141">Common</p>
<p style="position:absolute;top:864px;left:679px;white-space:nowrap" class="ft1413">&#160;</p>
<p style="position:absolute;top:906px;left:121px;white-space:nowrap" class="ft1410">+</p>
<p style="position:absolute;top:906px;left:127px;white-space:nowrap" class="ft1412">&#160;Denotes&#160;adverse&#160;reactions&#160;that&#160;have&#160;been&#160;reported&#160;in&#160;association&#160;with&#160;a&#160;fatal&#160;outcome.&#160;</p>
<p style="position:absolute;top:923px;left:121px;white-space:nowrap" class="ft1410">1</p>
<p style="position:absolute;top:923px;left:126px;white-space:nowrap" class="ft1412">&#160;Denotes&#160;adverse&#160;reactions&#160;that&#160;are&#160;reported&#160;largely&#160;in&#160;association&#160;with&#160;Infusion-related&#160;reactions.&#160;Specific&#160;</p>
<p style="position:absolute;top:941px;left:121px;white-space:nowrap" class="ft1412">percentages&#160;for&#160;these&#160;are&#160;not&#160;available.&#160;</p>
<p style="position:absolute;top:958px;left:121px;white-space:nowrap" class="ft1412">*&#160;Observed&#160;with&#160;combination&#160;therapy&#160;following&#160;anthracyclines&#160;and&#160;combined&#160;with&#160;taxanes&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft147">Description&#160;of&#160;selected adverse&#160;reactions&#160;<br/><i>&#160;<br/>Cardiac dysfunction&#160;</i></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft141">Congestive heart&#160;failure&#160;(NYHA&#160;Class II&#160;–&#160;IV)&#160;is a&#160;common adverse&#160;reaction associated with&#160;the use&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft141">of&#160;trastuzumab and&#160;has&#160;been associated with a&#160;fatal&#160;outcome&#160;(see&#160;section&#160;4.4).&#160;Signs and&#160;symptoms&#160;of&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft141">cardiac&#160;dysfunction such as&#160;dyspnoea, orthopnoea, increased&#160;cough, pulmonary&#160;oedema, S3 gallop, or&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft150">15&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft151">reduced ventricular&#160;ejection&#160;fraction, have&#160;been observed in patients&#160;treated with&#160;trastuzumab&#160;(see&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft151">section&#160;4.4).&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft151">In 3 pivotal&#160;clinical&#160;trials&#160;of&#160;adjuvant&#160;trastuzumab&#160;given in combination with chemotherapy,&#160;the&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft151">incidence of&#160;grade&#160;3/4 cardiac&#160;dysfunction (specifically&#160;symptomatic&#160;Congestive Heart&#160;Failure)&#160;was&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft151">similar&#160;in patients who were administered chemotherapy alone (i.e.&#160;did&#160;not&#160;receive trastuzumab)&#160;and&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft151">in&#160;patients who were administered trastuzumab sequentially after&#160;a taxane (0.3-0.4&#160;%). The rate&#160;was&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft151">highest&#160;in patients who were administered&#160;trastuzumab&#160;concurrently with a&#160;taxane&#160;(2.0&#160;%). In the&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft151">neoadjuvant&#160;setting, the experience of&#160;concurrent&#160;administration of&#160;trastuzumab and low&#160;dose&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft151">anthracycline&#160;regimen&#160;is&#160;limited&#160;(see section 4.4).&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft151">When&#160;trastuzumab was administered after&#160;completion&#160;of&#160;adjuvant&#160;chemotherapy&#160;NYHA&#160;Class III&#160;-&#160;IV&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft151">heart&#160;failure was observed&#160;in 0.6&#160;%&#160;of&#160;patients&#160;in the one-year&#160;arm&#160;after&#160;a&#160;median&#160;follow-up of&#160;12&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft151">months. In study BO16348,&#160;after&#160;a median follow-up of&#160;8 years&#160;the&#160;incidence&#160;of&#160;severe CHF&#160;(NYHA&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft151">Class III&#160;&amp;&#160;IV)&#160;in&#160;the&#160;trastuzumab 1 year&#160;treatment&#160;arm&#160;was&#160;0.8&#160;%,&#160;and&#160;the&#160;rate of&#160;mild&#160;symptomatic&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft151">and asymptomatic&#160;left&#160;ventricular&#160;dysfunction was 4.6&#160;%.&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft151">Reversibility&#160;of&#160;severe CHF (defined as&#160;a sequence&#160;of&#160;at&#160;least&#160;two consecutive LVEF&#160;values&#160;≥&#160;50&#160;%&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft151">after&#160;the&#160;event)&#160;was evident&#160;for&#160;71.4&#160;%&#160;of&#160;trastuzumab-treated patients. Reversibility of&#160;mild&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft151">symptomatic&#160;and&#160;asymptomatic&#160;left&#160;ventricular&#160;dysfunction was&#160;demonstrated for&#160;79.5&#160;%&#160;of&#160;patients.&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft151">Approximately 17&#160;%&#160;of&#160;cardiac&#160;dysfunction related&#160;events&#160;occurred after&#160;completion of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft151">In the pivotal&#160;metastatic trials of&#160;intravenous&#160;trastuzumab,&#160;the&#160;incidence&#160;of&#160;cardiac&#160;dysfunction varied&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft151">between 9&#160;%&#160;and&#160;12&#160;%&#160;when it&#160;was combined with&#160;paclitaxel&#160;compared with 1&#160;%&#160;–&#160;4&#160;%&#160;for&#160;paclitaxel&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft151">alone. For&#160;monotherapy, the rate was 6&#160;%&#160;–&#160;9&#160;%. The&#160;highest&#160;rate of&#160;cardiac&#160;dysfunction was seen in&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft151">patients receiving&#160;trastuzumab&#160;concurrently with anthracycline/cyclophosphamide (27&#160;%),&#160;and was&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft151">significantly higher&#160;than for&#160;anthracycline/cyclophosphamide&#160;alone (7&#160;%&#160;–&#160;10&#160;%). In a subsequent&#160;trial&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft151">with prospective monitoring of&#160;cardiac&#160;function,&#160;the&#160;incidence&#160;of&#160;symptomatic CHF was&#160;2.2&#160;%&#160;in&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft151">patients receiving&#160;trastuzumab&#160;and docetaxel, compared with 0&#160;%&#160;in&#160;patients&#160;receiving docetaxel&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft151">alone. Most&#160;of&#160;the patients&#160;(79&#160;%)&#160;who developed cardiac&#160;dysfunction&#160;in&#160;these&#160;trials experienced&#160;an&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft151">improvement&#160;after&#160;receiving standard treatment&#160;for&#160;CHF.&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft155">&#160;<br/><i>Infusion reactions,&#160;allergic-like&#160;reactions and hypersensitivity&#160;</i></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft151">It&#160;is estimated that&#160;approximately 40&#160;%&#160;of&#160;patients who are&#160;treated with&#160;trastuzumab will&#160;experience&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft151">some&#160;form&#160;of&#160;infusion-related reaction.&#160;However, the&#160;majority&#160;of&#160;infusion-related&#160;reactions&#160;are&#160;mild&#160;to&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft151">moderate&#160;in intensity&#160;(NCI-CTC&#160;grading system)&#160;and&#160;tend to&#160;occur&#160;earlier&#160;in treatment, i.e. during&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft151">infusions one, two&#160;and&#160;three and&#160;lessen&#160;in frequency&#160;in&#160;subsequent&#160;infusions. Reactions include chills,&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft151">fever, dyspnoea, hypotension, wheezing,&#160;bronchospasm, tachycardia, reduced&#160;oxygen saturation,&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft151">respiratory distress,&#160;rash,&#160;nausea, vomiting and headache (see&#160;section&#160;4.4).&#160;The&#160;rate of&#160;infusion-related&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft151">reactions of&#160;all&#160;grades&#160;varied between studies&#160;depending on the indication,&#160;the&#160;data&#160;collection&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft151">methodology,&#160;and whether&#160;trastuzumab was&#160;given concurrently with&#160;chemotherapy or&#160;as&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft151">monotherapy.&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft151">Severe anaphylactic&#160;reactions requiring immediate additional&#160;intervention can occur&#160;usually during&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft151">either&#160;the&#160;first&#160;or&#160;second&#160;infusion&#160;of&#160;trastuzumab&#160;(see section&#160;4.4)&#160;and have been associated with a&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft151">fatal&#160;outcome.&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft151">Anaphylactoid&#160;reactions&#160;have been observed in&#160;isolated cases.&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft155">&#160;<br/><i>Haematotoxicity&#160;</i></p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft151">Febrile&#160;neutropenia,&#160;leukopenia,&#160;anaemia,&#160;thrombocytopenia&#160;and neutropenia&#160;occurred&#160;very&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft151">commonly. The frequency&#160;of&#160;occurrence of&#160;hypoprothrombinemia&#160;is not&#160;known.&#160;The risk of&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft151">neutropenia&#160;may be slightly&#160;increased when&#160;trastuzumab is administered with docetaxel&#160;following&#160;</p>
<p style="position:absolute;top:1110px;left:106px;white-space:nowrap" class="ft155">anthracycline&#160;therapy.&#160;<br/><i>&#160;</i></p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1614{font-size:17px;font-family:FAEYNI+TimesNewRoman;color:#0000ff;}
	.ft1615{font-size:17px;font-family:FAEYNI+TimesNewRoman;color:#008000;}
-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft160">16&#160;</p>
<p style="position:absolute;top:110px;left:106px;white-space:nowrap" class="ft163"><i>Pulmonary events&#160;</i></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft161">Severe pulmonary&#160;adverse&#160;reactions occur&#160;in&#160;association with&#160;the use&#160;of&#160;trastuzumab&#160;and have been&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft161">associated with&#160;a fatal&#160;outcome. These&#160;include, but&#160;are&#160;not&#160;limited&#160;to, pulmonary&#160;infiltrates,&#160;acute&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft161">respiratory distress&#160;syndrome, pneumonia, pneumonitis, pleural&#160;effusion,&#160;respiratory distress, acute&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft161">pulmonary oedema and respiratory insufficiency&#160;(see&#160;section 4.4).&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft161">Details&#160;of&#160;risk minimisation measures&#160;that&#160;are consistent&#160;with the EU&#160;Risk Management&#160;Plan&#160;are&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft161">presented in (section&#160;4.4)&#160;Warnings and Precautions.&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft161">Immunogenicity&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft161">In the neoadjuvant-adjuvant&#160;EBC&#160;study (BO22227),&#160;at&#160;a median follow-up exceeding 70&#160;months,&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft161">10.1&#160;%&#160;(30/296)&#160;of&#160;patients&#160;treated with&#160;trastuzumab&#160;intravenous developed antibodies&#160;against&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft161">trastuzumab.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft161">Neutralizing anti-trastuzumab antibodies were detected&#160;in&#160;post-baseline&#160;samples&#160;in&#160;2 of&#160;30&#160;patients&#160;in&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft161">the&#160;trastuzumab&#160;intravenous arm.&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft161">The clinical&#160;relevance of&#160;these antibodies&#160;is not&#160;known. The presence&#160;of&#160;anti-trastuzumab antibodies&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft161">had no&#160;impact&#160;on pharmacokinetics, efficacy (determined by pathological&#160;Complete Response&#160;[pCR]&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft161">and event&#160;free&#160;survival&#160;[EFS])&#160;and safety determined by occurrence&#160;of&#160;administration related reactions&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft161">(ARRs)&#160;of&#160;trastuzumab&#160;intravenous.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft161">There&#160;are&#160;no immunogenicity data available&#160;for&#160;trastuzumab&#160;in gastric cancer.&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft161">Switching&#160;treatment&#160;between trastuzumab&#160;intravenous&#160;and trastuzumab subcutaneous formulation and&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft161">vice&#160;versa.&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft161">Study&#160;MO22982&#160;investigated switching between the&#160;trastuzumab&#160;intravenous&#160;and&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft161">subcutaneous&#160;formulation&#160;with a&#160;primary&#160;objective&#160;to&#160;evaluate patient&#160;preference&#160;for&#160;either&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft161">intravenous&#160;or&#160;the&#160;subcutaneous&#160;route of&#160;trastuzumab&#160;administration. In&#160;this trial,&#160;2 cohorts&#160;(one using&#160;</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft161">subcutaneous&#160;formulation&#160;in vial&#160;and&#160;one using subcutaneous&#160;formulation in&#160;administration system)&#160;</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft161">were&#160;investigated using&#160;a 2-arm, cross-over&#160;design with 488 patients being&#160;randomized&#160;to one of&#160;two&#160;</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft161">different&#160;three-weekly Trastuzumab&#160;treatment&#160;sequences&#160;(intravenous&#160;[Cycles 1-4]→ subcutaneous&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft161">[Cycles&#160;5-8],&#160;or&#160;subcutaneous [Cycles 1-4]→&#160;intravenous [Cycles 5-8]).&#160;Patients were either&#160;naïve&#160;to&#160;</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft161">trastuzumab&#160;intravenous&#160;treatment&#160;(20.3&#160;%)&#160;or&#160;pre-exposed&#160;to trastuzumab intravenous (79.7&#160;%). For&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft161">the sequence&#160;intravenous&#160;→&#160;subcutaneous&#160;(subcutaneous&#160;vial&#160;and&#160;subcutaneous&#160;formulation&#160;in&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft161">administration&#160;system&#160;cohorts&#160;combined),&#160;adverse event&#160;rates&#160;(all&#160;grades)&#160;were described&#160;pre-</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft161">switching (Cycles 1-4)&#160;and&#160;post-switching&#160;(Cycles&#160;5-8)&#160;as&#160;53.8&#160;%&#160;vs. 56.4&#160;%,&#160;respectively;&#160;for&#160;the&#160;</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft161">sequence&#160;subcutaneous&#160;→&#160;intravenous (subcutaneous&#160;vial&#160;and subcutaneous&#160;formulation&#160;in&#160;</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft161">administration&#160;system&#160;cohorts&#160;combined),&#160;adverse event&#160;rates (all&#160;grades)&#160;were described&#160;pre-&#160;and&#160;</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft161">post-switching&#160;as&#160;65.4&#160;%&#160;vs. 48.7&#160;%, respectively.&#160;</p>
<p style="position:absolute;top:890px;left:106px;white-space:nowrap" class="ft161">Pre-switching rates (Cycles&#160;1-4)&#160;for&#160;serious adverse&#160;events,&#160;grade 3&#160;adverse&#160;events and&#160;treatment&#160;</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft161">discontinuations due to adverse&#160;events were&#160;low&#160;(&lt;&#160;5&#160;%)&#160;and similar&#160;to post-switching&#160;rates&#160;(Cycles&#160;5-</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft161">8). No grade&#160;4 or&#160;grade 5 adverse events were reported.&#160;</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft161">Reporting&#160;of&#160;suspected adverse&#160;reactions&#160;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft161">Reporting&#160;suspected adverse reactions after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important. It&#160;</p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft161">allows continued&#160;monitoring of&#160;the benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft161">professionals&#160;are&#160;asked to report&#160;any&#160;suspected adverse reactions via&#160;the national&#160;reporting system&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft161">listed&#160;i<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">n&#160;Appendix V.</a>&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft170">17&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft172"><b>4.9&#160;</b></p>
<p style="position:absolute;top:104px;left:160px;white-space:nowrap" class="ft172"><b>Overdose&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft171">There&#160;is no experience with&#160;overdose&#160;in human clinical&#160;trials. Single doses&#160;of&#160;trastuzumab alone&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft171">greater&#160;than 10&#160;mg/kg have&#160;not&#160;been administered in&#160;the clinical&#160;trials;&#160;a&#160;maintenance&#160;dose&#160;of&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft171">10&#160;mg/kg q3w&#160;following a&#160;loading&#160;dose of&#160;8&#160;mg/kg&#160;has&#160;been studied&#160;in a&#160;clinical&#160;trial&#160;with&#160;metastatic&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft171">gastric cancer&#160;patients. Doses&#160;up&#160;to this&#160;level&#160;were well&#160;tolerated.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft172"><b>5.&#160;</b></p>
<p style="position:absolute;top:256px;left:160px;white-space:nowrap" class="ft172"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft172"><b>5.1&#160;&#160;</b></p>
<p style="position:absolute;top:294px;left:160px;white-space:nowrap" class="ft172"><b>Pharmacodynamic properties&#160;</b></p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft171">Pharmacotherapeutic group:&#160;Antineoplastic agents,&#160;monoclonal&#160;antibodies, ATC&#160;code:&#160;L01XC03&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft171">Ogivri&#160;is a&#160;biosimilar&#160;medicinal&#160;product. Detailed information is available on&#160;the&#160;website of&#160;the&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft171">European Medicines&#160;Agenc<a href="http://www.ema.europa.eu/">y&#160;http://www.ema.europa.eu.</a>&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft172"><b>&#160;</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft171">Trastuzumab&#160;is&#160;a recombinant&#160;humanised IgG1 monoclonal&#160;antibody against&#160;the&#160;human&#160;epidermal&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft171">growth&#160;factor&#160;receptor&#160;2 (HER2). Overexpression&#160;of&#160;HER2 is observed&#160;in 20&#160;%-30&#160;%&#160;of&#160;primary&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft171">breast&#160;cancers.&#160;Studies of&#160;HER2-positivity&#160;rates&#160;in gastric&#160;cancer&#160;(GC)&#160;using&#160;immunohistochemistry&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft171">(IHC)&#160;and fluorescence&#160;<i>in&#160;situ&#160;</i>hybridization&#160;(FISH)&#160;or&#160;chromogenic&#160;<i>in&#160;situ&#160;</i>hybridization&#160;(CISH)&#160;have&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft171">shown that&#160;there&#160;is a&#160;broad&#160;variation of&#160;HER2-positivity ranging&#160;from&#160;6.8&#160;%&#160;to 34.0&#160;%&#160;for&#160;IHC&#160;and&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft171">7.1&#160;%&#160;to 42.6&#160;%&#160;for&#160;FISH. Studies&#160;indicate&#160;that&#160;breast&#160;cancer&#160;patients whose tumours overexpress&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft171">HER2 have&#160;a&#160;shortened disease-free&#160;survival&#160;compared to patients whose tumours do not&#160;overexpress&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft171">HER2. The extracellular&#160;domain of&#160;the&#160;receptor&#160;(ECD,&#160;p105)&#160;can be shed into&#160;the&#160;blood&#160;stream&#160;and&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft171">measured in serum&#160;samples.</p>
<p style="position:absolute;top:579px;left:292px;white-space:nowrap" class="ft172"><b>&#160;</b></p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft172"><b>&#160;</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft171">Mechanism&#160;of&#160;action&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft171">Trastuzumab&#160;binds with high affinity and&#160;specificity to sub-domain IV, a&#160;juxta-membrane&#160;region&#160;of&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft171">HER2’s extracellular&#160;domain. Binding&#160;of&#160;trastuzumab&#160;to HER2 inhibits ligand-independent&#160;HER2&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft171">signalling&#160;and prevents the&#160;proteolytic cleavage&#160;of&#160;its extracellular&#160;domain, an&#160;activation&#160;mechanism&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft171">of&#160;HER2. As a&#160;result, trastuzumab has been shown,&#160;in&#160;both&#160;<i>in vitro&#160;</i>assays and&#160;in&#160;animals,&#160;to inhibit&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft171">the proliferation of&#160;human&#160;tumour&#160;cells that&#160;overexpress HER2. Additionally,&#160;trastuzumab is a&#160;potent&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft171">mediator&#160;of&#160;antibody-dependent&#160;cell-mediated&#160;cytotoxicity (ADCC).&#160;<i>In vitro</i>, trastuzumab-mediated&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft171">ADCC&#160;has&#160;been&#160;shown&#160;to be preferentially exerted on&#160;HER2 overexpressing cancer&#160;cells compared&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft171">with cancer&#160;cells&#160;that&#160;do not&#160;overexpress HER2.&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft171">Detection of&#160;HER2&#160;overexpression&#160;or&#160;HER2 gene&#160;amplification&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft175">&#160;<br/><i>Detection of&#160;HER2 overexpression or HER2 gene amplification&#160;in breast&#160;cancer&#160;</i></p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft171">Trastuzumab&#160;should only be used&#160;in patients whose&#160;tumours have HER2 overexpression&#160;or&#160;HER2&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft171">gene&#160;amplification&#160;as&#160;determined by&#160;an accurate and&#160;validated assay.&#160;HER2 overexpression should be&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft171">detected using an immunohistochemistry&#160;(IHC)-based&#160;assessment&#160;of&#160;fixed&#160;tumour&#160;blocks (see&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft171">section&#160;4.4). HER2&#160;gene&#160;amplification should be detected&#160;using fluorescence&#160;<i>in&#160;situ&#160;</i>hybridisation&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft171">(FISH)&#160;or&#160;chromogenic&#160;<i>in&#160;situ&#160;</i>hybridisation (CISH)&#160;of&#160;fixed tumour&#160;blocks. Patients are eligible&#160;for&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft171">Ogivri&#160;treatment&#160;if&#160;they show&#160;strong HER2 overexpression&#160;as&#160;described by&#160;a 3+ score&#160;by IHC&#160;or&#160;a&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft171">positive FISH&#160;or&#160;CISH&#160;result.&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft171">To ensure accurate and reproducible&#160;results,&#160;the&#160;testing&#160;must&#160;be&#160;performed in&#160;a specialised&#160;laboratory,&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft171">which can ensure validation of&#160;the&#160;testing procedures.&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft180">18&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft181">The recommended&#160;scoring&#160;system&#160;to&#160;evaluate the IHC&#160;staining patterns is as&#160;stated&#160;in Table 2:&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft181">Table&#160;2 Recommended&#160;scoring&#160;system&#160;to&#160;evaluate&#160;the&#160;IHC&#160;staining&#160;patterns in&#160;breast&#160;cancer&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:181px;left:112px;white-space:nowrap" class="ft182"><b>Score</b></p>
<p style="position:absolute;top:179px;left:151px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:181px;left:192px;white-space:nowrap" class="ft182"><b>Staining&#160;pattern</b></p>
<p style="position:absolute;top:179px;left:306px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:181px;left:573px;white-space:nowrap" class="ft182"><b>HER2&#160;overexpression&#160;</b></p>
<p style="position:absolute;top:200px;left:573px;white-space:nowrap" class="ft182"><b>assessment</b></p>
<p style="position:absolute;top:199px;left:650px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:219px;left:112px;white-space:nowrap" class="ft181">0</p>
<p style="position:absolute;top:218px;left:120px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:220px;left:192px;white-space:nowrap" class="ft181">No&#160;staining&#160;is&#160;observed&#160;or&#160;membrane&#160;staining&#160;is&#160;</p>
<p style="position:absolute;top:238px;left:192px;white-space:nowrap" class="ft181">observed&#160;in&#160;&lt;&#160;10&#160;%&#160;of&#160;the&#160;tumour&#160;cells</p>
<p style="position:absolute;top:237px;left:446px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:219px;left:573px;white-space:nowrap" class="ft181">Negative</p>
<p style="position:absolute;top:218px;left:632px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:258px;left:112px;white-space:nowrap" class="ft181">1+</p>
<p style="position:absolute;top:257px;left:130px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:258px;left:192px;white-space:nowrap" class="ft181">A&#160;faint/barely&#160;perceptible&#160;membrane&#160;staining&#160;is&#160;</p>
<p style="position:absolute;top:277px;left:192px;white-space:nowrap" class="ft181">detected&#160;in&#160;&gt;&#160;10&#160;%&#160;of&#160;the&#160;tumour&#160;cells.&#160;The&#160;cells&#160;are&#160;</p>
<p style="position:absolute;top:296px;left:192px;white-space:nowrap" class="ft181">only&#160;stained&#160;in&#160;part&#160;of&#160;their&#160;membrane.</p>
<p style="position:absolute;top:295px;left:447px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:258px;left:573px;white-space:nowrap" class="ft181">Negative</p>
<p style="position:absolute;top:257px;left:632px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:316px;left:112px;white-space:nowrap" class="ft181">2+</p>
<p style="position:absolute;top:314px;left:130px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:316px;left:192px;white-space:nowrap" class="ft181">A&#160;weak&#160;to&#160;moderate&#160;complete&#160;membrane&#160;staining&#160;is&#160;</p>
<p style="position:absolute;top:334px;left:192px;white-space:nowrap" class="ft181">detected&#160;in&#160;&gt;&#160;10&#160;%&#160;of&#160;the&#160;tumour&#160;cells.</p>
<p style="position:absolute;top:333px;left:446px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:316px;left:573px;white-space:nowrap" class="ft181">Equivocal</p>
<p style="position:absolute;top:314px;left:639px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:354px;left:112px;white-space:nowrap" class="ft181">3+</p>
<p style="position:absolute;top:353px;left:130px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:354px;left:192px;white-space:nowrap" class="ft181">Strong&#160;complete&#160;membrane&#160;staining&#160;is&#160;detected&#160;in&#160;</p>
<p style="position:absolute;top:373px;left:192px;white-space:nowrap" class="ft181">&gt; 10&#160;%&#160;of&#160;the&#160;tumour&#160;cells.</p>
<p style="position:absolute;top:372px;left:371px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:354px;left:573px;white-space:nowrap" class="ft181">Positive</p>
<p style="position:absolute;top:353px;left:626px;white-space:nowrap" class="ft1813">&#160;</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft181">In general, FISH&#160;is&#160;considered positive if&#160;the ratio of&#160;the HER2 gene&#160;copy&#160;number&#160;per&#160;tumour&#160;cell&#160;to&#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft181">the chromosome 17 copy number&#160;is greater&#160;than or&#160;equal&#160;to 2, or&#160;if&#160;there are&#160;more than 4 copies of&#160;the&#160;</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft181">HER2 gene&#160;per&#160;tumour&#160;cell&#160;if&#160;no&#160;chromosome 17&#160;control&#160;is used.&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft181">In general, CISH&#160;is&#160;considered positive if&#160;there are&#160;more than 5 copies of&#160;the&#160;HER2 gene&#160;per&#160;nucleus&#160;</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft181">in greater&#160;than 50&#160;%&#160;of&#160;tumour&#160;cells.&#160;</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft181">For full&#160;instructions on&#160;assay performance&#160;and interpretation please refer&#160;to the package&#160;inserts of&#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft181">validated FISH&#160;and CISH&#160;assays. Official&#160;recommendations on HER2&#160;testing may&#160;also&#160;apply.&#160;</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft181">For any&#160;other&#160;method&#160;that&#160;may be used for&#160;the assessment&#160;of&#160;HER2&#160;protein or&#160;gene&#160;expression, the&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft181">analyses&#160;should only&#160;be performed&#160;by laboratories&#160;that&#160;provide adequate&#160;state-of-the-art&#160;performance&#160;</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft181">of&#160;validated&#160;methods. Such&#160;methods&#160;must&#160;clearly be&#160;precise and accurate&#160;enough to demonstrate&#160;</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft181">overexpression of&#160;HER2 and must&#160;be able&#160;to distinguish between&#160;moderate (congruent&#160;with&#160;2+)&#160;and&#160;</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft186">strong (congruent&#160;with 3+)&#160;overexpression of&#160;HER2.&#160;<br/><i>&#160;<br/>Detection of&#160;HER2 over expression&#160;or HER2 gene amplification&#160;in gastric&#160;cancer&#160;</i></p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft181">Only an&#160;accurate and validated assay should be used to&#160;detect&#160;HER2 over&#160;expression or&#160;HER2 gene&#160;</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft181">amplification.&#160;IHC&#160;is&#160;recommended&#160;as&#160;the&#160;first&#160;testing modality&#160;and&#160;in cases&#160;where HER2 gene&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft181">amplification&#160;status is&#160;also&#160;required, either&#160;a&#160;silver-enhanced&#160;<i>in situ&#160;</i>hybridization&#160;(SISH)&#160;or&#160;a FISH&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft181">technique must&#160;be applied.&#160;SISH&#160;technology&#160;is however, recommended&#160;to&#160;allow&#160;for&#160;the parallel&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft181">evaluation of&#160;tumour&#160;histology and&#160;morphology. To&#160;ensure&#160;validation of&#160;testing procedures&#160;and&#160;the&#160;</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft181">generation of&#160;accurate and&#160;reproducible&#160;results, HER2&#160;testing&#160;must&#160;be&#160;performed in a laboratory&#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft181">staffed by&#160;trained personnel. Full&#160;instructions on assay&#160;performance&#160;and results&#160;interpretation should&#160;</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft181">be taken&#160;from&#160;the product&#160;information leaflet&#160;provided&#160;with&#160;the HER2&#160;testing assays used.&#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft181">In the ToGA&#160;(BO18255)&#160;trial, patients whose tumours&#160;were either&#160;IHC3+ or&#160;FISH&#160;positive were&#160;</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft181">defined&#160;as&#160;HER2 positive and thus included&#160;in the trial. Based on the clinical&#160;trial&#160;results, the&#160;</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft181">beneficial&#160;effects&#160;were&#160;limited&#160;to patients with the highest&#160;level&#160;of&#160;HER2 protein overexpression,&#160;</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft181">defined by a 3+&#160;score by IHC, or&#160;a 2+&#160;score by&#160;IHC&#160;and a&#160;positive FISH&#160;result.&#160;</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft181">In a method&#160;comparison study (study D008548)&#160;a high&#160;degree of&#160;concordance&#160;(&gt;95 %)&#160;was&#160;observed&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft181">for&#160;SISH&#160;and FISH&#160;techniques&#160;for&#160;the detection of&#160;HER2 gene&#160;amplification&#160;in gastric&#160;cancer&#160;patients.&#160;</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft181">HER2 over&#160;expression should be&#160;detected using an&#160;immunohistochemistry&#160;(IHC)-based&#160;assessment&#160;of&#160;</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft181">fixed tumour&#160;blocks;&#160;HER2&#160;gene&#160;amplification&#160;should&#160;be detected using&#160;<i>in&#160;situ&#160;</i>hybridisation using&#160;</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft181">either&#160;SISH&#160;or&#160;FISH&#160;on fixed tumour&#160;blocks.&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft190">19&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft191">The recommended&#160;scoring&#160;system&#160;to&#160;evaluate the IHC&#160;staining&#160;patterns is as&#160;stated&#160;in Table 3:&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft191">Table&#160;3 Recommended&#160;scoring&#160;system&#160;to&#160;evaluate&#160;the&#160;IHC&#160;staining&#160;patterns in&#160;gastric&#160;cancer&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:182px;left:108px;white-space:nowrap" class="ft192"><b>Score</b>&#160;</p>
<p style="position:absolute;top:182px;left:194px;white-space:nowrap" class="ft192"><b>Surgical&#160;specimen&#160;-&#160;staining&#160;</b></p>
<p style="position:absolute;top:201px;left:194px;white-space:nowrap" class="ft192"><b>pattern</b>&#160;</p>
<p style="position:absolute;top:182px;left:410px;white-space:nowrap" class="ft192"><b>Biopsy specimen&#160;–</b>&#160;</p>
<p style="position:absolute;top:201px;left:410px;white-space:nowrap" class="ft192"><b>staining pattern</b>&#160;</p>
<p style="position:absolute;top:182px;left:640px;white-space:nowrap" class="ft192"><b>HER2&#160;</b></p>
<p style="position:absolute;top:201px;left:640px;white-space:nowrap" class="ft192"><b>overexpression&#160;</b></p>
<p style="position:absolute;top:220px;left:640px;white-space:nowrap" class="ft192"><b>assessment</b>&#160;</p>
<p style="position:absolute;top:240px;left:108px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:259px;left:108px;white-space:nowrap" class="ft191">0&#160;</p>
<p style="position:absolute;top:240px;left:194px;white-space:nowrap" class="ft191">No reactivity or&#160;membranous&#160;</p>
<p style="position:absolute;top:259px;left:194px;white-space:nowrap" class="ft191">reactivity in &lt;&#160;10&#160;%&#160;of&#160;tumour&#160;</p>
<p style="position:absolute;top:278px;left:194px;white-space:nowrap" class="ft191">cells&#160;</p>
<p style="position:absolute;top:240px;left:410px;white-space:nowrap" class="ft191">No reactivity or&#160;membranous&#160;</p>
<p style="position:absolute;top:259px;left:410px;white-space:nowrap" class="ft191">reactivity in any&#160;tumour&#160;cell&#160;</p>
<p style="position:absolute;top:240px;left:640px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:259px;left:640px;white-space:nowrap" class="ft191">Negative&#160;</p>
<p style="position:absolute;top:299px;left:108px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:318px;left:108px;white-space:nowrap" class="ft191">1+&#160;</p>
<p style="position:absolute;top:299px;left:194px;white-space:nowrap" class="ft191">Faint&#160;⁄&#160;barely&#160;perceptible&#160;</p>
<p style="position:absolute;top:318px;left:194px;white-space:nowrap" class="ft191">membranous&#160;reactivity&#160;in&#160;</p>
<p style="position:absolute;top:337px;left:194px;white-space:nowrap" class="ft191">≥&#160;10&#160;%&#160;of&#160;tumour&#160;cells;&#160;cells&#160;</p>
<p style="position:absolute;top:356px;left:194px;white-space:nowrap" class="ft191">are&#160;reactive only&#160;in part&#160;of&#160;their&#160;</p>
<p style="position:absolute;top:374px;left:194px;white-space:nowrap" class="ft191">membrane&#160;</p>
<p style="position:absolute;top:299px;left:410px;white-space:nowrap" class="ft191">Tumour&#160;cell&#160;cluster&#160;with&#160;a faint&#160;⁄&#160;</p>
<p style="position:absolute;top:318px;left:410px;white-space:nowrap" class="ft191">barely perceptible&#160;membranous&#160;</p>
<p style="position:absolute;top:337px;left:410px;white-space:nowrap" class="ft191">reactivity irrespective&#160;of&#160;</p>
<p style="position:absolute;top:356px;left:410px;white-space:nowrap" class="ft191">percentage&#160;of&#160;tumour&#160;cells&#160;stained&#160;</p>
<p style="position:absolute;top:299px;left:640px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:318px;left:640px;white-space:nowrap" class="ft191">Negative&#160;</p>
<p style="position:absolute;top:395px;left:108px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft191">2+&#160;</p>
<p style="position:absolute;top:395px;left:194px;white-space:nowrap" class="ft191">Weak&#160;to&#160;moderate complete,&#160;</p>
<p style="position:absolute;top:414px;left:194px;white-space:nowrap" class="ft191">basolateral&#160;or&#160;lateral&#160;</p>
<p style="position:absolute;top:433px;left:194px;white-space:nowrap" class="ft191">membranous&#160;reactivity&#160;in&#160;</p>
<p style="position:absolute;top:452px;left:194px;white-space:nowrap" class="ft191">≥&#160;10&#160;%&#160;of&#160;tumour&#160;cells&#160;</p>
<p style="position:absolute;top:395px;left:410px;white-space:nowrap" class="ft191">Tumour&#160;cell&#160;cluster&#160;with&#160;a&#160;weak&#160;</p>
<p style="position:absolute;top:414px;left:410px;white-space:nowrap" class="ft191">to moderate complete, basolateral&#160;</p>
<p style="position:absolute;top:433px;left:410px;white-space:nowrap" class="ft191">or&#160;lateral&#160;membranous&#160;reactivity&#160;</p>
<p style="position:absolute;top:452px;left:410px;white-space:nowrap" class="ft191">irrespective&#160;of&#160;percentage&#160;of&#160;</p>
<p style="position:absolute;top:471px;left:410px;white-space:nowrap" class="ft191">tumour&#160;cells&#160;stained&#160;</p>
<p style="position:absolute;top:395px;left:640px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:414px;left:640px;white-space:nowrap" class="ft191">Equivocal&#160;</p>
<p style="position:absolute;top:510px;left:108px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:529px;left:108px;white-space:nowrap" class="ft191">3+&#160;</p>
<p style="position:absolute;top:510px;left:194px;white-space:nowrap" class="ft191">Strong complete, basolateral&#160;or&#160;</p>
<p style="position:absolute;top:529px;left:194px;white-space:nowrap" class="ft191">lateral&#160;membranous reactivity in&#160;</p>
<p style="position:absolute;top:548px;left:194px;white-space:nowrap" class="ft191">≥&#160;10&#160;%&#160;of&#160;tumour&#160;cells&#160;</p>
<p style="position:absolute;top:510px;left:410px;white-space:nowrap" class="ft191">Tumour&#160;cell&#160;cluster&#160;with&#160;a&#160;strong&#160;</p>
<p style="position:absolute;top:529px;left:410px;white-space:nowrap" class="ft191">complete, basolateral&#160;or&#160;lateral&#160;</p>
<p style="position:absolute;top:548px;left:410px;white-space:nowrap" class="ft191">membranous&#160;reactivity&#160;</p>
<p style="position:absolute;top:567px;left:410px;white-space:nowrap" class="ft191">irrespective&#160;of&#160;percentage&#160;of&#160;</p>
<p style="position:absolute;top:586px;left:410px;white-space:nowrap" class="ft191">tumour&#160;cells&#160;stained&#160;</p>
<p style="position:absolute;top:510px;left:640px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:529px;left:640px;white-space:nowrap" class="ft191">Positive&#160;</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft191">In general, SISH&#160;or&#160;FISH&#160;is&#160;considered positive if&#160;the&#160;ratio of&#160;the HER2 gene&#160;copy&#160;number&#160;per&#160;tumour&#160;</p>
<p style="position:absolute;top:645px;left:106px;white-space:nowrap" class="ft191">cell&#160;to&#160;the chromosome 17&#160;copy number&#160;is greater&#160;than&#160;or&#160;equal&#160;to 2.&#160;</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft197">Clinical&#160;efficacy and&#160;safety&#160;<br/><i>&#160;<br/>Metastatic breast&#160;cancer&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:759px;left:106px;white-space:nowrap" class="ft191">Trastuzumab&#160;has&#160;been&#160;used&#160;in clinical&#160;trials as monotherapy&#160;for&#160;patients with MBC&#160;who have&#160;tumours&#160;</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft191">that&#160;overexpress HER2 and&#160;who have&#160;failed one&#160;or&#160;more chemotherapy regimens&#160;for&#160;their&#160;metastatic&#160;</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft191">disease&#160;(trastuzumab alone).&#160;</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft191">Trastuzumab&#160;has&#160;also been&#160;used&#160;in combination with paclitaxel&#160;or&#160;docetaxel&#160;for&#160;the treatment&#160;of&#160;</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft191">patients who have&#160;not&#160;received chemotherapy&#160;for&#160;their&#160;metastatic&#160;disease. Patients&#160;who had previously&#160;</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft191">received anthracycline-based adjuvant&#160;chemotherapy were&#160;treated with paclitaxel&#160;(175&#160;mg/m2&#160;infused&#160;</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft191">over&#160;3&#160;hours)&#160;with&#160;or&#160;without&#160;trastuzumab. In the pivotal&#160;trial&#160;of&#160;docetaxel&#160;(100&#160;mg/m2&#160;infused&#160;over&#160;</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft191">1&#160;hour)&#160;with or&#160;without&#160;trastuzumab,&#160;60&#160;%&#160;of&#160;the&#160;patients had received&#160;prior&#160;anthracycline-based&#160;</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft191">adjuvant&#160;chemotherapy. Patients were treated with trastuzumab until&#160;progression of&#160;disease.&#160;</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft191">The efficacy&#160;of&#160;trastuzumab in combination with paclitaxel&#160;in patients who did not&#160;receive prior&#160;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft191">adjuvant&#160;anthracyclines&#160;has&#160;not&#160;been studied. However, trastuzumab plus&#160;docetaxel&#160;was&#160;efficacious&#160;in&#160;</p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft191">patients whether&#160;or&#160;not&#160;they&#160;had received&#160;prior&#160;adjuvant&#160;anthracyclines.&#160;</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft191">The test&#160;method&#160;for&#160;HER2&#160;overexpression used&#160;to determine&#160;eligibility of&#160;patients&#160;in the pivotal&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft191">trastuzumab&#160;monotherapy&#160;and trastuzumab&#160;plus paclitaxel&#160;clinical&#160;trials employed&#160;</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft191">immunohistochemical&#160;staining for&#160;HER2 of&#160;fixed&#160;material&#160;from&#160;breast&#160;tumours using the&#160;murine&#160;</p>
<p style="position:absolute;top:1100px;left:106px;white-space:nowrap" class="ft191">monoclonal&#160;antibodies&#160;CB11 and 4D5. These tissues&#160;were fixed in&#160;formalin or&#160;Bouin’s fixative. This&#160;</p>
<p style="position:absolute;top:1119px;left:106px;white-space:nowrap" class="ft191">investigative clinical&#160;trial&#160;assay performed&#160;in&#160;a central&#160;laboratory&#160;utilised&#160;a 0&#160;to 3+&#160;scale. Patients&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2016{font-size:10px;font-family:JOFRRA+TimesNewRoman,Bold;color:#000000;}
	.ft2017{font-size:15px;line-height:22px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft200">20&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft201">classified as staining&#160;2+ or&#160;3+ were&#160;included, while&#160;those&#160;staining 0 or&#160;1+ were excluded. Greater&#160;than&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft201">70&#160;%&#160;of&#160;patients enrolled&#160;exhibited 3+ overexpression.&#160;The data suggest&#160;that&#160;beneficial&#160;effects&#160;were&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft201">greater&#160;among&#160;those patients with&#160;higher&#160;levels of&#160;overexpression of&#160;HER2 (3+).&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft201">The main&#160;test&#160;method used&#160;to determine HER2 positivity in&#160;the pivotal&#160;trial&#160;of&#160;docetaxel, with&#160;or&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft205">without&#160;trastuzumab, was immunohistochemistry. A&#160;minority of&#160;patients was&#160;tested using&#160;fluorescence&#160;<br/><i>in-situ&#160;</i></p>
<p style="position:absolute;top:218px;left:153px;white-space:nowrap" class="ft201">hybridisation&#160;(FISH). In this&#160;trial,&#160;87&#160;%&#160;of&#160;patients entered&#160;had disease&#160;that&#160;was&#160;IHC3+, and&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft201">95&#160;%&#160;of&#160;patients entered had disease&#160;that&#160;was IHC3+ and/or&#160;FISH-positive.&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft205">&#160;<br/><i>Weekly&#160;dosing&#160;in metastatic breast&#160;cancer</i></p>
<p style="position:absolute;top:275px;left:385px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft201">The efficacy&#160;results&#160;from&#160;the monotherapy and&#160;combination therapy studies&#160;are&#160;summarised&#160;in&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft201">Table&#160;4:&#160;&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft201">Table&#160;4 Efficacy&#160;results&#160;from&#160;the&#160;monotherapy&#160;and&#160;combination&#160;therapy&#160;studies&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:389px;left:107px;white-space:nowrap" class="ft202"><b>Parameter</b>&#160;</p>
<p style="position:absolute;top:389px;left:248px;white-space:nowrap" class="ft202"><b>Monotherapy</b>&#160;&#160;<b>Combination&#160;Therapy</b>&#160;</p>
<p style="position:absolute;top:418px;left:107px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:418px;left:251px;white-space:nowrap" class="ft202"><b>Trastuzumab1</b>&#160;</p>
<p style="position:absolute;top:437px;left:301px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:456px;left:274px;white-space:nowrap" class="ft202"><b>N&#160;=&#160;172</b>&#160;</p>
<p style="position:absolute;top:418px;left:360px;white-space:nowrap" class="ft202"><b>Trastuzumab&#160;</b></p>
<p style="position:absolute;top:437px;left:393px;white-space:nowrap" class="ft202"><b>plus&#160;</b></p>
<p style="position:absolute;top:456px;left:371px;white-space:nowrap" class="ft202"><b>paclitaxel2</b>&#160;</p>
<p style="position:absolute;top:475px;left:384px;white-space:nowrap" class="ft202"><b>N&#160;=&#160;68</b>&#160;</p>
<p style="position:absolute;top:418px;left:463px;white-space:nowrap" class="ft202"><b>Paclitaxel2</b>&#160;</p>
<p style="position:absolute;top:437px;left:500px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:456px;left:477px;white-space:nowrap" class="ft202"><b>N&#160;=&#160;77</b>&#160;</p>
<p style="position:absolute;top:418px;left:543px;white-space:nowrap" class="ft202"><b>Trastuzumab&#160;</b></p>
<p style="position:absolute;top:437px;left:576px;white-space:nowrap" class="ft202"><b>plus&#160;</b></p>
<p style="position:absolute;top:456px;left:555px;white-space:nowrap" class="ft202"><b>docetaxel3</b>&#160;</p>
<p style="position:absolute;top:475px;left:568px;white-space:nowrap" class="ft202"><b>N&#160;=&#160;92</b>&#160;</p>
<p style="position:absolute;top:418px;left:647px;white-space:nowrap" class="ft202"><b>Docetaxel3</b>&#160;</p>
<p style="position:absolute;top:437px;left:684px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:456px;left:661px;white-space:nowrap" class="ft202"><b>N&#160;=&#160;94</b>&#160;</p>
<p style="position:absolute;top:495px;left:107px;white-space:nowrap" class="ft202"><b>Response&#160;rate</b>&#160;</p>
<p style="position:absolute;top:514px;left:107px;white-space:nowrap" class="ft202"><b>(95 %CI)</b>&#160;</p>
<p style="position:absolute;top:495px;left:284px;white-space:nowrap" class="ft201">18&#160;%&#160;</p>
<p style="position:absolute;top:514px;left:272px;white-space:nowrap" class="ft201">(13&#160;-&#160;25)&#160;</p>
<p style="position:absolute;top:495px;left:390px;white-space:nowrap" class="ft201">49&#160;%&#160;</p>
<p style="position:absolute;top:514px;left:379px;white-space:nowrap" class="ft201">(36&#160;-&#160;61)&#160;</p>
<p style="position:absolute;top:495px;left:483px;white-space:nowrap" class="ft201">17&#160;%&#160;</p>
<p style="position:absolute;top:514px;left:476px;white-space:nowrap" class="ft201">(9&#160;-&#160;27)&#160;</p>
<p style="position:absolute;top:495px;left:574px;white-space:nowrap" class="ft201">61&#160;%&#160;</p>
<p style="position:absolute;top:514px;left:566px;white-space:nowrap" class="ft201">(50-71)&#160;</p>
<p style="position:absolute;top:495px;left:667px;white-space:nowrap" class="ft201">34&#160;%&#160;</p>
<p style="position:absolute;top:514px;left:659px;white-space:nowrap" class="ft201">(25-45)&#160;</p>
<p style="position:absolute;top:547px;left:107px;white-space:nowrap" class="ft202"><b>Median duration&#160;of&#160;</b></p>
<p style="position:absolute;top:566px;left:107px;white-space:nowrap" class="ft202"><b>response (months)&#160;</b></p>
<p style="position:absolute;top:585px;left:107px;white-space:nowrap" class="ft202"><b>(95 %CI)</b>&#160;</p>
<p style="position:absolute;top:547px;left:291px;white-space:nowrap" class="ft201">9.1&#160;</p>
<p style="position:absolute;top:566px;left:268px;white-space:nowrap" class="ft201">(5.6-10.3)&#160;</p>
<p style="position:absolute;top:547px;left:397px;white-space:nowrap" class="ft201">8.3&#160;</p>
<p style="position:absolute;top:566px;left:379px;white-space:nowrap" class="ft201">(7.3-8.8)&#160;</p>
<p style="position:absolute;top:547px;left:490px;white-space:nowrap" class="ft201">4.6&#160;</p>
<p style="position:absolute;top:566px;left:471px;white-space:nowrap" class="ft201">(3.7-7.4)&#160;</p>
<p style="position:absolute;top:547px;left:576px;white-space:nowrap" class="ft201">11.7&#160;</p>
<p style="position:absolute;top:566px;left:591px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:585px;left:552px;white-space:nowrap" class="ft201">(9.3&#160;–&#160;15.0)&#160;</p>
<p style="position:absolute;top:547px;left:673px;white-space:nowrap" class="ft201">5.7&#160;</p>
<p style="position:absolute;top:566px;left:655px;white-space:nowrap" class="ft201">(4.6-7.6)&#160;</p>
<p style="position:absolute;top:613px;left:107px;white-space:nowrap" class="ft202"><b>Median TTP&#160;</b></p>
<p style="position:absolute;top:632px;left:107px;white-space:nowrap" class="ft202"><b>(months)&#160;(95&#160;%CI)</b>&#160;</p>
<p style="position:absolute;top:614px;left:291px;white-space:nowrap" class="ft201">3.2&#160;</p>
<p style="position:absolute;top:632px;left:272px;white-space:nowrap" class="ft201">(2.6-3.5)&#160;</p>
<p style="position:absolute;top:614px;left:397px;white-space:nowrap" class="ft201">7.1&#160;</p>
<p style="position:absolute;top:632px;left:374px;white-space:nowrap" class="ft201">(6.2-12.0)&#160;</p>
<p style="position:absolute;top:614px;left:490px;white-space:nowrap" class="ft201">3.0&#160;</p>
<p style="position:absolute;top:632px;left:471px;white-space:nowrap" class="ft201">(2.0-4.4)&#160;</p>
<p style="position:absolute;top:614px;left:576px;white-space:nowrap" class="ft201">11.7&#160;</p>
<p style="position:absolute;top:632px;left:558px;white-space:nowrap" class="ft201">(9.2-13.5)&#160;</p>
<p style="position:absolute;top:614px;left:673px;white-space:nowrap" class="ft201">6.1&#160;</p>
<p style="position:absolute;top:632px;left:655px;white-space:nowrap" class="ft201">(5.4-7.2)&#160;</p>
<p style="position:absolute;top:666px;left:107px;white-space:nowrap" class="ft202"><b>Median Survival</b>&#160;</p>
<p style="position:absolute;top:685px;left:107px;white-space:nowrap" class="ft202"><b>(months)&#160;(95&#160;%CI)</b>&#160;</p>
<p style="position:absolute;top:666px;left:287px;white-space:nowrap" class="ft201">16.4&#160;</p>
<p style="position:absolute;top:685px;left:271px;white-space:nowrap" class="ft201">(12.3-ne)&#160;</p>
<p style="position:absolute;top:666px;left:393px;white-space:nowrap" class="ft201">24.8&#160;</p>
<p style="position:absolute;top:685px;left:370px;white-space:nowrap" class="ft201">(18.6-33.7)&#160;</p>
<p style="position:absolute;top:666px;left:486px;white-space:nowrap" class="ft201">17.9&#160;</p>
<p style="position:absolute;top:685px;left:463px;white-space:nowrap" class="ft201">(11.2-23.8)&#160;</p>
<p style="position:absolute;top:666px;left:576px;white-space:nowrap" class="ft201">31.2&#160;</p>
<p style="position:absolute;top:685px;left:554px;white-space:nowrap" class="ft201">(27.3-40.8)&#160;</p>
<p style="position:absolute;top:666px;left:665px;white-space:nowrap" class="ft201">22.74&#160;</p>
<p style="position:absolute;top:685px;left:647px;white-space:nowrap" class="ft201">(19.1-30.8)&#160;</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft2012">TTP =&#160;time&#160;to&#160;progression; &#34;ne&#34;&#160;indicates&#160;that&#160;it could&#160;not be&#160;estimated&#160;or&#160;it was&#160;not yet&#160;reached.&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft2012">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;H0649g: IHC3+&#160;patient subset&#160;</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft2012">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;H0648g: IHC3+&#160;patient subset&#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft207">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;M77001: Full analysis&#160;set&#160;(intent-to-treat),&#160;24&#160;months&#160;results&#160;<br/><i>&#160;<br/>Combination&#160;treatment&#160;with Trastuzumab&#160;and anastrozole&#160;</i></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft201">Trastuzumab&#160;has&#160;been&#160;studied in&#160;combination with&#160;anastrozole for&#160;first&#160;line&#160;treatment&#160;of&#160;MBC&#160;in&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft201">HER2 overexpressing, hormone-receptor&#160;(i.e. estrogen-receptor&#160;(ER)&#160;and/or&#160;progesterone-receptor&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft201">(PR))&#160;positive postmenopausal&#160;patients. Progression free&#160;survival&#160;was&#160;doubled in&#160;the&#160;trastuzumab plus&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft201">anastrozole arm&#160;compared to anastrozole (4.8&#160;months versus 2.4&#160;months). For&#160;the&#160;other&#160;parameters the&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft201">improvements seen for&#160;the&#160;combination were for&#160;overall&#160;response&#160;(16.5&#160;%&#160;versus&#160;6.7&#160;%);&#160;clinical&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft201">benefit&#160;rate&#160;(42.7&#160;%&#160;versus&#160;27.9&#160;%);&#160;time&#160;to progression (4.8&#160;months versus&#160;2.4 months). For&#160;time to&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft201">response&#160;and duration of&#160;response&#160;no difference&#160;could&#160;be recorded between the arms.&#160;The median&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft201">overall&#160;survival&#160;was extended by 4.6&#160;months&#160;for&#160;patients in the combination arm.&#160;The difference&#160;was&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft201">not&#160;statistically&#160;significant,&#160;however&#160;more&#160;than&#160;half&#160;of&#160;the patients&#160;in&#160;the&#160;anastrozole alone arm&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft201">crossed over&#160;to a&#160;trastuzumab containing regimen&#160;after&#160;progression&#160;of&#160;disease.&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2118{font-size:8px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft210">21&#160;</p>
<p style="position:absolute;top:110px;left:106px;white-space:nowrap" class="ft213"><i>Three&#160;-weekly&#160;dosing&#160;in metastatic breast&#160;cancer</i></p>
<p style="position:absolute;top:104px;left:431px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft211">The efficacy&#160;results&#160;from&#160;the non-comparative&#160;monotherapy&#160;and&#160;combination&#160;therapy studies&#160;are&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft211">summarised&#160;in Table 5:&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft211">Table&#160;5&#160;Efficacy&#160;results&#160;from&#160;the non-comparative&#160;monotherapy&#160;and&#160;combination&#160;therapy&#160;studies&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:219px;left:107px;white-space:nowrap" class="ft212"><b>Parameter</b>&#160;</p>
<p style="position:absolute;top:219px;left:253px;white-space:nowrap" class="ft212"><b>Monotherapy</b>&#160;</p>
<p style="position:absolute;top:219px;left:487px;white-space:nowrap" class="ft212"><b>Combination&#160;Therapy</b>&#160;</p>
<p style="position:absolute;top:246px;left:107px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:246px;left:261px;white-space:nowrap" class="ft212"><b>Trastuzumab1</b>&#160;</p>
<p style="position:absolute;top:265px;left:311px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:284px;left:284px;white-space:nowrap" class="ft212"><b>N&#160;=&#160;105</b>&#160;</p>
<p style="position:absolute;top:246px;left:378px;white-space:nowrap" class="ft212"><b>Trastuzumab2</b>&#160;</p>
<p style="position:absolute;top:265px;left:428px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:284px;left:405px;white-space:nowrap" class="ft212"><b>N&#160;=&#160;72</b>&#160;</p>
<p style="position:absolute;top:246px;left:502px;white-space:nowrap" class="ft212"><b>Trastuzumab plus&#160;</b></p>
<p style="position:absolute;top:265px;left:530px;white-space:nowrap" class="ft212"><b>paclitaxel3</b>&#160;</p>
<p style="position:absolute;top:284px;left:543px;white-space:nowrap" class="ft212"><b>N&#160;=&#160;32</b>&#160;</p>
<p style="position:absolute;top:246px;left:657px;white-space:nowrap" class="ft212"><b>Trastuzumab plus&#160;</b></p>
<p style="position:absolute;top:265px;left:686px;white-space:nowrap" class="ft212"><b>docetaxel4</b>&#160;</p>
<p style="position:absolute;top:284px;left:695px;white-space:nowrap" class="ft212"><b>N&#160;=&#160;110</b>&#160;</p>
<p style="position:absolute;top:303px;left:107px;white-space:nowrap" class="ft212"><b>Response&#160;rate</b>&#160;</p>
<p style="position:absolute;top:322px;left:107px;white-space:nowrap" class="ft212"><b>(95&#160;%CI)</b>&#160;</p>
<p style="position:absolute;top:304px;left:263px;white-space:nowrap" class="ft211">24&#160;%&#160;(15&#160;-&#160;35)&#160;&#160;27&#160;%&#160;(14&#160;-&#160;43)&#160;</p>
<p style="position:absolute;top:304px;left:522px;white-space:nowrap" class="ft211">59&#160;%&#160;(41-76)&#160;</p>
<p style="position:absolute;top:304px;left:678px;white-space:nowrap" class="ft211">73&#160;%&#160;(63-81)&#160;</p>
<p style="position:absolute;top:356px;left:107px;white-space:nowrap" class="ft212"><b>Median duration&#160;of&#160;</b></p>
<p style="position:absolute;top:375px;left:107px;white-space:nowrap" class="ft212"><b>response (months)&#160;</b></p>
<p style="position:absolute;top:394px;left:107px;white-space:nowrap" class="ft212"><b>(range)</b>&#160;</p>
<p style="position:absolute;top:356px;left:261px;white-space:nowrap" class="ft211">10.1 (2.8-35.6)&#160;&#160;7.9 (2.1-18.8)&#160;</p>
<p style="position:absolute;top:356px;left:523px;white-space:nowrap" class="ft211">10.5 (1.8-21)&#160;</p>
<p style="position:absolute;top:356px;left:672px;white-space:nowrap" class="ft211">13.4 (2.1-55.1)&#160;</p>
<p style="position:absolute;top:422px;left:107px;white-space:nowrap" class="ft212"><b>Median TTP&#160;</b></p>
<p style="position:absolute;top:441px;left:107px;white-space:nowrap" class="ft212"><b>(months)&#160;(95&#160;%CI)</b>&#160;</p>
<p style="position:absolute;top:422px;left:270px;white-space:nowrap" class="ft211">3.4 (2.8-4.1)&#160;</p>
<p style="position:absolute;top:422px;left:387px;white-space:nowrap" class="ft211">7.7 (4.2-8.3)&#160;</p>
<p style="position:absolute;top:422px;left:523px;white-space:nowrap" class="ft211">12.2 (6.2-ne)&#160;</p>
<p style="position:absolute;top:422px;left:681px;white-space:nowrap" class="ft211">13.6 (11-16)&#160;</p>
<p style="position:absolute;top:474px;left:107px;white-space:nowrap" class="ft212"><b>Median Survival</b>&#160;</p>
<p style="position:absolute;top:494px;left:107px;white-space:nowrap" class="ft212"><b>(months)&#160;(95&#160;%CI)</b>&#160;</p>
<p style="position:absolute;top:475px;left:303px;white-space:nowrap" class="ft211">ne&#160;</p>
<p style="position:absolute;top:475px;left:420px;white-space:nowrap" class="ft211">ne&#160;</p>
<p style="position:absolute;top:475px;left:558px;white-space:nowrap" class="ft211">ne&#160;</p>
<p style="position:absolute;top:475px;left:681px;white-space:nowrap" class="ft211">47.3 (32-ne)&#160;</p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft2118">&#160;</p>
<p style="position:absolute;top:536px;left:115px;white-space:nowrap" class="ft2112">TTP&#160;=&#160;time&#160;to&#160;progression;&#160;&#34;ne&#34;&#160;indicates&#160;that&#160;it&#160;could&#160;not&#160;be&#160;estimated&#160;or&#160;it&#160;was&#160;not&#160;yet&#160;reached.&#160;</p>
<p style="position:absolute;top:553px;left:115px;white-space:nowrap" class="ft2112">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;WO16229:&#160;loading&#160;dose&#160;8&#160;mg/kg,&#160;followed&#160;by&#160;6&#160;mg/kg&#160;3&#160;weekly&#160;schedule&#160;</p>
<p style="position:absolute;top:572px;left:115px;white-space:nowrap" class="ft2112">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;MO16982:&#160;loading&#160;dose&#160;6&#160;mg/kg&#160;weekly&#160;x&#160;3;&#160;followed&#160;by&#160;6&#160;mg/kg&#160;3-weekly&#160;schedule&#160;</p>
<p style="position:absolute;top:589px;left:115px;white-space:nowrap" class="ft2112">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;BO15935&#160;</p>
<p style="position:absolute;top:607px;left:115px;white-space:nowrap" class="ft2112">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study&#160;MO16419&#160;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft215">&#160;<br/><i>Sites&#160;of&#160;progression</i></p>
<p style="position:absolute;top:642px;left:237px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft211">The frequency of&#160;progression in&#160;the&#160;liver&#160;was significantly&#160;reduced&#160;in patients&#160;treated with&#160;the&#160;</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft211">combination of&#160;trastuzumab and&#160;paclitaxel, compared&#160;to paclitaxel&#160;alone&#160;(21.8&#160;%&#160;versus 45.7&#160;%;&#160;</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft211">p&#160;=&#160;0.004). More&#160;patients&#160;treated with trastuzumab and&#160;paclitaxel&#160;progressed in&#160;the central&#160;nervous&#160;</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft211">system&#160;than those&#160;treated with paclitaxel&#160;alone (12.6&#160;%&#160;versus 6.5&#160;%;&#160;p&#160;=&#160;0.377).&#160;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft215">&#160;<br/><i>Early&#160;breast&#160;cancer&#160;(adjuvant&#160;setting)</i></p>
<p style="position:absolute;top:756px;left:358px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:794px;left:106px;white-space:nowrap" class="ft211">EBC&#160;is defined as non-metastatic primary invasive&#160;carcinoma of&#160;the breast.&#160;</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft211">In the adjuvant&#160;treatment&#160;setting,&#160;trastuzumab was investigated in 4 large&#160;multicentre, randomised,&#160;</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft211">trials.&#160;</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft211">-&#160;</p>
<p style="position:absolute;top:889px;left:149px;white-space:nowrap" class="ft211">Study BO16348 was&#160;designed to&#160;compare one&#160;and&#160;two&#160;years of&#160;three-weekly&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:908px;left:149px;white-space:nowrap" class="ft211">treatment&#160;versus observation in patients with HER2 positive EBC&#160;following surgery, established&#160;</p>
<p style="position:absolute;top:927px;left:149px;white-space:nowrap" class="ft211">chemotherapy and&#160;radiotherapy&#160;(if&#160;applicable). In addition,&#160;comparison of&#160;two years of&#160;</p>
<p style="position:absolute;top:946px;left:149px;white-space:nowrap" class="ft211">trastuzumab&#160;treatment&#160;versus one year&#160;of&#160;trastuzumab&#160;treatment&#160;was&#160;performed. Patients&#160;</p>
<p style="position:absolute;top:965px;left:149px;white-space:nowrap" class="ft211">assigned&#160;to&#160;receive trastuzumab were given an&#160;initial&#160;loading&#160;dose of&#160;8&#160;mg/kg,&#160;followed by&#160;</p>
<p style="position:absolute;top:984px;left:149px;white-space:nowrap" class="ft211">6&#160;mg/kg every&#160;three&#160;weeks&#160;for&#160;either&#160;one or&#160;two years.&#160;</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft211">-&#160;</p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft211">The NSABP B-31 and NCCTG&#160;N9831 studies that&#160;comprise&#160;the joint&#160;analysis were designed&#160;to&#160;</p>
<p style="position:absolute;top:1022px;left:149px;white-space:nowrap" class="ft211">investigate the clinical&#160;utility of&#160;combining trastuzumab treatment&#160;with paclitaxel&#160;following AC&#160;</p>
<p style="position:absolute;top:1041px;left:149px;white-space:nowrap" class="ft211">chemotherapy;&#160;additionally,&#160;the NCCTG&#160;N9831 study&#160;also&#160;investigated&#160;adding&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:1060px;left:149px;white-space:nowrap" class="ft211">sequentially&#160;to AC→P chemotherapy&#160;in patients with&#160;HER2 positive EBC&#160;following surgery.&#160;</p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft211">-&#160;</p>
<p style="position:absolute;top:1079px;left:149px;white-space:nowrap" class="ft211">The BCIRG&#160;006 study was&#160;designed&#160;to&#160;investigate combining trastuzumab treatment&#160;with&#160;</p>
<p style="position:absolute;top:1098px;left:149px;white-space:nowrap" class="ft211">docetaxel&#160;either&#160;following&#160;AC&#160;chemotherapy&#160;or&#160;in combination with&#160;docetaxel&#160;and carboplatin&#160;</p>
<p style="position:absolute;top:1117px;left:149px;white-space:nowrap" class="ft211">in patients with HER2 positive EBC&#160;following&#160;surgery.&#160;</p>
<p style="position:absolute;top:1136px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft220">22&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft221">EBC&#160;in the HERA&#160;trial&#160;was&#160;limited&#160;to operable, primary, invasive adenocarcinoma&#160;of&#160;the breast, with&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft221">axillary nodes&#160;positive or&#160;axillary nodes&#160;negative&#160;if&#160;tumours at&#160;least&#160;1 cm&#160;in diameter.&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft221">In the joint&#160;analysis&#160;of&#160;the&#160;NSABP B-31 and NCCTG&#160;N9831 studies, EBC&#160;was&#160;limited&#160;to women with&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft221">operable&#160;breast&#160;cancer&#160;at&#160;high risk, defined&#160;as&#160;HER2-positive and&#160;axillary&#160;lymph&#160;node positive or&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft221">HER2 positive and&#160;lymph&#160;node negative with&#160;high risk features&#160;(tumour&#160;size&#160;&gt;&#160;1&#160;cm&#160;and ER&#160;negative&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft221">or&#160;tumour&#160;size&#160;&gt;&#160;2&#160;cm,&#160;regardless&#160;of&#160;hormonal&#160;status).&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft221">In the BCIRG&#160;006 study HER2 positive, EBC&#160;was&#160;defined&#160;as&#160;either&#160;lymph node positive or&#160;high&#160;risk&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft221">node negative&#160;patients with&#160;no (pN0)&#160;lymph&#160;node&#160;involvement, and at&#160;least&#160;1 of&#160;the following factors:&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft221">tumour&#160;size greater&#160;than 2 cm, estrogen&#160;receptor&#160;and progesterone receptor&#160;negative, histological&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft221">and/or&#160;nuclear&#160;grade 2-3, or&#160;age&#160;&lt;&#160;35 years).&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft221">The efficacy&#160;results&#160;from&#160;the BO16348 trial&#160;following&#160;12 months* and&#160;8 years**&#160;median&#160;follow-up&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft221">are summarized&#160;in Table&#160;6:&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft221">Table&#160;6 Efficacy&#160;results&#160;from&#160;study BO16348&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:447px;left:403px;white-space:nowrap" class="ft222"><b>Median follow-up&#160;</b></p>
<p style="position:absolute;top:465px;left:425px;white-space:nowrap" class="ft222"><b>12 months*&#160;</b></p>
<p style="position:absolute;top:447px;left:637px;white-space:nowrap" class="ft222"><b>Median follow-up&#160;</b></p>
<p style="position:absolute;top:465px;left:666px;white-space:nowrap" class="ft222"><b>8 years**&#160;</b></p>
<p style="position:absolute;top:489px;left:107px;white-space:nowrap" class="ft222"><b>Parameter&#160;</b></p>
<p style="position:absolute;top:489px;left:363px;white-space:nowrap" class="ft222"><b>Observation&#160;</b></p>
<p style="position:absolute;top:508px;left:376px;white-space:nowrap" class="ft222"><b>N&#160;=&#160;1693&#160;</b></p>
<p style="position:absolute;top:489px;left:476px;white-space:nowrap" class="ft222"><b>Trastuzumab&#160;</b></p>
<p style="position:absolute;top:508px;left:501px;white-space:nowrap" class="ft222"><b>1 Year&#160;</b></p>
<p style="position:absolute;top:527px;left:493px;white-space:nowrap" class="ft222"><b>N&#160;=&#160;1693&#160;</b></p>
<p style="position:absolute;top:489px;left:598px;white-space:nowrap" class="ft222"><b>Observation&#160;</b></p>
<p style="position:absolute;top:508px;left:597px;white-space:nowrap" class="ft222"><b>N&#160;=&#160;1697***&#160;</b></p>
<p style="position:absolute;top:489px;left:710px;white-space:nowrap" class="ft222"><b>Trastuzumab&#160;</b></p>
<p style="position:absolute;top:508px;left:734px;white-space:nowrap" class="ft222"><b>1 Year&#160;</b></p>
<p style="position:absolute;top:527px;left:714px;white-space:nowrap" class="ft222"><b>N&#160;=&#160;1702***&#160;</b></p>
<p style="position:absolute;top:553px;left:107px;white-space:nowrap" class="ft221">Disease-free&#160;survival&#160;</p>
<p style="position:absolute;top:572px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients with event&#160;</p>
<p style="position:absolute;top:591px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients without&#160;event&#160;&#160;</p>
<p style="position:absolute;top:610px;left:107px;white-space:nowrap" class="ft221">P-value versus Observation&#160;&#160;</p>
<p style="position:absolute;top:629px;left:107px;white-space:nowrap" class="ft221">Hazard Ratio versus Observation&#160;</p>
<p style="position:absolute;top:553px;left:466px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:572px;left:367px;white-space:nowrap" class="ft221">219 (12.9&#160;%)&#160; &#160; &#160; &#160;&#160;127 (7.5&#160;%)&#160;</p>
<p style="position:absolute;top:591px;left:360px;white-space:nowrap" class="ft221">1474 (87.1&#160;%)&#160; &#160; &#160;1566&#160;(92.5&#160;%)&#160;</p>
<p style="position:absolute;top:610px;left:436px;white-space:nowrap" class="ft221">&lt; 0.0001&#160;</p>
<p style="position:absolute;top:629px;left:451px;white-space:nowrap" class="ft221">0.54&#160;</p>
<p style="position:absolute;top:553px;left:699px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:572px;left:598px;white-space:nowrap" class="ft221">570 (33.6&#160;%)&#160; &#160; &#160; &#160;471 (27.7&#160;%)&#160;</p>
<p style="position:absolute;top:591px;left:594px;white-space:nowrap" class="ft221">1127 (66.4&#160;%)&#160; &#160; &#160;1231&#160;(72.3&#160;%)&#160;</p>
<p style="position:absolute;top:610px;left:670px;white-space:nowrap" class="ft221">&lt; 0.0001&#160;</p>
<p style="position:absolute;top:629px;left:685px;white-space:nowrap" class="ft221">0.76&#160;</p>
<p style="position:absolute;top:659px;left:107px;white-space:nowrap" class="ft221">Recurrence-free survival&#160;</p>
<p style="position:absolute;top:678px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients with event&#160;</p>
<p style="position:absolute;top:697px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients without&#160;event&#160;&#160;</p>
<p style="position:absolute;top:716px;left:107px;white-space:nowrap" class="ft221">P-value versus Observation&#160;&#160;</p>
<p style="position:absolute;top:735px;left:107px;white-space:nowrap" class="ft221">Hazard Ratio versus Observation&#160;</p>
<p style="position:absolute;top:659px;left:466px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:678px;left:367px;white-space:nowrap" class="ft221">208 (12.3&#160;%)&#160; &#160; &#160; &#160;&#160;113 (6.7&#160;%)&#160;</p>
<p style="position:absolute;top:697px;left:360px;white-space:nowrap" class="ft221">1485 (87.7&#160;%)&#160; &#160; &#160;1580&#160;(93.3&#160;%)&#160;</p>
<p style="position:absolute;top:716px;left:436px;white-space:nowrap" class="ft221">&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:735px;left:451px;white-space:nowrap" class="ft221">0.51&#160;</p>
<p style="position:absolute;top:659px;left:699px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:678px;left:598px;white-space:nowrap" class="ft221">506 (29.8&#160;%)&#160; &#160; &#160; &#160;399 (23.4&#160;%)&#160;</p>
<p style="position:absolute;top:697px;left:594px;white-space:nowrap" class="ft221">1191 (70.2&#160;%)&#160; &#160; &#160;1303&#160;(76.6&#160;%)&#160;</p>
<p style="position:absolute;top:716px;left:670px;white-space:nowrap" class="ft221">&lt; 0.0001&#160;</p>
<p style="position:absolute;top:735px;left:685px;white-space:nowrap" class="ft221">0.73&#160;</p>
<p style="position:absolute;top:765px;left:107px;white-space:nowrap" class="ft221">Distant&#160;disease-free survival&#160;</p>
<p style="position:absolute;top:784px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients with event&#160;</p>
<p style="position:absolute;top:803px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients without&#160;event&#160;&#160;</p>
<p style="position:absolute;top:822px;left:107px;white-space:nowrap" class="ft221">P-value versus Observation&#160;&#160;</p>
<p style="position:absolute;top:841px;left:107px;white-space:nowrap" class="ft221">Hazard Ratio versus Observation&#160;</p>
<p style="position:absolute;top:765px;left:466px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:784px;left:369px;white-space:nowrap" class="ft221">184 (10.9&#160;%)&#160; &#160; &#160; &#160;&#160;&#160;99 (5.8&#160;%)&#160;</p>
<p style="position:absolute;top:803px;left:360px;white-space:nowrap" class="ft221">1508 (89.1&#160;%)&#160; &#160;&#160;&#160;1594&#160;(94.6&#160;%)&#160;</p>
<p style="position:absolute;top:822px;left:436px;white-space:nowrap" class="ft221">&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:841px;left:451px;white-space:nowrap" class="ft221">0.50&#160;</p>
<p style="position:absolute;top:765px;left:699px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:784px;left:598px;white-space:nowrap" class="ft221">488 (28.8&#160;%)&#160; &#160; &#160; &#160;399 (23.4&#160;%)&#160;</p>
<p style="position:absolute;top:803px;left:594px;white-space:nowrap" class="ft221">1209 (71.2&#160;%)&#160; &#160; &#160;1303&#160;(76.6&#160;%)&#160;</p>
<p style="position:absolute;top:822px;left:670px;white-space:nowrap" class="ft221">&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:841px;left:685px;white-space:nowrap" class="ft221">0.76&#160;</p>
<p style="position:absolute;top:871px;left:107px;white-space:nowrap" class="ft221">Overall&#160;survival&#160;(death)&#160;</p>
<p style="position:absolute;top:890px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients with event&#160;</p>
<p style="position:absolute;top:908px;left:107px;white-space:nowrap" class="ft221">-&#160;No. patients without&#160;event&#160;&#160;</p>
<p style="position:absolute;top:928px;left:107px;white-space:nowrap" class="ft221">P-value versus Observation&#160;&#160;</p>
<p style="position:absolute;top:946px;left:107px;white-space:nowrap" class="ft221">Hazard Ratio versus&#160;Observation&#160;</p>
<p style="position:absolute;top:871px;left:466px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:890px;left:373px;white-space:nowrap" class="ft221">40 (2.4&#160;%)&#160; &#160; &#160; &#160; &#160; &#160;31 (1.8&#160;%)&#160;</p>
<p style="position:absolute;top:908px;left:360px;white-space:nowrap" class="ft221">1653 (97.6&#160;%)&#160; &#160; &#160;1662&#160;(98.2&#160;%)&#160;</p>
<p style="position:absolute;top:928px;left:451px;white-space:nowrap" class="ft221">0.24&#160;</p>
<p style="position:absolute;top:946px;left:451px;white-space:nowrap" class="ft221">0.75&#160;</p>
<p style="position:absolute;top:871px;left:699px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:890px;left:598px;white-space:nowrap" class="ft221">350 (20.6&#160;%)&#160; &#160; &#160; &#160;278 (16.3&#160;%)&#160;</p>
<p style="position:absolute;top:908px;left:594px;white-space:nowrap" class="ft221">1347 (79.4&#160;%)&#160; &#160; &#160;1424&#160;(83.7&#160;%)&#160;</p>
<p style="position:absolute;top:928px;left:677px;white-space:nowrap" class="ft221">0.0005&#160;</p>
<p style="position:absolute;top:946px;left:685px;white-space:nowrap" class="ft221">0.76&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft2212">*Co-primary&#160;endpoint&#160;of&#160;DFS of&#160;1&#160;year&#160;versus&#160;observation&#160;met&#160;the&#160;pre-defined&#160;statistical&#160;boundary&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft2212">**Final&#160;analysis&#160;(including&#160;crossover&#160;of&#160;52&#160;% of&#160;patients&#160;from&#160;the&#160;observation&#160;arm&#160;to&#160;trastuzumab)&#160;</p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft2212">***&#160;There&#160;is&#160;a&#160;discrepancy&#160;in&#160;the&#160;overall&#160;sample&#160;size&#160;due&#160;to&#160;a&#160;small&#160;number&#160;of&#160;patients&#160;who&#160;were&#160;randomised&#160;</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft2212">after&#160;the&#160;cut-off&#160;date&#160;for&#160;the&#160;12-month&#160;median&#160;follow-up&#160;analysis&#160;</p>
<p style="position:absolute;top:1045px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft221">The efficacy&#160;results&#160;from&#160;the interim&#160;efficacy analysis&#160;crossed&#160;the protocol&#160;pre-specified statistical&#160;</p>
<p style="position:absolute;top:1083px;left:106px;white-space:nowrap" class="ft221">boundary for&#160;the comparison of&#160;1-year&#160;of&#160;trastuzumab&#160;versus observation. After&#160;a&#160;median&#160;follow-up of&#160;</p>
<p style="position:absolute;top:1102px;left:106px;white-space:nowrap" class="ft221">12 months, the hazard&#160;ratio&#160;(HR)&#160;for&#160;disease&#160;free survival&#160;(DFS)&#160;was&#160;0.54 (95&#160;%&#160;CI&#160;0.44, 0.67)&#160;which&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft230">23&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft231">translates into&#160;an absolute&#160;benefit,&#160;in&#160;terms of&#160;a 2-year&#160;disease-free&#160;survival&#160;rate, of&#160;7.6 percentage&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft231">points (85.8&#160;%&#160;versus 78.2&#160;%)&#160;in favour&#160;of&#160;the trastuzumab&#160;arm.&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft231">A&#160;final&#160;analysis was performed&#160;after&#160;a&#160;median&#160;follow-up of&#160;8&#160;years, which showed that&#160;1 year&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft231">trastuzumab&#160;treatment&#160;is associated with a 24 %&#160;risk reduction compared to&#160;observation only&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft231">(HR&#160;=&#160;0.76,&#160;95&#160;%&#160;CI&#160;0.67,&#160;0.86). This&#160;translates&#160;into an absolute benefit&#160;in&#160;terms&#160;of&#160;an 8&#160;year&#160;disease&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft231">free survival&#160;rate of&#160;6.4 percentage&#160;points&#160;in favour&#160;of&#160;1 year&#160;trastuzumab treatment.&#160;&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft231">In this&#160;final&#160;analysis,&#160;extending&#160;trastuzumab&#160;treatment&#160;for&#160;a duration of&#160;two&#160;years&#160;did not&#160;show&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft231">additional&#160;benefit&#160;over&#160;treatment&#160;for&#160;1 year&#160;[DFS&#160;HR&#160;in the&#160;intent&#160;to&#160;treat&#160;(ITT)&#160;population of&#160;2 years&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft231">versus 1 yea&#160;r=&#160;0.99&#160;(95&#160;%&#160;CI:&#160;0.87, 1.13), p-value&#160;=&#160;0.90 and OS&#160;HR&#160;=&#160;0.98 (0.83, 1.15);&#160;p-</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft231">value&#160;=&#160;0.78]. The rate&#160;of&#160;asymptomatic&#160;cardiac&#160;dysfunction was&#160;increased&#160;in&#160;the&#160;2-year&#160;treatment&#160;arm&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft231">(8.1&#160;%&#160;versus&#160;4.6&#160;%&#160;in&#160;the&#160;1-year&#160;treatment&#160;arm).&#160;More patients&#160;experienced at&#160;least&#160;one grade&#160;3 or&#160;4&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft231">adverse&#160;event&#160;in&#160;the&#160;2-year&#160;treatment&#160;arm&#160;(20.4&#160;%)&#160;compared with&#160;the&#160;1-year&#160;treatment&#160;arm&#160;(16.3&#160;%).&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft231">In the NSABP B-31 and NCCTG&#160;N9831 studies&#160;trastuzumab was&#160;administered in&#160;combination with&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft231">paclitaxel, following AC&#160;chemotherapy.&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft231">Doxorubicin and&#160;cyclophosphamide were&#160;administered&#160;concurrently as follows:&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft231">-&#160;</p>
<p style="position:absolute;top:465px;left:149px;white-space:nowrap" class="ft231">intravenous&#160;push doxorubicin, at&#160;60&#160;mg/&#160;m2,&#160;given every 3 weeks&#160;for&#160;4 cycles.&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft231">-&#160;</p>
<p style="position:absolute;top:484px;left:149px;white-space:nowrap" class="ft231">intravenous&#160;cyclophosphamide, at&#160;600&#160;mg/&#160;m2&#160;over&#160;30 minutes, given&#160;every 3 weeks&#160;for&#160;4&#160;</p>
<p style="position:absolute;top:503px;left:149px;white-space:nowrap" class="ft231">cycles&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft231">Paclitaxel, in&#160;combination&#160;with&#160;trastuzumab, was administered&#160;as&#160;follows:&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft231">-&#160;</p>
<p style="position:absolute;top:560px;left:149px;white-space:nowrap" class="ft231">intravenous&#160;paclitaxel&#160;–&#160;80&#160;mg/&#160;m2&#160;as a&#160;continuous intravenous infusion,&#160;given every week&#160;for&#160;</p>
<p style="position:absolute;top:579px;left:149px;white-space:nowrap" class="ft231">12 weeks.&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft231">or&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft231">-&#160;</p>
<p style="position:absolute;top:617px;left:149px;white-space:nowrap" class="ft231">intravenous&#160;paclitaxel&#160;–&#160;175&#160;mg/&#160;m2&#160;as&#160;a&#160;continuous&#160;intravenous infusion,&#160;given every 3 weeks&#160;</p>
<p style="position:absolute;top:636px;left:149px;white-space:nowrap" class="ft231">for&#160;4&#160;cycles&#160;(day 1 of&#160;each&#160;cycle).&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft231">The efficacy&#160;results&#160;from&#160;the joint&#160;analysis of&#160;the NSABP B-31 and NCCTG&#160;N9831 trials at&#160;the&#160;time&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft231">of&#160;the definitive analysis of&#160;DFS* are&#160;summarized&#160;in Table&#160;7. The&#160;median&#160;duration of&#160;follow&#160;up was&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft231">1.8 years&#160;for&#160;the&#160;patients&#160;in&#160;the AC→P arm&#160;and&#160;2.0 years for&#160;patients&#160;in the AC→PH&#160;arm.&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft231">Table&#160;7 Summary of&#160;efficacy results&#160;from&#160;the&#160;joint&#160;analysis of&#160;the NSABP B-31 and&#160;NCCTG&#160;N9831&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft231">trials at&#160;the time of&#160;the definitive DFS&#160;analysis*&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:807px;left:179px;white-space:nowrap" class="ft232"><b>Parameter&#160;</b></p>
<p style="position:absolute;top:807px;left:359px;white-space:nowrap" class="ft232"><b>AC→P&#160;</b></p>
<p style="position:absolute;top:826px;left:349px;white-space:nowrap" class="ft232"><b>(n&#160;=&#160;1679)&#160;</b></p>
<p style="position:absolute;top:807px;left:475px;white-space:nowrap" class="ft232"><b>AC→PH&#160;</b></p>
<p style="position:absolute;top:826px;left:471px;white-space:nowrap" class="ft232"><b>(n&#160;=&#160;1672)&#160;</b></p>
<p style="position:absolute;top:807px;left:587px;white-space:nowrap" class="ft232"><b>Hazard Ratio vs&#160;</b></p>
<p style="position:absolute;top:826px;left:619px;white-space:nowrap" class="ft232"><b>AC→P&#160;&#160;</b></p>
<p style="position:absolute;top:845px;left:611px;white-space:nowrap" class="ft232"><b>(95% CI)&#160;&#160;</b></p>
<p style="position:absolute;top:864px;left:618px;white-space:nowrap" class="ft232"><b>p-value&#160;</b></p>
<p style="position:absolute;top:885px;left:107px;white-space:nowrap" class="ft231">Disease-free&#160;survival&#160;</p>
<p style="position:absolute;top:904px;left:107px;white-space:nowrap" class="ft231">No. patients with event&#160;(%)&#160;</p>
<p style="position:absolute;top:923px;left:107px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:941px;left:107px;white-space:nowrap" class="ft231">Distant&#160;Recurrence&#160;</p>
<p style="position:absolute;top:961px;left:107px;white-space:nowrap" class="ft231">No. patients with event&#160;</p>
<p style="position:absolute;top:979px;left:107px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:998px;left:107px;white-space:nowrap" class="ft231">Death&#160;(OS&#160;event):&#160;</p>
<p style="position:absolute;top:1017px;left:107px;white-space:nowrap" class="ft231">No. patients with event&#160;</p>
<p style="position:absolute;top:885px;left:384px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:904px;left:349px;white-space:nowrap" class="ft231">261 (15.5)&#160;</p>
<p style="position:absolute;top:923px;left:384px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:941px;left:384px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:961px;left:349px;white-space:nowrap" class="ft231">193 (11.5)&#160;</p>
<p style="position:absolute;top:979px;left:384px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:998px;left:384px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:1017px;left:358px;white-space:nowrap" class="ft231">92 (5.5)&#160;</p>
<p style="position:absolute;top:885px;left:507px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:904px;left:477px;white-space:nowrap" class="ft231">133 (8.0)&#160;</p>
<p style="position:absolute;top:923px;left:507px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:941px;left:507px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:961px;left:481px;white-space:nowrap" class="ft231">96 (5.7)&#160;</p>
<p style="position:absolute;top:979px;left:507px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:998px;left:507px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:1017px;left:481px;white-space:nowrap" class="ft231">62 (3.7)&#160;</p>
<p style="position:absolute;top:885px;left:645px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:904px;left:590px;white-space:nowrap" class="ft231">0.48 (0.39, 0.59)&#160;</p>
<p style="position:absolute;top:923px;left:609px;white-space:nowrap" class="ft231">p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:941px;left:645px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:961px;left:590px;white-space:nowrap" class="ft231">0.47 (0.37, 0.60)&#160;</p>
<p style="position:absolute;top:979px;left:609px;white-space:nowrap" class="ft231">p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:998px;left:645px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:1017px;left:590px;white-space:nowrap" class="ft231">0.67 (0.48, 0.92)&#160;</p>
<p style="position:absolute;top:1036px;left:605px;white-space:nowrap" class="ft231">p&#160;=&#160;0.014**&#160;</p>
<p style="position:absolute;top:1056px;left:106px;white-space:nowrap" class="ft2312">A:&#160;doxorubicin; C:&#160;cyclophosphamide;&#160;P: paclitaxel;&#160;H:&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft2312">*&#160;At&#160;median&#160;duration&#160;of&#160;follow&#160;up&#160;of&#160;1.8&#160;years&#160;for&#160;the&#160;patients&#160;in&#160;the&#160;AC→P arm&#160;and&#160;2.0&#160;years&#160;for&#160;patients&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft2312">AC→PH&#160;arm&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft2312">**&#160;p&#160;value&#160;for&#160;OS did&#160;not cross&#160;the&#160;pre-specified&#160;statistical&#160;boundary&#160;for&#160;comparison&#160;of&#160;AC→PH vs.&#160;AC→P&#160;</p>
<p style="position:absolute;top:1125px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft240">24&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft241">For the&#160;primary endpoint,&#160;DFS, the addition of&#160;trastuzumab&#160;to paclitaxel&#160;chemotherapy&#160;resulted&#160;in a&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft241">52&#160;%&#160;decrease in&#160;the&#160;risk of&#160;disease&#160;recurrence. The&#160;hazard&#160;ratio&#160;translates&#160;into an&#160;absolute&#160;benefit,&#160;in&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft241">terms&#160;of&#160;3-year&#160;disease-free&#160;survival&#160;rate&#160;estimates&#160;of&#160;11.8 percentage points&#160;(87.2&#160;%&#160;versus&#160;75.4&#160;%)&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft241">in favour&#160;of&#160;the AC→PH&#160;(trastuzumab)&#160;arm.&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft241">At&#160;the&#160;time of&#160;a safety update after&#160;a&#160;median of&#160;3.5-3.8&#160;years follow&#160;up, an&#160;analysis&#160;of&#160;DFS&#160;reconfirms&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft241">the&#160;magnitude of&#160;the benefit&#160;shown&#160;in&#160;the definitive analysis of&#160;DFS. Despite&#160;the&#160;cross-over&#160;to&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft241">trastuzumab&#160;in the control&#160;arm,&#160;the&#160;addition of&#160;trastuzumab&#160;to paclitaxel&#160;chemotherapy&#160;resulted&#160;in a&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft241">52&#160;%&#160;decrease in&#160;the&#160;risk of&#160;disease&#160;recurrence. The&#160;addition of&#160;trastuzumab to paclitaxel&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft241">chemotherapy also&#160;resulted&#160;in a 37&#160;%&#160;decrease&#160;in the risk of&#160;death.&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft241">The pre-planned final&#160;analysis of&#160;OS from&#160;the joint&#160;analysis of&#160;studies&#160;NSABP B-31 and NCCTG&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft241">N9831 was&#160;performed when 707 deaths had&#160;occurred (median&#160;follow-up 8.3 years&#160;in the AC→P H&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft241">group). Treatment&#160;with AC→PH&#160;resulted&#160;in a&#160;statistically&#160;significant&#160;improvement&#160;in OS compared&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft241">with AC→P&#160;(stratified HR&#160;=&#160;0.64;&#160;95%&#160;CI&#160;[0.55, 0.74];&#160;log-rank p-value&#160;&lt;&#160;0.0001). At&#160;8 years,&#160;the&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft241">survival&#160;rate was&#160;estimated&#160;to be 86.9&#160;%&#160;in&#160;the&#160;AC→PH&#160;arm&#160;and 79.4&#160;%&#160;in&#160;the AC→P arm, an&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft241">absolute&#160;benefit&#160;of&#160;7.4&#160;%&#160;(95&#160;%&#160;CI&#160;4.9&#160;%, 10.0&#160;%).&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft241">The final&#160;OS results&#160;from&#160;the joint&#160;analysis of&#160;studies&#160;NSABP B-31 and NCCTG&#160;N9831 are&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft241">summarized&#160;in Table 8&#160;below:&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft241">Table&#160;8 Final&#160;overall&#160;survival&#160;analysis from&#160;the joint&#160;analysis of&#160;trials NSABP B-31 and&#160;NCCTG&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft241">N9831&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:560px;left:107px;white-space:nowrap" class="ft242"><b>Parameter&#160;</b></p>
<p style="position:absolute;top:560px;left:358px;white-space:nowrap" class="ft242"><b>AC→P&#160;</b></p>
<p style="position:absolute;top:579px;left:346px;white-space:nowrap" class="ft242"><b>(N&#160;=&#160;2032)&#160;</b></p>
<p style="position:absolute;top:560px;left:475px;white-space:nowrap" class="ft242"><b>AC→PH&#160;</b></p>
<p style="position:absolute;top:579px;left:469px;white-space:nowrap" class="ft242"><b>(N&#160;=&#160;2031)&#160;</b></p>
<p style="position:absolute;top:560px;left:582px;white-space:nowrap" class="ft242"><b>p-value versus&#160;</b></p>
<p style="position:absolute;top:579px;left:608px;white-space:nowrap" class="ft242"><b>AC→P&#160;</b></p>
<p style="position:absolute;top:560px;left:698px;white-space:nowrap" class="ft242"><b>Hazard Ratio&#160;</b></p>
<p style="position:absolute;top:579px;left:696px;white-space:nowrap" class="ft242"><b>versus&#160;AC→P&#160;</b></p>
<p style="position:absolute;top:598px;left:710px;white-space:nowrap" class="ft242"><b>(95&#160;% CI)&#160;</b></p>
<p style="position:absolute;top:637px;left:107px;white-space:nowrap" class="ft241">Death&#160;(OS event):&#160;</p>
<p style="position:absolute;top:656px;left:107px;white-space:nowrap" class="ft241">No. patients with event&#160;(%)&#160;</p>
<p style="position:absolute;top:637px;left:383px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:656px;left:340px;white-space:nowrap" class="ft241">418 (20.6&#160;%)&#160;</p>
<p style="position:absolute;top:637px;left:506px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:656px;left:463px;white-space:nowrap" class="ft241">289 (14.2&#160;%)&#160;</p>
<p style="position:absolute;top:637px;left:633px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:656px;left:604px;white-space:nowrap" class="ft241">&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:637px;left:746px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:656px;left:731px;white-space:nowrap" class="ft241">0.64&#160;&#160;</p>
<p style="position:absolute;top:675px;left:707px;white-space:nowrap" class="ft241">(0.55, 0.74)&#160;</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft2412">A:&#160;doxorubicin; C:&#160;cyclophosphamide;&#160;P: paclitaxel;&#160;H:&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft2412">&#160;</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft241">DFS&#160;analysis was also&#160;performed at&#160;the final&#160;analysis&#160;of&#160;OS from&#160;the&#160;joint&#160;analysis of&#160;studies&#160;NSABP&#160;</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft241">B-31 and NCCTG&#160;N9831. The updated DFS&#160;analysis&#160;results&#160;(stratified HR&#160;=&#160;0.61;&#160;95%&#160;CI&#160;[0.54,&#160;</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft241">0.69])&#160;showed a similar&#160;DFS benefit&#160;compared&#160;to&#160;the definitive primary&#160;DFS&#160;analysis,&#160;despite&#160;24.8&#160;%&#160;</p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft241">patients in the AC→P arm&#160;who crossed&#160;over&#160;to&#160;receive&#160;trastuzumab. At&#160;8 years, the disease-free&#160;</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft241">survival&#160;rate was&#160;estimated&#160;to be 77.2&#160;%&#160;(95&#160;%&#160;CI:&#160;75.4, 79.1)&#160;in&#160;the AC→PH&#160;arm, an&#160;absolute benefit&#160;</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft241">of&#160;11.8%&#160;compared with the AC→P arm.&#160;</p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft241">In the BCIRG&#160;006 study trastuzumab was&#160;administered&#160;either&#160;in&#160;combination with&#160;docetaxel,&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft241">following AC&#160;chemotherapy (AC→DH)&#160;or&#160;in&#160;combination with&#160;docetaxel&#160;and carboplatin (DCarbH).&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft241">Docetaxel&#160;was&#160;administered as&#160;follows:&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft241">-&#160;</p>
<p style="position:absolute;top:938px;left:149px;white-space:nowrap" class="ft241">intravenous&#160;docetaxel&#160;–&#160;100&#160;mg/m2&#160;as&#160;an&#160;intravenous infusion over&#160;1&#160;hour, given&#160;every&#160;3 weeks&#160;</p>
<p style="position:absolute;top:957px;left:149px;white-space:nowrap" class="ft241">for&#160;4&#160;cycles&#160;(day 2 of&#160;first&#160;docetaxel&#160;cycle,&#160;then day&#160;1 of&#160;each subsequent&#160;cycle).&#160;</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft241">or&#160;</p>
<p style="position:absolute;top:995px;left:106px;white-space:nowrap" class="ft241">-&#160;</p>
<p style="position:absolute;top:995px;left:149px;white-space:nowrap" class="ft241">intravenous&#160;docetaxel&#160;–&#160;75&#160;mg/m2&#160;as an&#160;intravenous infusion over&#160;1 hour,&#160;given every 3 weeks&#160;</p>
<p style="position:absolute;top:1014px;left:149px;white-space:nowrap" class="ft241">for&#160;6&#160;cycles&#160;(day 2 of&#160;cycle&#160;1, then&#160;day 1&#160;of&#160;each&#160;subsequent&#160;cycle).&#160;</p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft241">which was&#160;followed by:&#160;</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft241">-&#160;</p>
<p style="position:absolute;top:1052px;left:149px;white-space:nowrap" class="ft241">carboplatin&#160;–&#160;at&#160;target&#160;AUC&#160;=&#160;6&#160;mg/mL/min administered by intravenous&#160;infusion&#160;over&#160;30-</p>
<p style="position:absolute;top:1071px;left:149px;white-space:nowrap" class="ft241">60&#160;minutes&#160;repeated every&#160;3 weeks&#160;for&#160;a total&#160;of&#160;six cycles.&#160;</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:1109px;left:106px;white-space:nowrap" class="ft241">Trastuzumab&#160;was&#160;administered weekly with&#160;chemotherapy and&#160;3 weekly&#160;thereafter&#160;for&#160;a total&#160;of&#160;52&#160;</p>
<p style="position:absolute;top:1128px;left:106px;white-space:nowrap" class="ft241">weeks.&#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2519{font-size:17px;font-family:BCDFEE+SimSun;color:#000000;}
-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft250">25&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft251">The efficacy&#160;results&#160;from&#160;the BCIRG&#160;006 are summarized in Tables&#160;9&#160;and 10.&#160;The&#160;median duration of&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft251">follow&#160;up was 2.9 years in the AC→D&#160;arm&#160;and 3.0 years in each of&#160;the AC→DH&#160;and DCarbH&#160;arms.&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft251">Table&#160;9 Overview of&#160;efficacy&#160;analyses&#160;BCIRG&#160;006 AC→D&#160;versus AC→DH&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:221px;left:115px;white-space:nowrap" class="ft252"><b>Parameter&#160;</b></p>
<p style="position:absolute;top:223px;left:345px;white-space:nowrap" class="ft252"><b>AC</b>→<b>D&#160;</b></p>
<p style="position:absolute;top:243px;left:336px;white-space:nowrap" class="ft252"><b>(n&#160;=&#160;1073)&#160;</b></p>
<p style="position:absolute;top:223px;left:485px;white-space:nowrap" class="ft252"><b>AC</b>→<b>DH&#160;</b></p>
<p style="position:absolute;top:243px;left:482px;white-space:nowrap" class="ft252"><b>(n&#160;=&#160;1074)&#160;</b></p>
<p style="position:absolute;top:221px;left:613px;white-space:nowrap" class="ft252"><b>Hazard Ratio vs&#160;</b></p>
<p style="position:absolute;top:242px;left:645px;white-space:nowrap" class="ft252"><b>AC</b>→<b>D&#160;</b></p>
<p style="position:absolute;top:262px;left:635px;white-space:nowrap" class="ft252"><b>(95&#160;% CI)&#160;</b></p>
<p style="position:absolute;top:281px;left:645px;white-space:nowrap" class="ft252"><b>p-value&#160;</b></p>
<p style="position:absolute;top:301px;left:115px;white-space:nowrap" class="ft251">Disease-free&#160;survival&#160;</p>
<p style="position:absolute;top:319px;left:115px;white-space:nowrap" class="ft251">No. patients with event&#160;</p>
<p style="position:absolute;top:301px;left:359px;white-space:nowrap" class="ft251">195&#160;</p>
<p style="position:absolute;top:301px;left:505px;white-space:nowrap" class="ft251">134&#160;</p>
<p style="position:absolute;top:301px;left:616px;white-space:nowrap" class="ft251">0.61 (0.49, 0.77)&#160;</p>
<p style="position:absolute;top:319px;left:635px;white-space:nowrap" class="ft251">p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:341px;left:115px;white-space:nowrap" class="ft251">Distant&#160;recurrence&#160;</p>
<p style="position:absolute;top:360px;left:115px;white-space:nowrap" class="ft251">No. patients with event&#160;</p>
<p style="position:absolute;top:341px;left:359px;white-space:nowrap" class="ft251">144&#160;</p>
<p style="position:absolute;top:341px;left:510px;white-space:nowrap" class="ft251">95&#160;</p>
<p style="position:absolute;top:341px;left:616px;white-space:nowrap" class="ft251">0.59 (0.46, 0.77)&#160;</p>
<p style="position:absolute;top:360px;left:635px;white-space:nowrap" class="ft251">p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:384px;left:115px;white-space:nowrap" class="ft251">Death&#160;(OS event)&#160;</p>
<p style="position:absolute;top:403px;left:115px;white-space:nowrap" class="ft251">No. patients with event&#160;</p>
<p style="position:absolute;top:384px;left:363px;white-space:nowrap" class="ft251">80&#160;</p>
<p style="position:absolute;top:384px;left:510px;white-space:nowrap" class="ft251">49&#160;</p>
<p style="position:absolute;top:384px;left:616px;white-space:nowrap" class="ft251">0.58 (0.40, 0.83)&#160;</p>
<p style="position:absolute;top:403px;left:635px;white-space:nowrap" class="ft251">p&#160;=&#160;0.0024&#160;</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft2512">AC→D&#160;=&#160;doxorubicin&#160;plus&#160;cyclophosphamide,&#160;followed&#160;by&#160;docetaxel;&#160;AC→DH&#160;=&#160;doxorubicin&#160;plus&#160;</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft2512">cyclophosphamide,&#160;followed&#160;by&#160;docetaxel&#160;plus&#160;trastuzumab; CI&#160;=&#160;confidence&#160;interval&#160;</p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft251">Table&#160;10 Overview of&#160;efficacy&#160;analyses BCIRG&#160;006 AC→D&#160;versus DCarbH&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:526px;left:115px;white-space:nowrap" class="ft252"><b>Parameter&#160;</b></p>
<p style="position:absolute;top:527px;left:352px;white-space:nowrap" class="ft252"><b>AC</b>→<b>D&#160;</b></p>
<p style="position:absolute;top:547px;left:343px;white-space:nowrap" class="ft252"><b>(n&#160;=&#160;1073)&#160;</b></p>
<p style="position:absolute;top:526px;left:494px;white-space:nowrap" class="ft252"><b>DCarbH&#160;</b></p>
<p style="position:absolute;top:545px;left:489px;white-space:nowrap" class="ft252"><b>(n&#160;=&#160;1074)&#160;</b></p>
<p style="position:absolute;top:526px;left:613px;white-space:nowrap" class="ft252"><b>Hazard Ratio vs&#160;</b></p>
<p style="position:absolute;top:546px;left:645px;white-space:nowrap" class="ft252"><b>AC</b>→<b>D&#160;</b></p>
<p style="position:absolute;top:566px;left:635px;white-space:nowrap" class="ft252"><b>(95&#160;% CI)&#160;</b></p>
<p style="position:absolute;top:585px;left:645px;white-space:nowrap" class="ft252"><b>p-value&#160;</b></p>
<p style="position:absolute;top:605px;left:115px;white-space:nowrap" class="ft251">Disease-free&#160;survival&#160;</p>
<p style="position:absolute;top:624px;left:115px;white-space:nowrap" class="ft251">No. patients with event&#160;</p>
<p style="position:absolute;top:605px;left:366px;white-space:nowrap" class="ft251">195&#160;</p>
<p style="position:absolute;top:605px;left:512px;white-space:nowrap" class="ft251">145&#160;</p>
<p style="position:absolute;top:605px;left:616px;white-space:nowrap" class="ft251">0.67 (0.54, 0.83)&#160;</p>
<p style="position:absolute;top:624px;left:635px;white-space:nowrap" class="ft251">p&#160;=&#160;0.0003&#160;</p>
<p style="position:absolute;top:645px;left:115px;white-space:nowrap" class="ft251">Distant&#160;recurrence&#160;</p>
<p style="position:absolute;top:664px;left:115px;white-space:nowrap" class="ft251">No. patients with event&#160;</p>
<p style="position:absolute;top:645px;left:366px;white-space:nowrap" class="ft251">144&#160;</p>
<p style="position:absolute;top:645px;left:512px;white-space:nowrap" class="ft251">103&#160;</p>
<p style="position:absolute;top:645px;left:616px;white-space:nowrap" class="ft251">0.65 (0.50, 0.84)&#160;</p>
<p style="position:absolute;top:664px;left:635px;white-space:nowrap" class="ft251">p&#160;=&#160;0.0008&#160;</p>
<p style="position:absolute;top:687px;left:115px;white-space:nowrap" class="ft251">Death&#160;(OS event)&#160;</p>
<p style="position:absolute;top:706px;left:115px;white-space:nowrap" class="ft251">No.&#160;patients with event&#160;</p>
<p style="position:absolute;top:687px;left:370px;white-space:nowrap" class="ft251">80&#160;</p>
<p style="position:absolute;top:687px;left:516px;white-space:nowrap" class="ft251">56&#160;</p>
<p style="position:absolute;top:687px;left:616px;white-space:nowrap" class="ft251">0.66 (0.47, 0.93)&#160;</p>
<p style="position:absolute;top:706px;left:635px;white-space:nowrap" class="ft251">p&#160;=&#160;0.0182&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft251">AC→D&#160;= doxorubicin plus&#160;cyclophosphamide, followed by docetaxel;&#160;DCarbH&#160;=&#160;docetaxel,&#160;</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft251">carboplatin and&#160;trastuzumab;&#160;CI&#160;= confidence&#160;interval&#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft251">In the BCIRG&#160;006 study for&#160;the primary&#160;endpoint, DFS, the&#160;hazard&#160;ratio&#160;translates into an&#160;absolute&#160;</p>
<p style="position:absolute;top:808px;left:106px;white-space:nowrap" class="ft251">benefit, in&#160;terms of&#160;3-year&#160;disease-free&#160;survival&#160;rate estimates&#160;of&#160;5.8&#160;percentage points&#160;(86.7&#160;%&#160;versus&#160;</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft251">80.9&#160;%)&#160;in favour&#160;of&#160;the AC→DH&#160;(trastuzumab)&#160;arm&#160;and 4.6 percentage&#160;points&#160;(85.5&#160;%&#160;versus&#160;</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft251">80.9&#160;%)&#160;in favour&#160;of&#160;the DCarbH&#160;(trastuzumab)&#160;arm&#160;compared&#160;to AC→D.&#160;</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:890px;left:106px;white-space:nowrap" class="ft251">In study BCIRG&#160;006, 213/1075 patients&#160;in&#160;the DCarbH&#160;(TCH)&#160;arm,&#160;221/1074 patients&#160;in&#160;the AC→DH&#160;</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft251">(AC→TH)&#160;arm,&#160;and 217/1073 in&#160;the AC→D&#160;(AC→T)&#160;arm&#160;had&#160;a Karnofsky performance status&#160;≤&#160;90&#160;</p>
<p style="position:absolute;top:932px;left:106px;white-space:nowrap" class="ft251">(either&#160;80 or&#160;90). No disease-free&#160;survival&#160;(DFS)&#160;benefit&#160;was noticed in this&#160;subgroup of&#160;patients&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft251">(hazard&#160;ratio&#160;=&#160;1.16,&#160;95&#160;%&#160;CI&#160;[0.73, 1.83]&#160;for&#160;DCarbH&#160;(TCH)&#160;versus AC→D&#160;(AC→T);&#160;hazard&#160;ratio&#160;</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft251">0.97, 95&#160;%&#160;CI&#160;[0.60,&#160;1.55]&#160;for&#160;AC→DH&#160;(AC→TH)&#160;versus&#160;AC→D).&#160;</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft251">In addition,&#160;a post-hoc&#160;exploratory&#160;analysis was performed on the data sets from&#160;the joint&#160;analysis&#160;(JA)&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft251">NSABP B-31/NCCTG&#160;N9831* and BCIRG006 clinical&#160;studies&#160;combining DFS&#160;events&#160;and&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft251">symptomatic&#160;cardiac&#160;events&#160;and summarised in Table 11:&#160;</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft260">26&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft261">Table&#160;11 Post-Hoc&#160;exploratory&#160;analysis&#160;results&#160;from&#160;the&#160;joint&#160;analysis NSABP B-31/NCCTG&#160;N9831&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft261">and BCIRG006&#160;clinical&#160;studies&#160;combining DFS&#160;events&#160;and&#160;symptomatic&#160;cardiac&#160;events&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:162px;left:107px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:162px;left:377px;white-space:nowrap" class="ft262"><b>AC→PH&#160;&#160;</b></p>
<p style="position:absolute;top:181px;left:367px;white-space:nowrap" class="ft262"><b>(vs. AC→P)&#160;&#160;</b></p>
<p style="position:absolute;top:200px;left:345px;white-space:nowrap" class="ft262"><b>(NSABP B-31 and&#160;</b></p>
<p style="position:absolute;top:219px;left:348px;white-space:nowrap" class="ft262"><b>NCCTG&#160;N9831)*&#160;</b></p>
<p style="position:absolute;top:162px;left:534px;white-space:nowrap" class="ft262"><b>AC→DH&#160;&#160;</b></p>
<p style="position:absolute;top:181px;left:523px;white-space:nowrap" class="ft262"><b>(vs. AC→D)&#160;&#160;</b></p>
<p style="position:absolute;top:200px;left:520px;white-space:nowrap" class="ft262"><b>(BCIRG 006)&#160;</b></p>
<p style="position:absolute;top:162px;left:694px;white-space:nowrap" class="ft262"><b>DCarbH&#160;</b></p>
<p style="position:absolute;top:181px;left:681px;white-space:nowrap" class="ft262"><b>(vs. AC→D)&#160;&#160;</b></p>
<p style="position:absolute;top:200px;left:677px;white-space:nowrap" class="ft262"><b>(BCIRG 006)&#160;</b></p>
<p style="position:absolute;top:241px;left:107px;white-space:nowrap" class="ft261">Primary efficacy analysis&#160;</p>
<p style="position:absolute;top:260px;left:107px;white-space:nowrap" class="ft261">DFS&#160;Hazard&#160;ratios&#160;</p>
<p style="position:absolute;top:279px;left:107px;white-space:nowrap" class="ft261">(95&#160;%&#160;CI)&#160;</p>
<p style="position:absolute;top:298px;left:107px;white-space:nowrap" class="ft261">p-value&#160;</p>
<p style="position:absolute;top:241px;left:409px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:260px;left:394px;white-space:nowrap" class="ft261">0.48&#160;&#160;</p>
<p style="position:absolute;top:279px;left:370px;white-space:nowrap" class="ft261">(0.39, 0.59)&#160;</p>
<p style="position:absolute;top:298px;left:371px;white-space:nowrap" class="ft261">&#160;p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:241px;left:567px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:260px;left:552px;white-space:nowrap" class="ft261">0.61&#160;</p>
<p style="position:absolute;top:279px;left:528px;white-space:nowrap" class="ft261">(0.49, 0.77)&#160;</p>
<p style="position:absolute;top:298px;left:529px;white-space:nowrap" class="ft261">&#160;p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:241px;left:724px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:260px;left:710px;white-space:nowrap" class="ft261">0.67&#160;&#160;</p>
<p style="position:absolute;top:279px;left:686px;white-space:nowrap" class="ft261">(0.54, 0.83)&#160;&#160;</p>
<p style="position:absolute;top:298px;left:689px;white-space:nowrap" class="ft261">p&#160;=&#160;0.0003&#160;</p>
<p style="position:absolute;top:328px;left:107px;white-space:nowrap" class="ft261">Long term&#160;follow-up efficacy&#160;</p>
<p style="position:absolute;top:346px;left:107px;white-space:nowrap" class="ft261">analysis**&#160;</p>
<p style="position:absolute;top:365px;left:107px;white-space:nowrap" class="ft261">DFS&#160;Hazard&#160;ratios&#160;</p>
<p style="position:absolute;top:384px;left:107px;white-space:nowrap" class="ft261">(95&#160;%&#160;CI)&#160;</p>
<p style="position:absolute;top:404px;left:107px;white-space:nowrap" class="ft261">p-value&#160;</p>
<p style="position:absolute;top:328px;left:409px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:346px;left:409px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:365px;left:394px;white-space:nowrap" class="ft261">0.61&#160;</p>
<p style="position:absolute;top:384px;left:370px;white-space:nowrap" class="ft261">(0.54, 0.69)&#160;</p>
<p style="position:absolute;top:404px;left:373px;white-space:nowrap" class="ft261">p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:328px;left:567px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:346px;left:567px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:365px;left:552px;white-space:nowrap" class="ft261">0.72&#160;</p>
<p style="position:absolute;top:384px;left:528px;white-space:nowrap" class="ft261">(0.61, 0.85)&#160;</p>
<p style="position:absolute;top:404px;left:531px;white-space:nowrap" class="ft261">p&#160;&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:328px;left:724px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:346px;left:724px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:365px;left:710px;white-space:nowrap" class="ft261">0.77&#160;</p>
<p style="position:absolute;top:384px;left:686px;white-space:nowrap" class="ft261">(0.65, 0.90)&#160;</p>
<p style="position:absolute;top:404px;left:689px;white-space:nowrap" class="ft261">p&#160;=&#160;0.0011&#160;</p>
<p style="position:absolute;top:427px;left:107px;white-space:nowrap" class="ft261">Post-hoc&#160;exploratory analysis&#160;</p>
<p style="position:absolute;top:445px;left:107px;white-space:nowrap" class="ft261">with DFS&#160;and symptomatic&#160;</p>
<p style="position:absolute;top:465px;left:107px;white-space:nowrap" class="ft261">cardiac&#160;events&#160;&#160;</p>
<p style="position:absolute;top:483px;left:107px;white-space:nowrap" class="ft261">Long term&#160;follow-up**&#160;</p>
<p style="position:absolute;top:503px;left:107px;white-space:nowrap" class="ft261">Hazard&#160;ratios&#160;</p>
<p style="position:absolute;top:521px;left:107px;white-space:nowrap" class="ft261">(95&#160;%&#160;CI)&#160;</p>
<p style="position:absolute;top:427px;left:409px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:445px;left:409px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:465px;left:409px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:483px;left:394px;white-space:nowrap" class="ft261">0.67&#160;&#160;</p>
<p style="position:absolute;top:503px;left:370px;white-space:nowrap" class="ft261">(0.60, 0.75)&#160;</p>
<p style="position:absolute;top:427px;left:567px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:445px;left:567px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:465px;left:567px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:483px;left:552px;white-space:nowrap" class="ft261">0.77&#160;</p>
<p style="position:absolute;top:503px;left:528px;white-space:nowrap" class="ft261">(0.66, 0.90)&#160;</p>
<p style="position:absolute;top:427px;left:724px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:445px;left:724px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:465px;left:724px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:483px;left:710px;white-space:nowrap" class="ft261">0.77&#160;&#160;</p>
<p style="position:absolute;top:503px;left:686px;white-space:nowrap" class="ft261">(0.66, 0.90)&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft2612">A:&#160;doxorubicin; C:&#160;cyclophosphamide;&#160;P: paclitaxel;&#160;D:&#160;docetaxel;&#160;Carb: carboplatin; H: trastuzumab&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft2612">CI&#160;=&#160;confidence&#160;interval&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft2612">*&#160;At&#160;the&#160;time&#160;of&#160;the&#160;definitive&#160;analysis&#160;of&#160;DFS.&#160;Median&#160;duration&#160;of&#160;follow&#160;up&#160;was 1.8&#160;years&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:593px;left:106px;white-space:nowrap" class="ft2612">AC→P arm&#160;and&#160;2.0&#160;years&#160;in&#160;the&#160;AC→PH arm&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft261">** Median&#160;duration of&#160;long&#160;term&#160;follow-up for&#160;the Joint&#160;Analysis clinical&#160;studies&#160;was&#160;8.3 years (range:&#160;</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft261">0.1 to 12.1)&#160;for&#160;the AC→PH&#160;arm&#160;and 7.9 years&#160;(range:&#160;0.0 to&#160;12.2)&#160;for&#160;the AC→P&#160;arm;&#160;Median&#160;</p>
<p style="position:absolute;top:648px;left:106px;white-space:nowrap" class="ft261">duration&#160;of&#160;long&#160;term&#160;follow-up for&#160;the BCIRG&#160;006 study was&#160;10.3 years&#160;in both&#160;the AC→D&#160;arm&#160;</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft261">(range:&#160;0.0&#160;to 12.6)&#160;arm&#160;and the DCarbH&#160;arm&#160;(range:&#160;0.0 to 13.1),&#160;and was 10.4&#160;years&#160;(range:&#160;0.0&#160;to&#160;</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft261">12.7)&#160;in the AC→DH&#160;arm&#160;</p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft265">&#160;<br/><i>Early&#160;breast&#160;cancer&#160;(neoadjuvant-adjuvant&#160;setting)</i></p>
<p style="position:absolute;top:724px;left:445px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:762px;left:106px;white-space:nowrap" class="ft261">So far, no&#160;results are available which compare the efficacy of&#160;trastuzumab administered with&#160;</p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft261">chemotherapy in the adjuvant&#160;setting with&#160;that&#160;obtained in&#160;the neo-adjuvant/adjuvant&#160;setting.&#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft261">In the neoadjuvant-adjuvant&#160;treatment&#160;setting,&#160;study MO16432, a&#160;multicentre randomised&#160;trial, was&#160;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft261">designed&#160;to&#160;investigate the&#160;clinical&#160;efficacy of&#160;concurrent&#160;administration&#160;of&#160;trastuzumab with&#160;</p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft261">neoadjuvant&#160;chemotherapy&#160;including both an&#160;anthracycline and&#160;a taxane, followed&#160;by adjuvant&#160;</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft261">trastuzumab, up&#160;to&#160;a total&#160;treatment&#160;duration&#160;of&#160;1&#160;year.&#160;The study recruited patients&#160;with newly&#160;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft261">diagnosed&#160;locally advanced&#160;(Stage III)&#160;or&#160;inflammatory&#160;EBC. Patients with HER2+ tumours were&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft261">randomised&#160;to&#160;receive either&#160;neoadjuvant&#160;chemotherapy concurrently with neoadjuvant-adjuvant&#160;</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft261">trastuzumab, or&#160;neoadjuvant&#160;chemotherapy&#160;alone.&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:971px;left:106px;white-space:nowrap" class="ft261">In study&#160;MO16432,&#160;trastuzumab&#160;(8&#160;mg/kg loading dose, followed by&#160;6&#160;mg/kg&#160;maintenance&#160;every 3&#160;</p>
<p style="position:absolute;top:990px;left:106px;white-space:nowrap" class="ft261">weeks)&#160;was&#160;administered&#160;concurrently&#160;with 10 cycles&#160;of&#160;neoadjuvant&#160;chemotherapy as&#160;follows:&#160;</p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:1028px;left:133px;white-space:nowrap" class="ft261">-&#160;&#160;Doxorubicin 60&#160;mg/m2&#160;and&#160;paclitaxel&#160;150&#160;mg/m2,&#160;administered 3-weekly for&#160;3&#160;cycles,&#160;</p>
<p style="position:absolute;top:1047px;left:133px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:1066px;left:133px;white-space:nowrap" class="ft261">which was&#160;followed by&#160;</p>
<p style="position:absolute;top:1085px;left:133px;white-space:nowrap" class="ft261">-&#160;&#160;Paclitaxel&#160;175&#160;mg/m2&#160;administered 3-weekly for&#160;4&#160;cycles,&#160;</p>
<p style="position:absolute;top:1104px;left:133px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:1123px;left:133px;white-space:nowrap" class="ft261">which was&#160;followed by&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2720{font-size:12px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
	.ft2721{font-size:12px;line-height:19px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft270">27&#160;</p>
<p style="position:absolute;top:104px;left:133px;white-space:nowrap" class="ft271">-&#160;&#160;CMF on day&#160;1 and&#160;8 every&#160;4 weeks&#160;for&#160;3 cycles&#160;</p>
<p style="position:absolute;top:123px;left:133px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:142px;left:133px;white-space:nowrap" class="ft271">which was&#160;followed after&#160;surgery by&#160;</p>
<p style="position:absolute;top:161px;left:133px;white-space:nowrap" class="ft271">-&#160;&#160;additional&#160;cycles&#160;of&#160;adjuvant&#160;trastuzumab (to complete 1 year&#160;of&#160;treatment)&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft271">The efficacy&#160;results&#160;from&#160;Study MO16432 are summarized in Table 12.&#160;The&#160;median duration of&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft271">follow-up in&#160;the&#160;trastuzumab arm&#160;was&#160;3.8 years.&#160;&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft271">Table&#160;12 Efficacy&#160;results&#160;from&#160;MO16432&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:295px;left:107px;white-space:nowrap" class="ft272"><b>Parameter&#160;</b></p>
<p style="position:absolute;top:295px;left:352px;white-space:nowrap" class="ft272"><b>Chemo +&#160;</b></p>
<p style="position:absolute;top:314px;left:336px;white-space:nowrap" class="ft272"><b>Trastuzumab&#160;</b></p>
<p style="position:absolute;top:333px;left:353px;white-space:nowrap" class="ft272"><b>(n&#160;=&#160;115)&#160;</b></p>
<p style="position:absolute;top:295px;left:475px;white-space:nowrap" class="ft272"><b>Chemo only&#160;</b></p>
<p style="position:absolute;top:314px;left:486px;white-space:nowrap" class="ft272"><b>(n&#160;=&#160;116)&#160;</b></p>
<p style="position:absolute;top:295px;left:657px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:353px;left:107px;white-space:nowrap" class="ft271">Event-free&#160;survival&#160;</p>
<p style="position:absolute;top:372px;left:107px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:391px;left:107px;white-space:nowrap" class="ft271">No. patients with event&#160;</p>
<p style="position:absolute;top:353px;left:384px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:372px;left:384px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:391px;left:376px;white-space:nowrap" class="ft271">46&#160;</p>
<p style="position:absolute;top:353px;left:517px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:372px;left:517px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:391px;left:509px;white-space:nowrap" class="ft271">59&#160;</p>
<p style="position:absolute;top:353px;left:613px;white-space:nowrap" class="ft271">Hazard Ratio&#160;</p>
<p style="position:absolute;top:372px;left:624px;white-space:nowrap" class="ft271">(95&#160;%&#160;CI)&#160;</p>
<p style="position:absolute;top:391px;left:602px;white-space:nowrap" class="ft271">0.65 (0.44, 0.96)&#160;</p>
<p style="position:absolute;top:410px;left:621px;white-space:nowrap" class="ft271">p&#160;=&#160;0.0275&#160;</p>
<p style="position:absolute;top:430px;left:107px;white-space:nowrap" class="ft271">Total&#160;pathological&#160;complete&#160;</p>
<p style="position:absolute;top:449px;left:107px;white-space:nowrap" class="ft271">response*&#160;(95&#160;%&#160;CI)&#160;</p>
<p style="position:absolute;top:430px;left:367px;white-space:nowrap" class="ft271">40&#160;%&#160;</p>
<p style="position:absolute;top:449px;left:345px;white-space:nowrap" class="ft271">(31.0, 49.6)&#160;</p>
<p style="position:absolute;top:430px;left:494px;white-space:nowrap" class="ft271">20.7&#160;%&#160;</p>
<p style="position:absolute;top:449px;left:479px;white-space:nowrap" class="ft271">(13.7, 29.2)&#160;</p>
<p style="position:absolute;top:430px;left:621px;white-space:nowrap" class="ft271">p&#160;=&#160;0.0014&#160;</p>
<p style="position:absolute;top:469px;left:107px;white-space:nowrap" class="ft271">Overall&#160;survival&#160;</p>
<p style="position:absolute;top:488px;left:107px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:507px;left:107px;white-space:nowrap" class="ft271">No. patients with event&#160;</p>
<p style="position:absolute;top:469px;left:384px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:488px;left:384px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:507px;left:376px;white-space:nowrap" class="ft271">22&#160;</p>
<p style="position:absolute;top:469px;left:517px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:488px;left:517px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:507px;left:509px;white-space:nowrap" class="ft271">33&#160;</p>
<p style="position:absolute;top:469px;left:613px;white-space:nowrap" class="ft271">Hazard Ratio&#160;</p>
<p style="position:absolute;top:488px;left:624px;white-space:nowrap" class="ft271">(95&#160;%&#160;CI)&#160;</p>
<p style="position:absolute;top:507px;left:602px;white-space:nowrap" class="ft271">0.59 (0.35, 1.02)&#160;</p>
<p style="position:absolute;top:526px;left:621px;white-space:nowrap" class="ft271">p&#160;=&#160;0.0555&#160;</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft2712">*&#160;defined&#160;as absence&#160;of&#160;any&#160;invasive&#160;cancer&#160;both&#160;in&#160;the&#160;breast and&#160;axillary&#160;nodes&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft271">An absolute benefit&#160;of&#160;13 percentage points in favour&#160;of&#160;the trastuzumab arm&#160;was&#160;estimated in&#160;terms&#160;</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft271">of&#160;3-year&#160;event-free&#160;survival&#160;rate&#160;(65&#160;%&#160;versus 52&#160;%).&#160;</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft2721">&#160;<br/><i>Metastatic gastric&#160;cancer</i></p>
<p style="position:absolute;top:633px;left:275px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft2710">&#160;</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft271">Trastuzumab&#160;has&#160;been&#160;investigated in one&#160;randomised,&#160;open-label&#160;phase III&#160;trial&#160;ToGA&#160;(BO18255)&#160;in&#160;</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft271">combination with chemotherapy versus chemotherapy&#160;alone.&#160;</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft271">Chemotherapy was administered as follows:&#160;</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:759px;left:106px;white-space:nowrap" class="ft271">-&#160;</p>
<p style="position:absolute;top:759px;left:149px;white-space:nowrap" class="ft271">capecitabine&#160;–&#160;1000&#160;mg/m2&#160;orally&#160;twice daily for&#160;14 days every 3 weeks&#160;for&#160;6 cycles&#160;(evening of&#160;</p>
<p style="position:absolute;top:778px;left:149px;white-space:nowrap" class="ft271">day 1 to morning of&#160;day 15&#160;of&#160;each cycle)&#160;</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft271">or&#160;</p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft271">-&#160;</p>
<p style="position:absolute;top:816px;left:149px;white-space:nowrap" class="ft271">intravenous&#160;5-fluorouracil&#160;-&#160;800&#160;mg/m2/day as&#160;a continuous intravenous&#160;infusion over&#160;5 days,&#160;</p>
<p style="position:absolute;top:835px;left:149px;white-space:nowrap" class="ft271">given&#160;every 3 weeks&#160;for&#160;6&#160;cycles (days&#160;1&#160;to 5&#160;of&#160;each&#160;cycle)&#160;</p>
<p style="position:absolute;top:854px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft271">Either&#160;of&#160;which was&#160;administered with:&#160;</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft271">-&#160;</p>
<p style="position:absolute;top:911px;left:149px;white-space:nowrap" class="ft271">cisplatin&#160;–&#160;80&#160;mg/m2&#160;every&#160;3 weeks&#160;for&#160;6 cycles on day&#160;1 of&#160;each&#160;cycle.&#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2822{font-size:14px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft280">28&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft281">The efficacy&#160;results&#160;from&#160;study BO18225 are&#160;summarised in Table 13:&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft281">Table&#160;13 Efficacy&#160;results&#160;from&#160;BO18225&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2810">&#160;</p>
<p style="position:absolute;top:174px;left:107px;white-space:nowrap" class="ft282"><b>Parameter</b>&#160;</p>
<p style="position:absolute;top:174px;left:381px;white-space:nowrap" class="ft282"><b>FP</b>&#160;</p>
<p style="position:absolute;top:193px;left:364px;white-space:nowrap" class="ft282"><b>N&#160;=&#160;290</b>&#160;</p>
<p style="position:absolute;top:174px;left:453px;white-space:nowrap" class="ft282"><b>FP&#160;+H&#160;&#160;</b></p>
<p style="position:absolute;top:193px;left:449px;white-space:nowrap" class="ft282"><b>N&#160;=&#160;294</b>&#160;</p>
<p style="position:absolute;top:174px;left:537px;white-space:nowrap" class="ft282"><b>HR&#160;(95&#160;% CI)</b>&#160;</p>
<p style="position:absolute;top:174px;left:673px;white-space:nowrap" class="ft282"><b>p-value</b>&#160;</p>
<p style="position:absolute;top:213px;left:107px;white-space:nowrap" class="ft281">Overall&#160;Survival, Median&#160;months&#160;</p>
<p style="position:absolute;top:213px;left:377px;white-space:nowrap" class="ft281">11.1&#160;</p>
<p style="position:absolute;top:213px;left:462px;white-space:nowrap" class="ft281">13.8&#160;</p>
<p style="position:absolute;top:213px;left:533px;white-space:nowrap" class="ft281">0.74 (0.60-0.91)&#160;</p>
<p style="position:absolute;top:213px;left:677px;white-space:nowrap" class="ft281">0.0046&#160;</p>
<p style="position:absolute;top:232px;left:107px;white-space:nowrap" class="ft281">Progression-Free Survival,&#160;</p>
<p style="position:absolute;top:252px;left:107px;white-space:nowrap" class="ft281">Median&#160;months&#160;</p>
<p style="position:absolute;top:232px;left:381px;white-space:nowrap" class="ft281">5.5&#160;</p>
<p style="position:absolute;top:232px;left:466px;white-space:nowrap" class="ft281">6.7&#160;</p>
<p style="position:absolute;top:232px;left:533px;white-space:nowrap" class="ft281">0.71 (0.59-0.85)&#160;</p>
<p style="position:absolute;top:232px;left:677px;white-space:nowrap" class="ft281">0.0002&#160;</p>
<p style="position:absolute;top:271px;left:107px;white-space:nowrap" class="ft281">Time to Disease Progression,&#160;</p>
<p style="position:absolute;top:290px;left:107px;white-space:nowrap" class="ft281">Median&#160;months&#160;</p>
<p style="position:absolute;top:271px;left:381px;white-space:nowrap" class="ft281">5.6&#160;</p>
<p style="position:absolute;top:271px;left:466px;white-space:nowrap" class="ft281">7.1&#160;</p>
<p style="position:absolute;top:271px;left:533px;white-space:nowrap" class="ft281">0.70&#160;(0.58-0.85)&#160;</p>
<p style="position:absolute;top:271px;left:677px;white-space:nowrap" class="ft281">0.0003&#160;</p>
<p style="position:absolute;top:310px;left:107px;white-space:nowrap" class="ft281">Overall&#160;Response Rate,&#160;%&#160;</p>
<p style="position:absolute;top:310px;left:368px;white-space:nowrap" class="ft281">34.5&#160;%&#160;</p>
<p style="position:absolute;top:310px;left:453px;white-space:nowrap" class="ft281">47.3&#160;%&#160;</p>
<p style="position:absolute;top:310px;left:529px;white-space:nowrap" class="ft281">1.70a&#160;(1.22, 2.38)&#160;</p>
<p style="position:absolute;top:310px;left:677px;white-space:nowrap" class="ft281">0.0017&#160;</p>
<p style="position:absolute;top:330px;left:107px;white-space:nowrap" class="ft281">Duration of&#160;Response, Median&#160;</p>
<p style="position:absolute;top:349px;left:107px;white-space:nowrap" class="ft281">months&#160;</p>
<p style="position:absolute;top:330px;left:381px;white-space:nowrap" class="ft281">4.8&#160;</p>
<p style="position:absolute;top:330px;left:466px;white-space:nowrap" class="ft281">6.9&#160;</p>
<p style="position:absolute;top:330px;left:533px;white-space:nowrap" class="ft281">0.54 (0.40-0.73)&#160;</p>
<p style="position:absolute;top:330px;left:670px;white-space:nowrap" class="ft281">&lt;&#160;0.0001&#160;</p>
<p style="position:absolute;top:369px;left:106px;white-space:nowrap" class="ft2812">FP&#160;+&#160;H:&#160;Fluoropyrimidine/cisplatin&#160;+&#160;Trastuzumab&#160;</p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2812">FP:&#160;Fluoropyrimidine/cisplatin&#160;</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft2812">a&#160;Odds&#160;ratio&#160;</p>
<p style="position:absolute;top:421px;left:106px;white-space:nowrap" class="ft2822">&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft281">Patients were recruited&#160;to the trial&#160;who were previously untreated&#160;for&#160;HER2-positive&#160;inoperable&#160;locally&#160;</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft281">advanced or&#160;recurrent&#160;and/or&#160;metastatic adenocarcinoma of&#160;the stomach&#160;or&#160;gastro-oesophageal&#160;</p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft281">junction not&#160;amenable&#160;to&#160;curative&#160;therapy. The primary&#160;endpoint&#160;was overall&#160;survival&#160;which was&#160;</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft281">defined&#160;as&#160;the&#160;time&#160;from&#160;the date of&#160;randomisation&#160;to the date of&#160;death&#160;from&#160;any cause. At&#160;the time of&#160;</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft281">the analysis a&#160;total&#160;of&#160;349 randomised patients had&#160;died:&#160;182&#160;patients&#160;(62.8&#160;%)&#160;in&#160;the control&#160;arm&#160;and&#160;</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft281">167 patients&#160;(56.8&#160;%)&#160;in the&#160;treatment&#160;arm. The&#160;majority of&#160;the deaths were due to&#160;events related to&#160;the&#160;</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft281">underlying cancer.&#160;</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2822">&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft281">Post-hoc&#160;subgroup analyses&#160;indicate&#160;that&#160;positive&#160;treatment&#160;effects are limited&#160;to targeting tumours&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft281">with&#160;higher&#160;levels of&#160;HER2&#160;protein&#160;(IHC&#160;2+/FISH+ or&#160;IHC&#160;3+). The&#160;median overall&#160;survival&#160;for&#160;the&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft281">high HER2 expressing group was&#160;11.8&#160;months&#160;versus&#160;16 months, HR&#160;0.65 (95&#160;%&#160;CI&#160;0.51-0.83)&#160;and&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft281">the&#160;median&#160;progression free&#160;survival&#160;was&#160;5.5&#160;months versus 7.6&#160;months,&#160;HR&#160;0.64&#160;(95&#160;%&#160;CI&#160;0.51-0.79)&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft281">for&#160;FP&#160;versus&#160;FP&#160;+ H, respectively. For&#160;overall&#160;survival, the HR&#160;was&#160;0.75&#160;(95&#160;%&#160;CI&#160;0.51-1.11)&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft281">IHC&#160;2+/FISH+ group and the HR&#160;was&#160;0.58&#160;(95&#160;%&#160;CI&#160;0.41-0.81)&#160;in the IHC&#160;3+/FISH+ group.&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft2822">&#160;</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft281">In an exploratory subgroup&#160;analysis performed&#160;in the TOGA&#160;(BO18255)&#160;trial&#160;there&#160;was&#160;no apparent&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft281">benefit&#160;on overall&#160;survival&#160;with&#160;the addition of&#160;trastuzumab&#160;in patients with ECOG&#160;PS&#160;2 at&#160;baseline&#160;</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft281">[HR&#160;0.96 (95&#160;%&#160;CI&#160;0.51-1.79)],&#160;non-measurable&#160;[HR&#160;1.78 (95&#160;%&#160;CI&#160;0.87-3.66)]&#160;and locally advanced&#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft281">disease&#160;[HR&#160;1.20&#160;(95&#160;%&#160;CI&#160;0.29-4.97)].&#160;</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft2822">&#160;</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft281">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft281">The European&#160;Medicines Agency has&#160;waived&#160;the&#160;obligation to&#160;submit&#160;the&#160;results of&#160;studies&#160;with&#160;the&#160;</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft281">reference&#160;medicinal&#160;product&#160;containing&#160;trastuzumab&#160;in&#160;all&#160;subsets of&#160;the&#160;paediatric&#160;population&#160;for&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft281">breast&#160;and gastric cancer&#160;(see&#160;section 4.2 for&#160;information&#160;on paediatric&#160;use).&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft282"><b>5.2&#160;</b></p>
<p style="position:absolute;top:919px;left:160px;white-space:nowrap" class="ft282"><b>Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft281">The pharmacokinetics&#160;of&#160;trastuzumab were evaluated in a population pharmacokinetic&#160;model&#160;analysis&#160;</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft281">using&#160;pooled data&#160;from&#160;1,582 subjects,&#160;including patients with HER2 positive MBC, EBC, AGC&#160;or&#160;</p>
<p style="position:absolute;top:995px;left:106px;white-space:nowrap" class="ft281">other&#160;tumour&#160;types, and&#160;healthy&#160;volunteers, in&#160;18 Phase&#160;I, II&#160;and III&#160;trials receiving&#160;trastuzumab IV. A&#160;</p>
<p style="position:absolute;top:1014px;left:106px;white-space:nowrap" class="ft281">two-compartment&#160;model&#160;with parallel&#160;linear&#160;and non-linear&#160;elimination from&#160;the central&#160;compartment&#160;</p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft281">described the trastuzumab concentration-time&#160;profile.&#160;Due&#160;to non-linear&#160;elimination, total&#160;clearance&#160;</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft281">increased with decreasing&#160;concentration. Therefore, no&#160;constant&#160;value&#160;for&#160;half-life&#160;of&#160;trastuzumab can&#160;</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft281">be deduced. The t1/2&#160;decreases with decreasing&#160;concentrations&#160;within&#160;a dosing&#160;interval&#160;(see&#160;Table&#160;16).&#160;</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft281">MBC&#160;and EBC&#160;patients had similar&#160;PK&#160;parameters (e.g. clearance&#160;(CL),&#160;the&#160;central&#160;compartment&#160;</p>
<p style="position:absolute;top:1109px;left:106px;white-space:nowrap" class="ft281">volume&#160;(Vc))&#160;and population-predicted steady-state exposures&#160;(Cmin, Cmax&#160;and AUC). Linear&#160;clearance&#160;</p>
<p style="position:absolute;top:1128px;left:106px;white-space:nowrap" class="ft281">was&#160;0.136&#160;L/day&#160;for&#160;MBC,&#160;0.112&#160;L/day&#160;for&#160;EBC&#160;and 0.176&#160;L/day for&#160;AGC. The non-linear&#160;elimination&#160;</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page29-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft290">29&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft291">parameter&#160;values&#160;were&#160;8.81&#160;mg/day&#160;for&#160;the&#160;maximum&#160;elimination&#160;rate (Vmax)&#160;and 8.92&#160;mcg/mL for&#160;the&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft291">Michaelis-Menten constant&#160;(Km)&#160;for&#160;the MBC, EBC, and AGC&#160;patients. The&#160;central&#160;compartment&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft291">volume was 2.62&#160;L&#160;for&#160;patients with&#160;MBC&#160;and&#160;EBC&#160;and 3.63&#160;L&#160;for&#160;patients with&#160;AGC. In the final&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft291">population PK&#160;model, in addition&#160;to primary tumour&#160;type, body-weight,&#160;serum&#160;aspartate&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft291">aminotransferase&#160;and albumin were&#160;identified&#160;as&#160;a&#160;statistically&#160;significant&#160;covariates&#160;affecting the&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft291">exposure of&#160;trastuzumab. However,&#160;the&#160;magnitude&#160;of&#160;effect&#160;of&#160;these covariates&#160;on&#160;trastuzumab&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft291">exposure suggests&#160;that&#160;these covariates are unlikely to&#160;have&#160;a&#160;clinically&#160;meaningful&#160;effect&#160;on&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft291">trastuzumab concentrations.&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft291">The population&#160;predicted&#160;PK&#160;exposure values&#160;(median&#160;with 5th&#160;-&#160;95th Percentiles)&#160;and PK&#160;parameter&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft291">values at&#160;clinically relevant&#160;concentrations (Cmax&#160;and Cmin)&#160;for&#160;MBC, EBC&#160;and AGC&#160;patients treated&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft291">with&#160;the approved q1w&#160;and&#160;q3w&#160;dosing regimens are shown in Table&#160;14 (cycle 1),&#160;Table&#160;15 (steady-&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft291">state), and&#160;Table 16&#160;(PK&#160;parameters).&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:371px;left:106px;white-space:nowrap" class="ft291">Table&#160;14 Population&#160;predicted&#160;cycle 1&#160;PK&#160;exposure&#160;values&#160;(median with 5th&#160;-&#160;95th&#160;percentiles)&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft291">fortrastuzumab&#160;intravenous&#160;dosing&#160;regimens in&#160;MBC,&#160;EBC&#160;and AGC&#160;patients&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:444px;left:128px;white-space:nowrap" class="ft292"><b>Regimen&#160;</b></p>
<p style="position:absolute;top:435px;left:223px;white-space:nowrap" class="ft292"><b>Primary&#160;tumour&#160;</b></p>
<p style="position:absolute;top:454px;left:266px;white-space:nowrap" class="ft292"><b>type&#160;</b></p>
<p style="position:absolute;top:444px;left:385px;white-space:nowrap" class="ft292"><b>N&#160;</b></p>
<p style="position:absolute;top:435px;left:470px;white-space:nowrap" class="ft292"><b>Cmin&#160;</b></p>
<p style="position:absolute;top:454px;left:450px;white-space:nowrap" class="ft292"><b>(mcg/mL)&#160;</b></p>
<p style="position:absolute;top:435px;left:581px;white-space:nowrap" class="ft292"><b>Cmax&#160;</b></p>
<p style="position:absolute;top:454px;left:562px;white-space:nowrap" class="ft292"><b>(mcg/mL)&#160;</b></p>
<p style="position:absolute;top:435px;left:683px;white-space:nowrap" class="ft292"><b>AUC0-21days&#160;</b></p>
<p style="position:absolute;top:454px;left:671px;white-space:nowrap" class="ft292"><b>(mcg.day/mL)&#160;</b></p>
<p style="position:absolute;top:480px;left:159px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:499px;left:125px;white-space:nowrap" class="ft291">8&#160;mg/kg +&#160;</p>
<p style="position:absolute;top:518px;left:116px;white-space:nowrap" class="ft291">6&#160;mg/kg q3w&#160;</p>
<p style="position:absolute;top:480px;left:281px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:499px;left:263px;white-space:nowrap" class="ft291">MBC&#160;</p>
<p style="position:absolute;top:480px;left:391px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:499px;left:378px;white-space:nowrap" class="ft291">805&#160;</p>
<p style="position:absolute;top:480px;left:485px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:499px;left:471px;white-space:nowrap" class="ft291">28.7&#160;</p>
<p style="position:absolute;top:518px;left:448px;white-space:nowrap" class="ft291">(2.9&#160;-&#160;46.3)&#160;</p>
<p style="position:absolute;top:480px;left:597px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:499px;left:585px;white-space:nowrap" class="ft291">182&#160;</p>
<p style="position:absolute;top:518px;left:560px;white-space:nowrap" class="ft291">(134&#160;-&#160;280)&#160;</p>
<p style="position:absolute;top:480px;left:721px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:499px;left:705px;white-space:nowrap" class="ft291">1376&#160;</p>
<p style="position:absolute;top:518px;left:680px;white-space:nowrap" class="ft291">(728&#160;-&#160;1998)&#160;</p>
<p style="position:absolute;top:536px;left:281px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:555px;left:265px;white-space:nowrap" class="ft291">EBC&#160;</p>
<p style="position:absolute;top:536px;left:391px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:555px;left:378px;white-space:nowrap" class="ft291">390&#160;</p>
<p style="position:absolute;top:536px;left:471px;white-space:nowrap" class="ft291">30.9&#160;</p>
<p style="position:absolute;top:555px;left:444px;white-space:nowrap" class="ft291">(18.7&#160;-&#160;45.5)&#160;</p>
<p style="position:absolute;top:536px;left:585px;white-space:nowrap" class="ft291">176&#160;</p>
<p style="position:absolute;top:555px;left:560px;white-space:nowrap" class="ft291">(127&#160;-&#160;227)&#160;</p>
<p style="position:absolute;top:536px;left:705px;white-space:nowrap" class="ft291">1390&#160;</p>
<p style="position:absolute;top:555px;left:676px;white-space:nowrap" class="ft291">(1039&#160;-&#160;1895)&#160;</p>
<p style="position:absolute;top:583px;left:281px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:602px;left:264px;white-space:nowrap" class="ft291">AGC&#160;</p>
<p style="position:absolute;top:583px;left:391px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:602px;left:378px;white-space:nowrap" class="ft291">274&#160;</p>
<p style="position:absolute;top:583px;left:471px;white-space:nowrap" class="ft291">23.1&#160;</p>
<p style="position:absolute;top:602px;left:448px;white-space:nowrap" class="ft291">(6.1&#160;-&#160;50.3)&#160;</p>
<p style="position:absolute;top:583px;left:585px;white-space:nowrap" class="ft291">132&#160;</p>
<p style="position:absolute;top:602px;left:556px;white-space:nowrap" class="ft291">(84.2&#160;–&#160;225)&#160;</p>
<p style="position:absolute;top:583px;left:705px;white-space:nowrap" class="ft291">1109&#160;</p>
<p style="position:absolute;top:602px;left:678px;white-space:nowrap" class="ft291">(588&#160;–&#160;1938)&#160;</p>
<p style="position:absolute;top:631px;left:159px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:650px;left:125px;white-space:nowrap" class="ft291">4&#160;mg/kg +&#160;</p>
<p style="position:absolute;top:669px;left:120px;white-space:nowrap" class="ft291">2&#160;mg/kg qw&#160;</p>
<p style="position:absolute;top:631px;left:281px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:650px;left:263px;white-space:nowrap" class="ft291">MBC&#160;</p>
<p style="position:absolute;top:631px;left:391px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:650px;left:378px;white-space:nowrap" class="ft291">805&#160;</p>
<p style="position:absolute;top:631px;left:471px;white-space:nowrap" class="ft291">37.4&#160;</p>
<p style="position:absolute;top:650px;left:448px;white-space:nowrap" class="ft291">(8.7&#160;-&#160;58.9)&#160;</p>
<p style="position:absolute;top:631px;left:583px;white-space:nowrap" class="ft291">76.5&#160;</p>
<p style="position:absolute;top:650px;left:558px;white-space:nowrap" class="ft291">(49.4&#160;-&#160;114)&#160;</p>
<p style="position:absolute;top:631px;left:705px;white-space:nowrap" class="ft291">1073&#160;</p>
<p style="position:absolute;top:650px;left:678px;white-space:nowrap" class="ft291">(597&#160;–&#160;1584)&#160;</p>
<p style="position:absolute;top:678px;left:281px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:697px;left:265px;white-space:nowrap" class="ft291">EBC&#160;</p>
<p style="position:absolute;top:678px;left:391px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:697px;left:378px;white-space:nowrap" class="ft291">390&#160;</p>
<p style="position:absolute;top:678px;left:471px;white-space:nowrap" class="ft291">38.9&#160;</p>
<p style="position:absolute;top:697px;left:444px;white-space:nowrap" class="ft291">(25.3&#160;-&#160;58.8)&#160;</p>
<p style="position:absolute;top:678px;left:583px;white-space:nowrap" class="ft291">76.0&#160;</p>
<p style="position:absolute;top:697px;left:558px;white-space:nowrap" class="ft291">(54.7&#160;-&#160;104)&#160;</p>
<p style="position:absolute;top:678px;left:705px;white-space:nowrap" class="ft291">1074&#160;</p>
<p style="position:absolute;top:697px;left:680px;white-space:nowrap" class="ft291">(783&#160;-&#160;1502)&#160;</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft300">30&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft301">Table&#160;15 Population&#160;predicted&#160;steady&#160;state&#160;PK&#160;exposure&#160;values&#160;(median with 5th&#160;-&#160;95th&#160;percentiles)for&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft301">trastuzumab&#160;intravenous&#160;dosing&#160;regimens&#160;in&#160;MBC, EBC&#160;and AGC&#160;patients&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:162px;left:107px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:107px;white-space:nowrap" class="ft302"><b>Regimen&#160;</b></p>
<p style="position:absolute;top:162px;left:261px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:232px;white-space:nowrap" class="ft302"><b>Primary&#160;</b></p>
<p style="position:absolute;top:200px;left:218px;white-space:nowrap" class="ft302"><b>tumour type&#160;</b></p>
<p style="position:absolute;top:162px;left:353px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:347px;white-space:nowrap" class="ft302"><b>N&#160;</b></p>
<p style="position:absolute;top:162px;left:443px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:421px;white-space:nowrap" class="ft302"><b>Cmin,ss*&#160;</b></p>
<p style="position:absolute;top:200px;left:409px;white-space:nowrap" class="ft302"><b>(mcg/mL)&#160;</b></p>
<p style="position:absolute;top:162px;left:550px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:524px;white-space:nowrap" class="ft302"><b>Cmax,ss**&#160;</b></p>
<p style="position:absolute;top:200px;left:515px;white-space:nowrap" class="ft302"><b>(mcg/mL)&#160;</b></p>
<p style="position:absolute;top:162px;left:651px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:607px;white-space:nowrap" class="ft302"><b>AUCss, 0-21days&#160;</b></p>
<p style="position:absolute;top:200px;left:601px;white-space:nowrap" class="ft302"><b>(mcg.day/mL)&#160;</b></p>
<p style="position:absolute;top:162px;left:717px;white-space:nowrap" class="ft302"><b>Time&#160;to&#160;</b></p>
<p style="position:absolute;top:181px;left:719px;white-space:nowrap" class="ft302"><b>steady-&#160;</b></p>
<p style="position:absolute;top:200px;left:716px;white-space:nowrap" class="ft302"><b>state***&#160;</b></p>
<p style="position:absolute;top:219px;left:721px;white-space:nowrap" class="ft302"><b>(week)&#160;</b></p>
<p style="position:absolute;top:259px;left:156px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:278px;left:122px;white-space:nowrap" class="ft301">8&#160;mg/kg +&#160;</p>
<p style="position:absolute;top:297px;left:113px;white-space:nowrap" class="ft301">6&#160;mg/kg q3w&#160;</p>
<p style="position:absolute;top:259px;left:261px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:278px;left:243px;white-space:nowrap" class="ft301">MBC&#160;</p>
<p style="position:absolute;top:259px;left:353px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:278px;left:340px;white-space:nowrap" class="ft301">805&#160;</p>
<p style="position:absolute;top:259px;left:429px;white-space:nowrap" class="ft301">44.2&#160;</p>
<p style="position:absolute;top:278px;left:404px;white-space:nowrap" class="ft301">&#160;(1.8&#160;-&#160;85.4)&#160;</p>
<p style="position:absolute;top:259px;left:537px;white-space:nowrap" class="ft301">179&#160;&#160;</p>
<p style="position:absolute;top:278px;left:513px;white-space:nowrap" class="ft301">(123&#160;-&#160;266)&#160;</p>
<p style="position:absolute;top:259px;left:634px;white-space:nowrap" class="ft301">1736&#160;&#160;</p>
<p style="position:absolute;top:278px;left:610px;white-space:nowrap" class="ft301">(618&#160;-&#160;2756)&#160;</p>
<p style="position:absolute;top:259px;left:745px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:278px;left:736px;white-space:nowrap" class="ft301">12&#160;</p>
<p style="position:absolute;top:309px;left:261px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:328px;left:245px;white-space:nowrap" class="ft301">EBC&#160;</p>
<p style="position:absolute;top:309px;left:353px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:328px;left:340px;white-space:nowrap" class="ft301">390&#160;</p>
<p style="position:absolute;top:309px;left:429px;white-space:nowrap" class="ft301">53.8&#160;&#160;</p>
<p style="position:absolute;top:328px;left:402px;white-space:nowrap" class="ft301">(28.7&#160;-&#160;85.8)&#160;</p>
<p style="position:absolute;top:309px;left:537px;white-space:nowrap" class="ft301">184&#160;&#160;</p>
<p style="position:absolute;top:328px;left:513px;white-space:nowrap" class="ft301">(134&#160;-&#160;247)&#160;</p>
<p style="position:absolute;top:309px;left:634px;white-space:nowrap" class="ft301">1927&#160;&#160;</p>
<p style="position:absolute;top:328px;left:608px;white-space:nowrap" class="ft301">(1332&#160;-2771)&#160;</p>
<p style="position:absolute;top:309px;left:745px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:328px;left:736px;white-space:nowrap" class="ft301">15&#160;</p>
<p style="position:absolute;top:358px;left:261px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:377px;left:244px;white-space:nowrap" class="ft301">AGC&#160;</p>
<p style="position:absolute;top:358px;left:353px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:377px;left:340px;white-space:nowrap" class="ft301">274&#160;</p>
<p style="position:absolute;top:358px;left:429px;white-space:nowrap" class="ft301">32.9&#160;</p>
<p style="position:absolute;top:377px;left:405px;white-space:nowrap" class="ft301">(6.1&#160;–&#160;88.9)&#160;</p>
<p style="position:absolute;top:358px;left:537px;white-space:nowrap" class="ft301">131&#160;&#160;</p>
<p style="position:absolute;top:377px;left:513px;white-space:nowrap" class="ft301">(72.5&#160;-251)&#160;</p>
<p style="position:absolute;top:358px;left:634px;white-space:nowrap" class="ft301">1338&#160;&#160;</p>
<p style="position:absolute;top:377px;left:610px;white-space:nowrap" class="ft301">(557&#160;-&#160;2875)&#160;</p>
<p style="position:absolute;top:358px;left:745px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:377px;left:740px;white-space:nowrap" class="ft301">9&#160;</p>
<p style="position:absolute;top:407px;left:156px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:426px;left:122px;white-space:nowrap" class="ft301">4&#160;mg/kg +&#160;</p>
<p style="position:absolute;top:445px;left:117px;white-space:nowrap" class="ft301">2&#160;mg/kg qw&#160;</p>
<p style="position:absolute;top:407px;left:261px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:426px;left:243px;white-space:nowrap" class="ft301">MBC&#160;</p>
<p style="position:absolute;top:407px;left:353px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:426px;left:340px;white-space:nowrap" class="ft301">805&#160;</p>
<p style="position:absolute;top:407px;left:429px;white-space:nowrap" class="ft301">63.1&#160;&#160;</p>
<p style="position:absolute;top:426px;left:404px;white-space:nowrap" class="ft301">(11.7&#160;-&#160;107)&#160;</p>
<p style="position:absolute;top:407px;left:537px;white-space:nowrap" class="ft301">107&#160;</p>
<p style="position:absolute;top:426px;left:508px;white-space:nowrap" class="ft301">&#160;(54.2&#160;-&#160;164)&#160;</p>
<p style="position:absolute;top:407px;left:634px;white-space:nowrap" class="ft301">1710&#160;&#160;</p>
<p style="position:absolute;top:426px;left:610px;white-space:nowrap" class="ft301">(581&#160;-&#160;2715)&#160;</p>
<p style="position:absolute;top:407px;left:745px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:426px;left:736px;white-space:nowrap" class="ft301">12&#160;</p>
<p style="position:absolute;top:456px;left:261px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:475px;left:245px;white-space:nowrap" class="ft301">EBC&#160;</p>
<p style="position:absolute;top:456px;left:353px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:475px;left:340px;white-space:nowrap" class="ft301">390&#160;</p>
<p style="position:absolute;top:456px;left:429px;white-space:nowrap" class="ft301">72.6&#160;&#160;</p>
<p style="position:absolute;top:475px;left:410px;white-space:nowrap" class="ft301">(46&#160;-&#160;109)&#160;</p>
<p style="position:absolute;top:456px;left:537px;white-space:nowrap" class="ft301">115&#160;&#160;</p>
<p style="position:absolute;top:475px;left:511px;white-space:nowrap" class="ft301">(82.6&#160;-&#160;160)&#160;</p>
<p style="position:absolute;top:456px;left:634px;white-space:nowrap" class="ft301">1893&#160;&#160;</p>
<p style="position:absolute;top:475px;left:608px;white-space:nowrap" class="ft301">(1309&#160;-2734)&#160;</p>
<p style="position:absolute;top:456px;left:745px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:475px;left:736px;white-space:nowrap" class="ft301">14&#160;</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3012">*Cmin,ss&#160;–&#160;Cmin&#160;at&#160;steady&#160;state&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft3012">**Cmax,ss&#160;= Cmax&#160;at&#160;steady&#160;state&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft3012">***&#160;time&#160;to&#160;90% of&#160;steady-state&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft301">Table&#160;16 Population&#160;predicted PK&#160;parameter&#160;values&#160;at&#160;steady&#160;state for&#160;trastuzumab&#160;intravenous&#160;dosing&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft301">regimens&#160;in MBC, EBC&#160;and AGC&#160;patients&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:665px;left:178px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:684px;left:146px;white-space:nowrap" class="ft302"><b>Regimen&#160;</b></p>
<p style="position:absolute;top:656px;left:301px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:675px;left:271px;white-space:nowrap" class="ft302"><b>Primary&#160;</b></p>
<p style="position:absolute;top:694px;left:257px;white-space:nowrap" class="ft302"><b>tumour type&#160;</b></p>
<p style="position:absolute;top:665px;left:387px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:684px;left:381px;white-space:nowrap" class="ft302"><b>N&#160;</b></p>
<p style="position:absolute;top:646px;left:439px;white-space:nowrap" class="ft302"><b>Total&#160;CL&#160;range&#160;</b></p>
<p style="position:absolute;top:665px;left:453px;white-space:nowrap" class="ft302"><b>from&#160;Cmax,ss&#160;</b></p>
<p style="position:absolute;top:684px;left:464px;white-space:nowrap" class="ft302"><b>to Cmin,ss&#160;</b></p>
<p style="position:absolute;top:703px;left:467px;white-space:nowrap" class="ft302"><b>(L/day)&#160;</b></p>
<p style="position:absolute;top:646px;left:664px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:665px;left:581px;white-space:nowrap" class="ft302"><b>t1/2&#160;range&#160;from&#160;Cmax,ss&#160;to&#160;</b></p>
<p style="position:absolute;top:684px;left:643px;white-space:nowrap" class="ft302"><b>Cmin,ss&#160;</b></p>
<p style="position:absolute;top:703px;left:645px;white-space:nowrap" class="ft302"><b>(day)&#160;</b></p>
<p style="position:absolute;top:767px;left:143px;white-space:nowrap" class="ft301">8&#160;mg/kg +&#160;</p>
<p style="position:absolute;top:786px;left:134px;white-space:nowrap" class="ft301">6&#160;mg/kg q3w&#160;</p>
<p style="position:absolute;top:744px;left:283px;white-space:nowrap" class="ft301">MBC&#160;</p>
<p style="position:absolute;top:744px;left:374px;white-space:nowrap" class="ft301">805&#160;</p>
<p style="position:absolute;top:744px;left:449px;white-space:nowrap" class="ft301">0.183&#160;-&#160;0.302&#160;</p>
<p style="position:absolute;top:744px;left:628px;white-space:nowrap" class="ft301">15.1&#160;-&#160;23.3&#160;</p>
<p style="position:absolute;top:779px;left:285px;white-space:nowrap" class="ft301">EBC&#160;</p>
<p style="position:absolute;top:779px;left:374px;white-space:nowrap" class="ft301">390&#160;</p>
<p style="position:absolute;top:779px;left:449px;white-space:nowrap" class="ft301">0.158&#160;-&#160;0.253&#160;</p>
<p style="position:absolute;top:779px;left:626px;white-space:nowrap" class="ft301">17.5&#160;–&#160;26.6&#160;</p>
<p style="position:absolute;top:812px;left:284px;white-space:nowrap" class="ft301">AGC&#160;</p>
<p style="position:absolute;top:812px;left:374px;white-space:nowrap" class="ft301">274&#160;</p>
<p style="position:absolute;top:812px;left:449px;white-space:nowrap" class="ft301">0.189&#160;-&#160;0.337&#160;</p>
<p style="position:absolute;top:812px;left:628px;white-space:nowrap" class="ft301">12.6&#160;-&#160;20.6&#160;</p>
<p style="position:absolute;top:849px;left:143px;white-space:nowrap" class="ft301">4&#160;mg/kg +&#160;</p>
<p style="position:absolute;top:868px;left:138px;white-space:nowrap" class="ft301">2&#160;mg/kg qw&#160;</p>
<p style="position:absolute;top:843px;left:283px;white-space:nowrap" class="ft301">MBC&#160;</p>
<p style="position:absolute;top:843px;left:374px;white-space:nowrap" class="ft301">805&#160;</p>
<p style="position:absolute;top:843px;left:449px;white-space:nowrap" class="ft301">0.213&#160;-&#160;0.259&#160;</p>
<p style="position:absolute;top:843px;left:628px;white-space:nowrap" class="ft301">17.2&#160;-&#160;20.4&#160;</p>
<p style="position:absolute;top:874px;left:285px;white-space:nowrap" class="ft301">EBC&#160;</p>
<p style="position:absolute;top:874px;left:374px;white-space:nowrap" class="ft301">390&#160;</p>
<p style="position:absolute;top:874px;left:449px;white-space:nowrap" class="ft301">0.184&#160;-&#160;0.221&#160;</p>
<p style="position:absolute;top:874px;left:628px;white-space:nowrap" class="ft301">19.7&#160;-&#160;23.2&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft305">&#160;<br/><i>Trastuzumab washout</i></p>
<p style="position:absolute;top:918px;left:251px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft301">Trastuzumab&#160;washout&#160;period was&#160;assessed&#160;following q1w&#160;or&#160;q3w&#160;intravenous&#160;administration using the&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft301">population PK&#160;model. The&#160;results of&#160;these&#160;simulations&#160;indicate that&#160;at&#160;least&#160;95&#160;%&#160;of&#160;patients will&#160;reach&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft301">concentrations&#160;that&#160;are&#160;&lt;&#160;1&#160;mcg/mL&#160;(approximately&#160;3&#160;%&#160;of&#160;the&#160;population&#160;predicted Cmin,ss,&#160;or&#160;about&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft301">97&#160;%&#160;washout)&#160;by&#160;7 months.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft305">&#160;<br/><i>Circulating&#160;shed&#160;HER2-ECD</i></p>
<p style="position:absolute;top:1032px;left:300px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft301">The exploratory analyses of&#160;covariates with information in only a&#160;subset&#160;of&#160;patients suggested that&#160;</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft301">patients with greater&#160;shed&#160;HER2-ECD&#160;level&#160;had faster&#160;nonlinear&#160;clearance&#160;(lower&#160;Km)&#160;(P&#160;&lt;&#160;0.001).&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft301">There was a&#160;correlation between shed antigen and SGOT/AST levels;&#160;part&#160;of&#160;the&#160;impact&#160;of&#160;shed&#160;</p>
<p style="position:absolute;top:1107px;left:106px;white-space:nowrap" class="ft301">antigen on clearance may have&#160;been explained by SGOT/AST levels.&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft310">31&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft311">Baseline&#160;levels of&#160;the&#160;shed&#160;HER2-ECD&#160;observed&#160;in MGC&#160;patients were comparable to those&#160;in&#160;MBC&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft311">and EBC&#160;patients&#160;and no&#160;apparent&#160;impact&#160;on&#160;trastuzumab clearance was observed.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft312"><b>5.3&#160;</b></p>
<p style="position:absolute;top:162px;left:160px;white-space:nowrap" class="ft312"><b>Preclinical&#160;safety data&#160;</b></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft311">There was no&#160;evidence of&#160;acute&#160;or&#160;multiple dose-related toxicity&#160;in studies&#160;of&#160;up&#160;to 6 months, or&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft311">reproductive toxicity in teratology, female fertility or&#160;late gestational&#160;toxicity/placental&#160;transfer&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft311">studies.&#160;Trastuzumab&#160;is not&#160;genotoxic.&#160;&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft311">No long-term&#160;animal&#160;studies have&#160;been&#160;performed to&#160;establish the carcinogenic potential&#160;of&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft311">trastuzumab, or&#160;to determine its effects on&#160;fertility&#160;in&#160;males.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft312"><b>6.&#160;</b></p>
<p style="position:absolute;top:351px;left:160px;white-space:nowrap" class="ft312"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:371px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft312"><b>6.1&#160;</b></p>
<p style="position:absolute;top:389px;left:160px;white-space:nowrap" class="ft312"><b>List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft313"><i>&#160;</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft311">L-histidine hydrochloride&#160;</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft311">L-histidine&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft311">Sorbitol&#160;(E420)&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft311">Macrogol&#160;3350&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft311">Hydrochloric&#160;acid (for&#160;pH&#160;adjustment)&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft311">Sodium&#160;hydroxide&#160;(for&#160;pH&#160;adjustment)&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft312"><b>6.2&#160;</b></p>
<p style="position:absolute;top:560px;left:160px;white-space:nowrap" class="ft312"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft311">This&#160;medicinal&#160;product&#160;must&#160;not&#160;be&#160;mixed&#160;or&#160;diluted&#160;with other&#160;medicinal&#160;products&#160;except&#160;those&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft311">mentioned&#160;in section 6.6.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft311">Glucose solutions&#160;must&#160;not&#160;be used for&#160;dilution&#160;since&#160;these cause&#160;aggregation of&#160;the protein.&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft312"><b>6.3&#160;</b></p>
<p style="position:absolute;top:693px;left:160px;white-space:nowrap" class="ft312"><b>Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft311">4 years.&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft311">After&#160;reconstitution with sterile water&#160;for&#160;injections,&#160;the reconstituted solution is&#160;physically and&#160;</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft311">chemically stable&#160;for&#160;10&#160;days&#160;at&#160;2°C&#160;–&#160;8°C. Any remaining&#160;reconstituted solution&#160;should be discarded.&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft311">Solutions of&#160;Ogivri&#160;for&#160;intravenous infusion&#160;are&#160;physically and&#160;chemically&#160;stable&#160;in polyvinylchloride,&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft311">polyethylene or&#160;polypropylene&#160;bags containing sodium&#160;chloride 9&#160;mg/mL&#160;(0.9&#160;%)&#160;solution for&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft311">injection&#160;for&#160;up to&#160;90&#160;days&#160;at&#160;2°C&#160;–&#160;8°C&#160;and&#160;24 hours&#160;at&#160;temperatures not&#160;exceeding 30°C.&#160;</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft311">From&#160;a&#160;microbiological&#160;point&#160;of&#160;view,&#160;the&#160;reconstituted solution and&#160;Ogivri&#160;infusion solution should&#160;</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft311">be used immediately.&#160;The product&#160;is not&#160;intended&#160;to be&#160;stored after&#160;reconstitution and dilution unless&#160;</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft311">this has&#160;taken place under&#160;controlled and&#160;validated aseptic conditions. If&#160;not&#160;used&#160;immediately, in-use&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft311">storage&#160;times and&#160;conditions are&#160;the responsibility of&#160;the user.&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft312"><b>6.4&#160;</b></p>
<p style="position:absolute;top:997px;left:160px;white-space:nowrap" class="ft312"><b>Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft311">Store&#160;in&#160;a refrigerator&#160;(2°C&#160;–&#160;8°C).&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft311">For storage&#160;conditions&#160;after&#160;reconstitution&#160;of&#160;the&#160;medicinal&#160;product, see sections&#160;6.3&#160;and 6.6.&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page32-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft320">32&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft322"><b>6.5&#160;</b></p>
<p style="position:absolute;top:104px;left:160px;white-space:nowrap" class="ft322"><b>Nature and&#160;contents of&#160;container&#160;&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft321">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft321">15&#160;mL clear&#160;glass&#160;type I&#160;vial&#160;with butyl&#160;rubber&#160;stopper&#160;laminated with a&#160;fluoro-resin film&#160;containing&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft321">150&#160;mg&#160;of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft321">Each carton contains&#160;one vial.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft321">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft321">50&#160;mL clear&#160;glass&#160;type I&#160;vial&#160;with butyl&#160;rubber&#160;stopper&#160;laminated with a&#160;fluoro-resin film&#160;containing&#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft321">420&#160;mg&#160;of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:371px;left:106px;white-space:nowrap" class="ft321">Each carton contains&#160;one vial.&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft322"><b>6.6&#160;</b></p>
<p style="position:absolute;top:408px;left:160px;white-space:nowrap" class="ft322"><b>Special&#160;precautions for disposal&#160;and&#160;other handling&#160;</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft321">Ogivri&#160;should be carefully&#160;handled during reconstitution. Causing excessive foaming during&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft321">reconstitution or&#160;shaking&#160;the reconstituted solution may result&#160;in&#160;problems with&#160;the amount&#160;of&#160;Ogivri&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft321">that&#160;can&#160;be withdrawn&#160;from&#160;the vial.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft321">The reconstituted solution should not&#160;be frozen.&#160;&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft321">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft321">Appropriate aseptic technique should be used. Each&#160;150 mg&#160;vial&#160;of&#160;Ogivri&#160;is&#160;reconstituted with 7.2 mL&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft321">of&#160;sterile water&#160;for&#160;injections&#160;(not&#160;supplied). Use&#160;of&#160;other&#160;reconstitution solvents&#160;should be avoided.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft321">This&#160;yields&#160;a 7.4&#160;mL solution for&#160;single-dose&#160;use,&#160;containing approximately&#160;21&#160;mg/mL&#160;trastuzumab, at&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft321">a pH of approximately 6.0.&#160;A&#160;volume overage of&#160;4&#160;%&#160;ensures that&#160;the&#160;labelled&#160;dose of&#160;150&#160;mg can&#160;be&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft321">withdrawn from&#160;each vial.&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft321">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft321">Each&#160;420&#160;mg&#160;vial&#160;of&#160;Ogivri&#160;is reconstituted with&#160;20&#160;mL of sterile water&#160;for&#160;injections&#160;(not&#160;supplied).&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft321">Use&#160;of&#160;other&#160;reconstitution&#160;solvents should be avoided.&#160;This&#160;yields&#160;a&#160;21&#160;mL solution for&#160;single-dose&#160;</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft321">use, containing approximately 21&#160;mg/mL trastuzumab,&#160;at&#160;a&#160;pH&#160;of&#160;approximately 6.0. A&#160;volume&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft321">overage of&#160;4.8&#160;%&#160;ensures&#160;that&#160;the&#160;labelled dose&#160;of&#160;420&#160;mg can be&#160;withdrawn&#160;from&#160;each vial.&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:846px;left:122px;white-space:nowrap" class="ft321">Ogivri&#160;vial&#160;</p>
<p style="position:absolute;top:846px;left:287px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:846px;left:317px;white-space:nowrap" class="ft321">Volume of&#160;sterile&#160;water&#160;for&#160;</p>
<p style="position:absolute;top:865px;left:317px;white-space:nowrap" class="ft321">injections&#160;</p>
<p style="position:absolute;top:846px;left:553px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:846px;left:582px;white-space:nowrap" class="ft321">Final&#160;concentration&#160;</p>
<p style="position:absolute;top:884px;left:122px;white-space:nowrap" class="ft321">150 mg&#160;vial&#160;</p>
<p style="position:absolute;top:884px;left:282px;white-space:nowrap" class="ft321">+&#160;&#160;7.2 mL&#160;</p>
<p style="position:absolute;top:884px;left:548px;white-space:nowrap" class="ft321">=&#160;&#160;21 mg/mL&#160;</p>
<p style="position:absolute;top:904px;left:122px;white-space:nowrap" class="ft321">420 mg&#160;vial&#160;</p>
<p style="position:absolute;top:904px;left:282px;white-space:nowrap" class="ft321">+&#160;&#160;20 mL&#160;</p>
<p style="position:absolute;top:904px;left:548px;white-space:nowrap" class="ft321">=&#160;&#160;21 mg/mL&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft321">Instructions&#160;for&#160;reconstitution&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft321">1)&#160;Using a sterile&#160;syringe,&#160;slowly&#160;inject&#160;the appropriate&#160;volume&#160;(as&#160;noted above)&#160;of&#160;sterile water&#160;for&#160;</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft321">injections&#160;in&#160;the&#160;vial&#160;containing&#160;the&#160;lyophilised&#160;Ogivri,&#160;directing&#160;the&#160;stream&#160;into the&#160;lyophilised cake.&#160;</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft321">2)&#160;Swirl&#160;the vial&#160;gently to&#160;aid reconstitution. DO&#160;NOT SHAKE!&#160;</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft321">Slight&#160;foaming of&#160;the&#160;product&#160;upon reconstitution is&#160;not&#160;unusual. Allow&#160;the&#160;vial&#160;to&#160;stand&#160;undisturbed&#160;</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft321">for&#160;approximately 5&#160;minutes. The&#160;reconstituted&#160;Ogivri&#160;results in&#160;a colourless&#160;to pale yellow&#160;transparent&#160;</p>
<p style="position:absolute;top:1114px;left:106px;white-space:nowrap" class="ft321">solution and&#160;should be&#160;essentially free&#160;of&#160;visible particulates.&#160;</p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page33-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft330">33&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft331">Determine&#160;the volume&#160;of&#160;the solution&#160;required:&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft331">• &#160; &#160;based on a&#160;loading&#160;dose&#160;of&#160;4&#160;mg trastuzumab/kg body weight, or&#160;a subsequent&#160;weekly&#160;dose&#160;of&#160;2&#160;mg&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft331">trastuzumab/kg body weight:&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:199px;left:141px;white-space:nowrap" class="ft332"><b>Volume&#160;</b>(mL)&#160;=&#160;<b>Body&#160;weight&#160;</b>(kg)&#160;x&#160;<b>dose&#160;</b>(<b>4&#160;</b>mg/kg&#160;for&#160;loading or&#160;<b>2&#160;</b>mg/kg for&#160;maintenance)&#160;</p>
<p style="position:absolute;top:218px;left:275px;white-space:nowrap" class="ft332"><b>21&#160;</b>(mg/mL, concentration&#160;of&#160;reconstituted&#160;solution)&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft331">• &#160; &#160;based on a&#160;loading&#160;dose&#160;of&#160;8&#160;mg trastuzumab/kg body weight, or&#160;a subsequent&#160;3-weekly dose&#160;of&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft331">6&#160;mg&#160;trastuzumab/kg body&#160;weight:&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:313px;left:141px;white-space:nowrap" class="ft332"><b>Volume&#160;</b>(mL)&#160;=&#160;<b>Body&#160;weight&#160;</b>(kg)&#160;x&#160;<b>dose&#160;</b>(<b>8&#160;</b>mg/kg&#160;for&#160;loading or&#160;<b>6&#160;</b>mg/kg for&#160;maintenance)&#160;</p>
<p style="position:absolute;top:332px;left:275px;white-space:nowrap" class="ft332"><b>21&#160;</b>(mg/mL, concentration&#160;of&#160;reconstituted&#160;solution)&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft331">The appropriate&#160;amount&#160;of&#160;solution should be withdrawn from&#160;the vial&#160;using a&#160;sterile needle and&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft331">syringe&#160;and added&#160;to an&#160;infusion&#160;bag containing 250&#160;mL of&#160;sodium&#160;chloride 9&#160;mg/mL&#160;(0.9&#160;%)&#160;solution&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft331">for&#160;injection. Do not&#160;use&#160;with glucose-containing&#160;solutions (see&#160;section 6.2). The bag should be gently&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft331">inverted to&#160;mix the solution&#160;in order&#160;to&#160;avoid foaming.&#160;Once&#160;the infusion&#160;is prepared it&#160;should be&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft331">administered immediately.&#160;If&#160;diluted&#160;aseptically, it&#160;may be stored for&#160;up&#160;to&#160;90&#160;days at&#160;2°C&#160;–&#160;8°C&#160;and&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft331">24 hours&#160;at&#160;temperatures&#160;not&#160;exceeding 30°C.&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft331">Parenteral&#160;medicinal&#160;products&#160;should be&#160;inspected visually for&#160;particulate&#160;matter&#160;and discoloration&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft331">prior&#160;to administration.&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft331">Ogivri&#160;is for&#160;single-use&#160;only, as&#160;the product&#160;contains no preservatives.&#160;&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft331">No incompatibilities&#160;between&#160;Ogivri&#160;and polyvinylchloride, polyethylene&#160;or&#160;polypropylene&#160;bags&#160;have&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft331">been observed.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft331">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be disposed of&#160;in&#160;accordance&#160;with local&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft331">requirements.&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft332"><b>7.&#160;</b></p>
<p style="position:absolute;top:730px;left:160px;white-space:nowrap" class="ft332"><b>MARKETING AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft331">Viatris&#160;Limited&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft331">Damastown&#160;Industrial&#160;Park&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft331">Mulhuddart&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft331">Dublin&#160;15&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft331">DUBLIN&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft331">Ireland&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft332"><b>8.&#160;</b></p>
<p style="position:absolute;top:920px;left:160px;white-space:nowrap" class="ft332"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;&#160;</b></p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft331">EU/1/18/1341/001&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft331">EU/1/18/1341/002&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft332"><b>9.&#160;</b></p>
<p style="position:absolute;top:1034px;left:160px;white-space:nowrap" class="ft332"><b>DATE&#160;OF FIRST&#160;AUTHORISATION/RENEWAL&#160;OF THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft331">Date of&#160;first&#160;authorisation:&#160;12 December&#160;2018&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:1110px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft340">34&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft342"><b>10.&#160;</b></p>
<p style="position:absolute;top:104px;left:160px;white-space:nowrap" class="ft342"><b>DATE&#160;OF&#160;REVISION&#160;OF THE&#160;TEXT&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft341">Detailed&#160;information on&#160;this medicinal&#160;product&#160;is available&#160;on the website of&#160;the European Medicines&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft341">Agenc<a href="http://www.ema.europa.eu/">y&#160;http://www.ema.europa.eu.</a>&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:219px;left:116px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:219px;left:332px;white-space:nowrap" class="ft341">&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft350">35&#160;</p>
<p style="position:absolute;top:105px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:124px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:144px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:163px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:183px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:202px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:222px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:241px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:261px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:280px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:300px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:319px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:339px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:358px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:378px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:397px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:417px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:457px;left:409px;white-space:nowrap" class="ft352"><b>ANNEX&#160;II&#160;</b></p>
<p style="position:absolute;top:493px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:533px;left:106px;white-space:nowrap" class="ft352"><b>A.&#160;&#160;MANUFACTURER(S) OF THE&#160;BIOLOGICAL&#160;ACTIVE&#160;SUBSTANCE(S)&#160;AND&#160;</b></p>
<p style="position:absolute;top:553px;left:149px;white-space:nowrap" class="ft352"><b>MANUFACTURER(S) RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;&#160;</b></p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft352"><b>B.&#160;</b></p>
<p style="position:absolute;top:594px;left:149px;white-space:nowrap" class="ft352"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS REGARDING&#160;SUPPLY&#160;AND&#160;USE&#160;</b></p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:649px;left:106px;white-space:nowrap" class="ft352"><b>C.&#160;&#160;OTHER&#160;CONDITIONS&#160;AND&#160;REQUIREMENTS OF THE&#160;MARKETING&#160;</b></p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft352"><b>AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:688px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:708px;left:106px;white-space:nowrap" class="ft352"><b>D.&#160;&#160;CONDITIONS&#160;OR&#160;RESTRICTIONS WITH&#160;REGARD&#160;TO&#160;THE&#160;SAFE&#160;AND&#160;</b></p>
<p style="position:absolute;top:727px;left:149px;white-space:nowrap" class="ft352"><b>EFFECTIVE&#160;USE&#160;OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:747px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:787px;left:116px;white-space:nowrap" class="ft351">&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3623{font-size:17px;font-family:TimesNewRomanPS;color:#339966;}
	.ft3624{font-size:17px;line-height:29px;font-family:TimesNewRomanPS;color:#339966;}
	.ft3625{font-size:17px;line-height:29px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page36-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft360">36&#160;</p>
<p style="position:absolute;top:104px;left:116px;white-space:nowrap" class="ft362"><b>A.&#160;&#160;MANUFACTURER(S) OF THE&#160;BIOLOGICAL&#160;ACTIVE&#160;SUBSTANCE(S)&#160;AND&#160;</b></p>
<p style="position:absolute;top:124px;left:116px;white-space:nowrap" class="ft362"><b>MANUFACTURER(S) RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:162px;left:116px;white-space:nowrap" class="ft3624">Name&#160;and address&#160;of&#160;the&#160;manufacturer(s)&#160;of&#160;the biological&#160;active substance(s)&#160;<i>&#160;<br/></i>Biocon&#160;Biologics&#160;Limited&#160;</p>
<p style="position:absolute;top:211px;left:116px;white-space:nowrap" class="ft361">Block No. B1, B2,&#160;B3,&#160;Q13&#160;of&#160;Q1 and&#160;W20&#160;&amp;&#160;&#160;</p>
<p style="position:absolute;top:231px;left:116px;white-space:nowrap" class="ft361">Unit&#160;S18, 1st&#160;Floor, Block&#160;B4&#160;</p>
<p style="position:absolute;top:250px;left:116px;white-space:nowrap" class="ft361">Special&#160;Economic Zone Plot&#160;Nos. 2,&#160;3, 4&#160;&amp;&#160;5&#160;</p>
<p style="position:absolute;top:270px;left:116px;white-space:nowrap" class="ft361">Phase-IV-Bommasandra-Jigani&#160;Link Road-Bommasandra Post&#160;</p>
<p style="position:absolute;top:289px;left:116px;white-space:nowrap" class="ft361">Bengaluru&#160;-&#160;560 099&#160;</p>
<p style="position:absolute;top:309px;left:116px;white-space:nowrap" class="ft361">INDIA&#160;</p>
<p style="position:absolute;top:328px;left:116px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:349px;left:116px;white-space:nowrap" class="ft3625">Name&#160;and address&#160;of&#160;the&#160;manufacturer(s)&#160;responsible&#160;for&#160;batch&#160;release&#160;<br/>McDermott&#160;Laboratories&#160;Limited T/A&#160;Mylan Dublin Biologics&#160;</p>
<p style="position:absolute;top:399px;left:116px;white-space:nowrap" class="ft361">Newenham&#160;Court&#160;</p>
<p style="position:absolute;top:418px;left:116px;white-space:nowrap" class="ft361">Northern Cross&#160;</p>
<p style="position:absolute;top:438px;left:116px;white-space:nowrap" class="ft361">Malahide Road&#160;</p>
<p style="position:absolute;top:457px;left:116px;white-space:nowrap" class="ft361">Dublin&#160;17&#160;</p>
<p style="position:absolute;top:477px;left:116px;white-space:nowrap" class="ft361">Ireland&#160;</p>
<p style="position:absolute;top:496px;left:116px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:516px;left:116px;white-space:nowrap" class="ft361">Mylan Germany GmbH&#160;</p>
<p style="position:absolute;top:535px;left:116px;white-space:nowrap" class="ft361">Zweigniederlassung Bad Homburg v. d.&#160;Hoehe,&#160;Benzstrasse&#160;1&#160;</p>
<p style="position:absolute;top:555px;left:116px;white-space:nowrap" class="ft361">Bad Homburg v.&#160;d. Hoehe&#160;</p>
<p style="position:absolute;top:574px;left:116px;white-space:nowrap" class="ft361">Hessen,&#160;61352,&#160;&#160;</p>
<p style="position:absolute;top:594px;left:116px;white-space:nowrap" class="ft361">Germany&#160;</p>
<p style="position:absolute;top:613px;left:106px;white-space:nowrap" class="ft362"><b>&#160;</b></p>
<p style="position:absolute;top:632px;left:116px;white-space:nowrap" class="ft361">The printed package leaflet&#160;of&#160;the medicinal&#160;product&#160;must&#160;state&#160;the name and&#160;address of&#160;the&#160;</p>
<p style="position:absolute;top:652px;left:116px;white-space:nowrap" class="ft361">manufacturer&#160;responsible for&#160;the release&#160;of&#160;the&#160;concerned batch.&#160;</p>
<p style="position:absolute;top:671px;left:116px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:712px;left:116px;white-space:nowrap" class="ft362"><b>B.&#160;&#160;CONDITIONS&#160;OR&#160;RESTRICTIONS REGARDING&#160;SUPPLY&#160;AND&#160;USE&#160;</b></p>
<p style="position:absolute;top:749px;left:116px;white-space:nowrap" class="ft361">Medicinal&#160;product&#160;subject&#160;to restricted&#160;medical&#160;prescription (see&#160;Annex I:&#160;Summary of&#160;Product&#160;</p>
<p style="position:absolute;top:770px;left:116px;white-space:nowrap" class="ft361">Characteristics,&#160;section 4.2).&#160;</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:831px;left:116px;white-space:nowrap" class="ft362"><b>C.&#160;&#160;OTHER&#160;CONDITIONS&#160;AND&#160;REQUIREMENTS OF THE&#160;MARKETING&#160;</b></p>
<p style="position:absolute;top:851px;left:170px;white-space:nowrap" class="ft362"><b>AUTHORISATION&#160;&#160;</b></p>
<p style="position:absolute;top:889px;left:114px;white-space:nowrap" class="ft368">•&#160;</p>
<p style="position:absolute;top:888px;left:141px;white-space:nowrap" class="ft362"><b>Periodic&#160;safety update&#160;reports&#160;(PSURs)</b>&#160;</p>
<p style="position:absolute;top:913px;left:116px;white-space:nowrap" class="ft3623"><i>&#160;</i></p>
<p style="position:absolute;top:927px;left:116px;white-space:nowrap" class="ft361">The requirements&#160;for&#160;submission of&#160;PSURs&#160;for&#160;this&#160;medicinal&#160;product&#160;are set&#160;out&#160;in the&#160;list&#160;of&#160;</p>
<p style="position:absolute;top:946px;left:116px;white-space:nowrap" class="ft361">Union reference&#160;dates (EURD&#160;list)&#160;provided&#160;for&#160;under&#160;Article 107c(7)&#160;of&#160;Directive 2001/83/EC&#160;and&#160;</p>
<p style="position:absolute;top:966px;left:116px;white-space:nowrap" class="ft361">any subsequent&#160;updates&#160;published on the European medicines&#160;web-portal.&#160;</p>
<p style="position:absolute;top:986px;left:116px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:1026px;left:116px;white-space:nowrap" class="ft362"><b>D.&#160;&#160;CONDITIONS&#160;OR&#160;RESTRICTIONS WITH&#160;REGARD&#160;TO&#160;THE&#160;SAFE&#160;AND&#160;</b></p>
<p style="position:absolute;top:1045px;left:170px;white-space:nowrap" class="ft362"><b>EFFECTIVE&#160;USE&#160;OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:1083px;left:114px;white-space:nowrap" class="ft368">•&#160;</p>
<p style="position:absolute;top:1082px;left:141px;white-space:nowrap" class="ft362"><b>Risk&#160;management&#160;plan&#160;(RMP)</b>&#160;</p>
<p style="position:absolute;top:1102px;left:116px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:1123px;left:116px;white-space:nowrap" class="ft361">The&#160;marketing authorisation holder&#160;(MAH)&#160;shall&#160;perform&#160;the&#160;required pharmacovigilance&#160;activities&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3726{font-size:17px;line-height:31px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page37-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft370">37&#160;</p>
<p style="position:absolute;top:106px;left:116px;white-space:nowrap" class="ft371">and interventions detailed&#160;in the&#160;agreed RMP&#160;presented in&#160;Module 1.8.2 of&#160;the&#160;marketing&#160;</p>
<p style="position:absolute;top:128px;left:116px;white-space:nowrap" class="ft3726">authorisation&#160;and any agreed subsequent&#160;updates&#160;of&#160;the&#160;RMP.&#160;<br/>An updated RMP&#160;should be&#160;submitted:&#160;</p>
<p style="position:absolute;top:190px;left:142px;white-space:nowrap" class="ft378">•&#160;</p>
<p style="position:absolute;top:190px;left:168px;white-space:nowrap" class="ft371">At&#160;the&#160;request&#160;of&#160;the European Medicines&#160;Agency;&#160;</p>
<p style="position:absolute;top:210px;left:142px;white-space:nowrap" class="ft378">•&#160;</p>
<p style="position:absolute;top:210px;left:168px;white-space:nowrap" class="ft371">Whenever&#160;the&#160;risk&#160;management&#160;system&#160;is&#160;modified,&#160;especially as the result&#160;of&#160;new&#160;</p>
<p style="position:absolute;top:229px;left:168px;white-space:nowrap" class="ft371">information being received&#160;that&#160;may lead&#160;to a&#160;significant&#160;change&#160;to&#160;the benefit/risk&#160;profile&#160;</p>
<p style="position:absolute;top:248px;left:168px;white-space:nowrap" class="ft371">or&#160;as&#160;the&#160;result&#160;of&#160;an&#160;important&#160;(pharmacovigilance&#160;or&#160;risk&#160;minimisation)&#160;milestone being&#160;</p>
<p style="position:absolute;top:267px;left:168px;white-space:nowrap" class="ft371">reached.&#160;&#160;</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:286px;left:322px;white-space:nowrap" class="ft371">&#160;</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft380">38&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:434px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:454px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:473px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:492px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:531px;left:405px;white-space:nowrap" class="ft382"><b>ANNEX&#160;III&#160;</b></p>
<p style="position:absolute;top:550px;left:446px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:569px;left:293px;white-space:nowrap" class="ft382"><b>LABELLING AND&#160;PACKAGE&#160;LEAFLET&#160;</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:589px;left:322px;white-space:nowrap" class="ft381">&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft390">39&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:533px;left:387px;white-space:nowrap" class="ft392"><b>A. LABELLING</b>&#160;</p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:552px;left:322px;white-space:nowrap" class="ft391">&#160;</p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft400">40&#160;</p>
<p style="position:absolute;top:106px;left:106px;white-space:nowrap" class="ft402"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft402"><b>CARTON</b>&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft402"><b>1.&#160;</b></p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft402"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft401">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft401">trastuzumab&#160;</p>
<p style="position:absolute;top:285px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:304px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft402"><b>2.&#160;</b></p>
<p style="position:absolute;top:325px;left:149px;white-space:nowrap" class="ft402"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft401">The vial&#160;contains 150&#160;mg&#160;trastuzumab.&#160;&#160;</p>
<p style="position:absolute;top:385px;left:106px;white-space:nowrap" class="ft401">After&#160;reconstitution,&#160;1&#160;mL&#160;concentrate contains 21&#160;mg&#160;of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft402"><b>3.&#160;</b></p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft402"><b>LIST&#160;OF EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft401">L-histidine&#160;hydrochloride,&#160;L-histidine, sorbitol&#160;(E420),&#160;macrogol&#160;3350,&#160;hydrochloric&#160;acid&#160;and&#160;sodium&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft401">hydroxide.&#160;&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft402"><b>4.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft402"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:606px;left:106px;white-space:nowrap" class="ft401">Powder&#160;for&#160;concentrate&#160;for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft401">1&#160;vial&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:662px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft402"><b>5.&#160;</b></p>
<p style="position:absolute;top:683px;left:149px;white-space:nowrap" class="ft402"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft401">Read the&#160;package leaflet&#160;before&#160;use.&#160;</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft401">For intravenous use&#160;only after&#160;reconstitution&#160;and dilution&#160;</p>
<p style="position:absolute;top:762px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:802px;left:106px;white-space:nowrap" class="ft402"><b>6.&#160;</b></p>
<p style="position:absolute;top:802px;left:149px;white-space:nowrap" class="ft402"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;</b></p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft402"><b>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft401">Keep&#160;out&#160;of&#160;the&#160;sight&#160;and&#160;reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft402"><b>7.&#160;</b></p>
<p style="position:absolute;top:922px;left:149px;white-space:nowrap" class="ft402"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft402"><b>8.&#160;</b></p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft402"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft401">EXP&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:1081px;left:322px;white-space:nowrap" class="ft401">&#160;</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4127{font-size:17px;line-height:27px;font-family:JOFRRA+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page41-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft410">41&#160;</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft412"><b>9.&#160;</b></p>
<p style="position:absolute;top:107px;left:149px;white-space:nowrap" class="ft412"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft411">Store&#160;in&#160;a refrigerator.&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft412"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft412"><b>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;</b></p>
<p style="position:absolute;top:246px;left:106px;white-space:nowrap" class="ft412"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:308px;left:106px;white-space:nowrap" class="ft412"><b>11.&#160;&#160;NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:329px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft411">Viatris&#160;Limited&#160;</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft411">Damastown Industrial&#160;Park&#160;</p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft411">Mulhuddart&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft411">Dublin&#160;15&#160;</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft411">DUBLIN&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft411">Ireland&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft412"><b>12.&#160;&#160;MARKETING AUTHORISATION&#160;NUMBER(S)&#160;&#160;</b></p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft411">EU/1/18/1341/001&#160;</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:581px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft4127"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;<br/></b><i>&#160;</i></p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft411">Lot&#160;</p>
<p style="position:absolute;top:662px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:681px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft416"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;<br/></b><i>&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:762px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft412"><b>15.&#160;&#160;INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft412"><b>16.&#160;&#160;INFORMATION&#160;IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:903px;left:106px;white-space:nowrap" class="ft411">Justification for&#160;not&#160;including Braille accepted.&#160;</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:941px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft412"><b>17.&#160;</b></p>
<p style="position:absolute;top:962px;left:160px;white-space:nowrap" class="ft412"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft411">2D&#160;barcode carrying&#160;the unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page42-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft420">42&#160;</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft422"><b>18.&#160;</b></p>
<p style="position:absolute;top:107px;left:160px;white-space:nowrap" class="ft422"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft4215">&#160;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft421">PC&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft421">SN&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft421">NN&#160;</p>
<p style="position:absolute;top:205px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:205px;left:322px;white-space:nowrap" class="ft422"><b>&#160;</b></p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft430">43&#160;</p>
<p style="position:absolute;top:106px;left:106px;white-space:nowrap" class="ft432"><b>MINIMUM&#160;PARTICULARS TO&#160;APPEAR&#160;ON&#160;SMALL&#160;IMMEDIATE&#160;PACKAGING&#160;UNITS&#160;</b></p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft432"><b>&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft432"><b>VIAL&#160;LABEL&#160;</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft432"><b>1.&#160;</b></p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft432"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;AND&#160;ROUTE(S)&#160;OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft431">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate&#160;</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft431">trastuzumab&#160;</p>
<p style="position:absolute;top:285px;left:106px;white-space:nowrap" class="ft431">For&#160;IV&#160;use&#160;only&#160;</p>
<p style="position:absolute;top:304px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft432"><b>2.&#160;</b></p>
<p style="position:absolute;top:344px;left:149px;white-space:nowrap" class="ft432"><b>METHOD&#160;OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:385px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft432"><b>3.&#160;</b></p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft432"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft431">EXP&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft432"><b>4.&#160;</b></p>
<p style="position:absolute;top:525px;left:149px;white-space:nowrap" class="ft432"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft431">Lot&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft432"><b>5.&#160;</b></p>
<p style="position:absolute;top:625px;left:149px;white-space:nowrap" class="ft432"><b>CONTENTS BY&#160;WEIGHT, BY&#160;VOLUME&#160;OR&#160;BY&#160;UNIT&#160;</b></p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft432"><b>6.&#160;</b></p>
<p style="position:absolute;top:706px;left:149px;white-space:nowrap" class="ft432"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:727px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:746px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:804px;left:322px;white-space:nowrap" class="ft431">&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft440">44&#160;</p>
<p style="position:absolute;top:106px;left:106px;white-space:nowrap" class="ft442"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft442"><b>CARTON</b>&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft442"><b>1.&#160;</b></p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft442"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft441">Ogivri&#160;420&#160;mg&#160;powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft441">trastuzumab&#160;</p>
<p style="position:absolute;top:285px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:304px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft442"><b>2.&#160;</b></p>
<p style="position:absolute;top:325px;left:149px;white-space:nowrap" class="ft442"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft441">The vial&#160;contains 420&#160;mg&#160;trastuzumab.&#160;&#160;</p>
<p style="position:absolute;top:385px;left:106px;white-space:nowrap" class="ft441">After&#160;reconstitution,&#160;1&#160;mL&#160;concentrate contains 21&#160;mg&#160;of&#160;trastuzumab.&#160;</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft442"><b>3.&#160;</b></p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft442"><b>LIST&#160;OF EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft441">L-histidine&#160;hydrochloride,&#160;L-histidine, sorbitol&#160;(E420),&#160;macrogol&#160;3350, hydrochloric&#160;acid&#160;and&#160;sodium&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft441">hydroxide.&#160;&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft442"><b>4.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft442"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS&#160;</b></p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:606px;left:106px;white-space:nowrap" class="ft441">Powder&#160;for&#160;concentrate&#160;for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft441">1&#160;vial&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:662px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft442"><b>5.&#160;</b></p>
<p style="position:absolute;top:683px;left:149px;white-space:nowrap" class="ft442"><b>METHOD&#160;AND&#160;ROUTE(S) OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft441">Read the&#160;package leaflet&#160;before&#160;use.&#160;</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft441">For intravenous use&#160;only after&#160;reconstitution&#160;and dilution&#160;</p>
<p style="position:absolute;top:762px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:802px;left:106px;white-space:nowrap" class="ft442"><b>6.&#160;</b></p>
<p style="position:absolute;top:802px;left:149px;white-space:nowrap" class="ft442"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;</b></p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft442"><b>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN&#160;</b></p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft441">Keep&#160;out&#160;of&#160;the&#160;sight&#160;and&#160;reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:901px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft442"><b>7.&#160;</b></p>
<p style="position:absolute;top:922px;left:149px;white-space:nowrap" class="ft442"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY&#160;</b></p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft442"><b>8.&#160;</b></p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft442"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft441">EXP&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:1081px;left:322px;white-space:nowrap" class="ft441">&#160;</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page45-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft450">45&#160;</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft452"><b>9.&#160;</b></p>
<p style="position:absolute;top:107px;left:149px;white-space:nowrap" class="ft452"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft451">Store&#160;in&#160;a refrigerator.&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft452"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft452"><b>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;</b></p>
<p style="position:absolute;top:246px;left:106px;white-space:nowrap" class="ft452"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:308px;left:106px;white-space:nowrap" class="ft452"><b>11.&#160;&#160;NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:329px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft451">Viatris&#160;Limited&#160;</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft451">Damastown Industrial&#160;Park&#160;</p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft451">Mulhuddart&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft451">Dublin&#160;15&#160;</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft451">DUBLIN&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft451">Ireland&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft452"><b>12.&#160;&#160;MARKETING AUTHORISATION&#160;NUMBER(S)&#160;&#160;</b></p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft451">EU/1/18/1341/002&#160;</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:581px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft4527"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;<br/></b><i>&#160;</i></p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft451">Lot&#160;</p>
<p style="position:absolute;top:662px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:681px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft456"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY&#160;<br/></b><i>&#160;<br/>&#160;</i></p>
<p style="position:absolute;top:762px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft452"><b>15.&#160;&#160;INSTRUCTIONS ON USE&#160;</b></p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft452"><b>16.&#160;&#160;INFORMATION&#160;IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:903px;left:106px;white-space:nowrap" class="ft451">Justification for&#160;not&#160;including Braille accepted.&#160;</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:941px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft452"><b>17.&#160;</b></p>
<p style="position:absolute;top:962px;left:160px;white-space:nowrap" class="ft452"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft451">2D&#160;barcode carrying the unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft460">46&#160;</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft462"><b>18.&#160;</b></p>
<p style="position:absolute;top:107px;left:160px;white-space:nowrap" class="ft462"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft4615">&#160;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft461">PC&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft461">SN&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft461">NN&#160;</p>
<p style="position:absolute;top:185px;left:346px;white-space:nowrap" class="ft461">&#160;</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page47-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft470">47&#160;</p>
<p style="position:absolute;top:106px;left:106px;white-space:nowrap" class="ft472"><b>MINIMUM PARTICULARS TO&#160;APPEAR&#160;ON&#160;SMALL&#160;IMMEDIATE&#160;PACKAGING&#160;UNITS&#160;</b></p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft472"><b>&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft472"><b>VIAL&#160;LABEL&#160;</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft472"><b>1.&#160;</b></p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft472"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;AND&#160;ROUTE(S)&#160;OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft471">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate&#160;</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft471">trastuzumab&#160;</p>
<p style="position:absolute;top:285px;left:106px;white-space:nowrap" class="ft471">For&#160;IV&#160;use&#160;only&#160;</p>
<p style="position:absolute;top:304px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft472"><b>2.&#160;</b></p>
<p style="position:absolute;top:344px;left:149px;white-space:nowrap" class="ft472"><b>METHOD&#160;OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:385px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft472"><b>3.&#160;</b></p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft472"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft471">EXP&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft472"><b>4.&#160;</b></p>
<p style="position:absolute;top:525px;left:149px;white-space:nowrap" class="ft472"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft471">Lot&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft472"><b>5.&#160;</b></p>
<p style="position:absolute;top:625px;left:149px;white-space:nowrap" class="ft472"><b>CONTENTS BY&#160;WEIGHT, BY&#160;VOLUME&#160;OR&#160;BY&#160;UNIT&#160;</b></p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft472"><b>6.&#160;</b></p>
<p style="position:absolute;top:706px;left:149px;white-space:nowrap" class="ft472"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:727px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:746px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:746px;left:322px;white-space:nowrap" class="ft472"><b>&#160;</b></p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page48-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft480">48&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:533px;left:355px;white-space:nowrap" class="ft482"><b>B. PACKAGE&#160;LEAFLET&#160;</b></p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft490">49&#160;</p>
<p style="position:absolute;top:104px;left:303px;white-space:nowrap" class="ft492"><b>Package&#160;leaflet:&#160;Information for&#160;the user&#160;</b></p>
<p style="position:absolute;top:123px;left:446px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:142px;left:226px;white-space:nowrap" class="ft492"><b>Ogivri&#160;150&#160;mg&#160;powder for&#160;concentrate for solution&#160;for infusion&#160;</b></p>
<p style="position:absolute;top:161px;left:226px;white-space:nowrap" class="ft492"><b>Ogivri&#160;420&#160;mg powder for&#160;concentrate for solution&#160;for infusion&#160;</b></p>
<p style="position:absolute;top:180px;left:406px;white-space:nowrap" class="ft491">trastuzumab&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:223px;left:130px;white-space:nowrap" class="ft491">This&#160;medicine&#160;is subject&#160;to&#160;additional&#160;monitoring. This&#160;will&#160;allow&#160;quick&#160;identification of&#160;new&#160;</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft491">safety&#160;information.&#160;You can help&#160;by&#160;reporting any side effects you may get. See&#160;the end of&#160;section&#160;4&#160;</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft491">for&#160;how&#160;to&#160;report&#160;side effects.&#160;</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft492"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully&#160;before&#160;you&#160;start&#160;using&#160;this&#160;medicine&#160;because&#160;it&#160;contains&#160;</b></p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft492"><b>important&#160;information&#160;for&#160;you.</b>&#160;</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft491">-&#160;</p>
<p style="position:absolute;top:338px;left:149px;white-space:nowrap" class="ft491">Keep this&#160;leaflet. You may&#160;need&#160;to read&#160;it&#160;again.&#160;&#160;</p>
<p style="position:absolute;top:357px;left:106px;white-space:nowrap" class="ft491">-&#160;</p>
<p style="position:absolute;top:357px;left:149px;white-space:nowrap" class="ft491">If&#160;you have any&#160;further&#160;questions,&#160;ask your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse.&#160;</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft491">-&#160;</p>
<p style="position:absolute;top:376px;left:149px;white-space:nowrap" class="ft491">If&#160;you get&#160;any&#160;side effects, talk&#160;to your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse.&#160;This&#160;includes&#160;any possible&#160;</p>
<p style="position:absolute;top:395px;left:149px;white-space:nowrap" class="ft491">side&#160;effects not&#160;listed in&#160;this leaflet.&#160;See&#160;section 4.&#160;</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft492"><b>What&#160;is&#160;in this&#160;leaflet&#160;</b></p>
<p style="position:absolute;top:452px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:472px;left:106px;white-space:nowrap" class="ft491">1.&#160;</p>
<p style="position:absolute;top:472px;left:149px;white-space:nowrap" class="ft491">What&#160;Ogivri&#160;is&#160;and what&#160;it&#160;is used&#160;for&#160;&#160;</p>
<p style="position:absolute;top:491px;left:106px;white-space:nowrap" class="ft491">2.&#160;</p>
<p style="position:absolute;top:491px;left:149px;white-space:nowrap" class="ft491">What&#160;you need&#160;to know&#160;before you&#160;are given Ogivri&#160;&#160;</p>
<p style="position:absolute;top:510px;left:106px;white-space:nowrap" class="ft491">3.&#160;</p>
<p style="position:absolute;top:510px;left:149px;white-space:nowrap" class="ft491">How&#160;Ogivri&#160;is&#160;given&#160;</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft491">4.&#160;</p>
<p style="position:absolute;top:528px;left:149px;white-space:nowrap" class="ft491">Possible&#160;side effects&#160;&#160;</p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft491">5.&#160;</p>
<p style="position:absolute;top:548px;left:149px;white-space:nowrap" class="ft491">How&#160;to store Ogivri&#160;</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft491">6.&#160;</p>
<p style="position:absolute;top:566px;left:149px;white-space:nowrap" class="ft491">Contents of&#160;the pack and other&#160;information&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft492"><b>1.&#160;</b></p>
<p style="position:absolute;top:623px;left:149px;white-space:nowrap" class="ft492"><b>What&#160;Ogivri&#160;is&#160;and&#160;what&#160;it&#160;is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:662px;left:106px;white-space:nowrap" class="ft491">Ogivri&#160;contains&#160;the&#160;active&#160;substance&#160;trastuzumab,&#160;which&#160;is&#160;a&#160;monoclonal&#160;antibody.&#160;Monoclonal&#160;</p>
<p style="position:absolute;top:681px;left:106px;white-space:nowrap" class="ft491">antibodies&#160;attach&#160;to&#160;specific&#160;proteins&#160;or&#160;antigens.&#160;Trastuzumab&#160;is&#160;designed&#160;to&#160;bind&#160;selectively&#160;to&#160;an&#160;</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft491">antigen&#160;called&#160;human&#160;epidermal&#160;growth&#160;factor&#160;receptor&#160;2&#160;(HER2).&#160;&#160;HER2&#160;is&#160;found&#160;in&#160;large&#160;amounts&#160;on&#160;</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft491">the&#160;surface&#160;of&#160;some&#160;cancer&#160;cells where&#160;it&#160;stimulates&#160;their&#160;growth.&#160;&#160;When&#160;Ogivri&#160;binds&#160;to&#160;HER2&#160;it&#160;stops&#160;</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft491">the&#160;growth&#160;of&#160;such&#160;cells&#160;and&#160;causes&#160;them&#160;to&#160;die.&#160;</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft4913">&#160;</p>
<p style="position:absolute;top:778px;left:106px;white-space:nowrap" class="ft491">Your&#160;doctor&#160;may&#160;prescribe&#160;Ogivri&#160;for&#160;the&#160;treatment&#160;of&#160;breast&#160;and&#160;gastric&#160;cancer&#160;when:&#160;</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft498">•&#160;</p>
<p style="position:absolute;top:799px;left:149px;white-space:nowrap" class="ft491">You&#160;have&#160;early&#160;breast&#160;cancer,&#160;with&#160;high&#160;levels&#160;of&#160;a protein&#160;called&#160;HER2.&#160;</p>
<p style="position:absolute;top:820px;left:106px;white-space:nowrap" class="ft498">•&#160;</p>
<p style="position:absolute;top:820px;left:149px;white-space:nowrap" class="ft491">You&#160;have&#160;metastatic&#160;breast&#160;cancer&#160;(breast&#160;cancer&#160;that&#160;has&#160;spread&#160;beyond&#160;the&#160;original&#160;tumour)&#160;</p>
<p style="position:absolute;top:839px;left:149px;white-space:nowrap" class="ft491">with&#160;high&#160;levels&#160;of&#160;HER2.&#160;Ogivri&#160;may&#160;be&#160;prescribed&#160;in&#160;combination&#160;with&#160;the&#160;chemotherapy&#160;</p>
<p style="position:absolute;top:859px;left:149px;white-space:nowrap" class="ft491">medicine&#160;paclitaxel&#160;or&#160;docetaxel&#160;as&#160;first&#160;treatment&#160;for&#160;metastatic&#160;breast&#160;cancer&#160;or&#160;it&#160;may&#160;be&#160;</p>
<p style="position:absolute;top:878px;left:149px;white-space:nowrap" class="ft491">prescribed&#160;alone&#160;if&#160;other&#160;treatments&#160;have&#160;proved&#160;unsuccessful.&#160;It&#160;is&#160;also&#160;used&#160;in&#160;combination&#160;</p>
<p style="position:absolute;top:898px;left:149px;white-space:nowrap" class="ft491">with&#160;medicines&#160;called&#160;aromatase&#160;inhibitors&#160;with&#160;patients&#160;with&#160;high&#160;levels&#160;of&#160;HER2&#160;and&#160;hormone&#160;</p>
<p style="position:absolute;top:917px;left:149px;white-space:nowrap" class="ft491">receptor-positive&#160;metastatic&#160;breast&#160;cancer&#160;(cancer&#160;that&#160;is&#160;sensitive&#160;to&#160;the&#160;presence&#160;of&#160;female&#160;sex&#160;</p>
<p style="position:absolute;top:937px;left:149px;white-space:nowrap" class="ft491">hormones).&#160;</p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft498">•&#160;</p>
<p style="position:absolute;top:957px;left:149px;white-space:nowrap" class="ft491">You&#160;have&#160;metastatic&#160;gastric&#160;cancer&#160;with&#160;high&#160;levels&#160;of&#160;HER2,&#160;when&#160;it&#160;is&#160;in&#160;combination&#160;with&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft491">the&#160;other&#160;cancer&#160;medicines&#160;capecitabine&#160;or&#160;5-fluorouracil&#160;and&#160;cisplatin.&#160;</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft492"><b>2.&#160;</b></p>
<p style="position:absolute;top:1031px;left:149px;white-space:nowrap" class="ft492"><b>What you need&#160;to know&#160;before you&#160;are&#160;given&#160;Ogivri&#160;&#160;</b></p>
<p style="position:absolute;top:1056px;left:106px;white-space:nowrap" class="ft493"><i>&#160;</i></p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft492"><b>Do not&#160;use&#160;Ogivri:&#160;</b></p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft498">•&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft491">if&#160;you are allergic&#160;to&#160;trastuzumab,&#160;murine (mouse)&#160;proteins,&#160;or&#160;any of&#160;the other&#160;ingredients&#160;</p>
<p style="position:absolute;top:1107px;left:149px;white-space:nowrap" class="ft491">of&#160;this&#160;medicine&#160;(listed&#160;in section 6).&#160;</p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft5028{font-size:19px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page50-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft500">50&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft508">•&#160;</p>
<p style="position:absolute;top:103px;left:149px;white-space:nowrap" class="ft501">if&#160;you have severe breathing problems at&#160;rest&#160;due&#160;to your&#160;cancer&#160;or&#160;if&#160;you need oxygen&#160;</p>
<p style="position:absolute;top:121px;left:149px;white-space:nowrap" class="ft501">treatment.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft502"><b>&#160;</b></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft502"><b>Warnings and precautions&#160;&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft501">Your&#160;doctor&#160;will&#160;closely&#160;supervise&#160;your&#160;therapy.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft501">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft502"><b>Heart&#160;checks&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft501">Treatment&#160;with&#160;Ogivri&#160;alone&#160;or&#160;with&#160;a taxane&#160;may&#160;affect&#160;the&#160;heart,&#160;especially&#160;if&#160;you&#160;have&#160;ever&#160;used an&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft501">anthracycline&#160;(taxanes&#160;and&#160;anthracyclines&#160;are&#160;two&#160;other&#160;kinds&#160;of&#160;medicine&#160;used&#160;to&#160;treat&#160;cancer).&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft501">The&#160;effects&#160;may&#160;be&#160;moderate&#160;to&#160;severe&#160;and&#160;could&#160;cause&#160;death.&#160;Therefore,&#160;your&#160;heart&#160;function&#160;will&#160;be&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft501">checked&#160;before,&#160;during&#160;(every&#160;three&#160;months)&#160;and&#160;after&#160;(up&#160;to&#160;two&#160;to&#160;five&#160;years)&#160;treatment&#160;with Ogivri.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft501">If&#160;you&#160;develop&#160;any&#160;signs&#160;of&#160;heart&#160;failure&#160;(inadequate&#160;pumping&#160;of&#160;blood&#160;by&#160;the&#160;heart),&#160;your&#160;heart&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft501">function&#160;may&#160;be&#160;checked&#160;more&#160;frequently&#160;(every&#160;six&#160;to&#160;eight&#160;weeks),&#160;you&#160;may&#160;receive&#160;treatment&#160;for&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft501">heart&#160;failure&#160;or&#160;you&#160;may&#160;have&#160;to&#160;stop&#160;Ogivri&#160;treatment.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft5013">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft501">Talk&#160;to&#160;your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse&#160;before&#160;you&#160;are&#160;given&#160;Ogivri&#160;if:&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft5028">&#160;</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft501">•&#160;</p>
<p style="position:absolute;top:429px;left:149px;white-space:nowrap" class="ft501">you&#160;have&#160;had&#160;heart&#160;failure,&#160;coronary&#160;artery&#160;disease,&#160;heart&#160;valve&#160;disease&#160;(heart&#160;murmurs),&#160;high&#160;</p>
<p style="position:absolute;top:449px;left:149px;white-space:nowrap" class="ft501">blood&#160;pressure,&#160;taken&#160;any&#160;high&#160;blood&#160;pressure&#160;medicine&#160;or&#160;are&#160;currently&#160;taking&#160;any&#160;high&#160;blood&#160;</p>
<p style="position:absolute;top:468px;left:149px;white-space:nowrap" class="ft501">pressure&#160;medicine.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft5028">&#160;</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft501">•&#160;</p>
<p style="position:absolute;top:508px;left:149px;white-space:nowrap" class="ft501">you&#160;have&#160;ever&#160;had&#160;or&#160;are&#160;currently&#160;using&#160;a&#160;medicine&#160;called&#160;doxorubicin&#160;or&#160;epirubicin&#160;(medicines&#160;</p>
<p style="position:absolute;top:527px;left:149px;white-space:nowrap" class="ft501">used&#160;to&#160;treat&#160;cancer).&#160;&#160;These&#160;medicines&#160;(or&#160;any&#160;other&#160;anthracyclines)&#160;can&#160;damage&#160;heart&#160;muscle&#160;</p>
<p style="position:absolute;top:547px;left:149px;white-space:nowrap" class="ft501">and&#160;increase&#160;the&#160;risk&#160;of&#160;heart&#160;problems&#160;with&#160;Ogivri.&#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft5028">&#160;</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft501">•&#160;</p>
<p style="position:absolute;top:587px;left:149px;white-space:nowrap" class="ft501">you&#160;suffer&#160;from&#160;breathlessness,&#160;especially&#160;if&#160;you&#160;are&#160;currently&#160;using&#160;a&#160;taxane.&#160;Ogivri&#160;can cause&#160;</p>
<p style="position:absolute;top:606px;left:149px;white-space:nowrap" class="ft501">breathing&#160;difficulties,&#160;especially&#160;when&#160;it&#160;is&#160;first&#160;given.&#160;This&#160;could&#160;be&#160;more&#160;serious&#160;if&#160;you are&#160;</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft501">already&#160;breathless.&#160;Very&#160;rarely,&#160;patients&#160;with&#160;severe&#160;breathing&#160;difficulties&#160;before&#160;treatment&#160;</p>
<p style="position:absolute;top:645px;left:149px;white-space:nowrap" class="ft501">have&#160;died&#160;when&#160;they&#160;were&#160;given&#160;Ogivri.&#160;</p>
<p style="position:absolute;top:662px;left:106px;white-space:nowrap" class="ft5028">&#160;</p>
<p style="position:absolute;top:685px;left:106px;white-space:nowrap" class="ft501">•&#160;</p>
<p style="position:absolute;top:685px;left:149px;white-space:nowrap" class="ft501">you&#160;have&#160;ever&#160;had&#160;any&#160;other&#160;treatment&#160;for&#160;cancer.&#160;</p>
<p style="position:absolute;top:703px;left:106px;white-space:nowrap" class="ft5013">&#160;</p>
<p style="position:absolute;top:723px;left:106px;white-space:nowrap" class="ft501">If&#160;you&#160;receive&#160;Ogivri&#160;with&#160;any&#160;other&#160;medicine&#160;to&#160;treat&#160;cancer,&#160;such&#160;as&#160;paclitaxel,&#160;docetaxel,&#160;an&#160;</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft501">aromatase&#160;inhibitor,&#160;capecitabine,&#160;5-fluorouracil,&#160;or&#160;cisplatin&#160;you&#160;should&#160;also&#160;read&#160;the&#160;patient&#160;</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft501">information&#160;leaflets&#160;for&#160;these&#160;products.&#160;</p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft501">&#160;</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft502"><b>Children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft501">Ogivri&#160;is not&#160;recommended&#160;for&#160;anyone under&#160;the age of&#160;18 years.&#160;</p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft502"><b>&#160;</b></p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft502"><b>Other&#160;medicines&#160;and&#160;Ogivri</b>&#160;</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft501">Tell&#160;your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse&#160;if&#160;you&#160;are&#160;taking,&#160;have&#160;recently&#160;taken&#160;or&#160;might&#160;take&#160;any&#160;</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft501">other&#160;medicines.&#160;</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft5013">&#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft501">It&#160;may&#160;take&#160;up&#160;to&#160;7&#160;months&#160;for&#160;Ogivri&#160;to&#160;be&#160;removed&#160;from&#160;the&#160;body.&#160;Therefore,&#160;you&#160;should&#160;tell&#160;your&#160;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft501">doctor,&#160;pharmacist&#160;or&#160;nurse&#160;that&#160;you&#160;have&#160;had&#160;Ogivri&#160;if&#160;you&#160;start&#160;any&#160;new&#160;medicine&#160;in&#160;the&#160;7&#160;months&#160;after&#160;</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft501">stopping&#160;treatment.&#160;</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft501">&#160;</p>
<p style="position:absolute;top:1007px;left:106px;white-space:nowrap" class="ft502"><b>Pregnancy&#160;and&#160;breast-feeding&#160;&#160;</b></p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft501">If&#160;you are pregnant&#160;or&#160;breast-feeding,&#160;think you&#160;may be&#160;pregnant&#160;or&#160;are planning to&#160;have&#160;a&#160;baby,&#160;</p>
<p style="position:absolute;top:1045px;left:106px;white-space:nowrap" class="ft501">ask your&#160;doctor, pharmacist&#160;or&#160;nurse&#160;for&#160;advice&#160;before&#160;taking&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft501">&#160;</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft5129{font-size:17px;line-height:23px;font-family:FAEYNI+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page51-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft510">51&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft511">Pregnancy&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft518">•&#160;</p>
<p style="position:absolute;top:144px;left:149px;white-space:nowrap" class="ft511">You should use effective contraception during&#160;treatment&#160;with Ogivri&#160;and&#160;for&#160;at&#160;least&#160;7&#160;</p>
<p style="position:absolute;top:162px;left:149px;white-space:nowrap" class="ft511">months after&#160;treatment&#160;has&#160;ended.&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft518">•&#160;</p>
<p style="position:absolute;top:182px;left:149px;white-space:nowrap" class="ft511">Your&#160;doctor&#160;will&#160;advise&#160;you of&#160;the&#160;risks and benefits&#160;of&#160;taking Ogivri&#160;during pregnancy. In&#160;</p>
<p style="position:absolute;top:200px;left:149px;white-space:nowrap" class="ft511">rare cases,&#160;a reduction in&#160;the amount&#160;of&#160;(amniotic)&#160;fluid that&#160;surrounds&#160;the&#160;developing baby&#160;</p>
<p style="position:absolute;top:218px;left:149px;white-space:nowrap" class="ft511">within the womb has been&#160;observed&#160;in pregnant&#160;women receiving&#160;trastuzumab. This&#160;</p>
<p style="position:absolute;top:236px;left:149px;white-space:nowrap" class="ft511">condition may be harmful&#160;to your&#160;baby&#160;in the womb and has&#160;been&#160;associated with&#160;the&#160;lungs&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft511">not&#160;developing fully resulting in&#160;foetal&#160;death.&#160;</p>
<p style="position:absolute;top:271px;left:106px;white-space:nowrap" class="ft5113">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft511">Breast-feeding&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft511">Do&#160;not&#160;breast-feed&#160;your&#160;baby&#160;during&#160;Ogivri&#160;therapy&#160;and&#160;for&#160;7&#160;months&#160;after&#160;the&#160;last&#160;dose&#160;of&#160;Ogivri&#160;as&#160;</p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft511">this medicine&#160;may&#160;pass&#160;to&#160;your&#160;baby&#160;through&#160;your&#160;breast&#160;milk. Ask&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;for&#160;</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft511">advice&#160;before&#160;taking&#160;any&#160;medicine.&#160;</p>
<p style="position:absolute;top:385px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft512"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:422px;left:106px;white-space:nowrap" class="ft511">Ogivri&#160;may&#160;affect&#160;your&#160;ability&#160;to&#160;drive&#160;a car&#160;or&#160;operate&#160;machines.&#160;If&#160;during&#160;treatment&#160;you&#160;experience&#160;</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft511">symptoms,&#160;such&#160;as&#160;dizziness,&#160;sleepiness,&#160;chills&#160;or&#160;fever,&#160;you&#160;should&#160;not&#160;drive&#160;or&#160;use&#160;machines&#160;until&#160;</p>
<p style="position:absolute;top:458px;left:106px;white-space:nowrap" class="ft511">these&#160;symptoms&#160;disappear.&#160;</p>
<p style="position:absolute;top:477px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft512"><b>Ogivri&#160;contains&#160;sorbitol&#160;(E420)&#160;and&#160;sodium.&#160;</b></p>
<p style="position:absolute;top:515px;left:106px;white-space:nowrap" class="ft511">Ogivri&#160;150&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion.&#160;</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft511">This&#160;medicine&#160;contains 115.2&#160;mg&#160;sorbitol&#160;in each vial.&#160;&#160;</p>
<p style="position:absolute;top:553px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft511">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion.&#160;</p>
<p style="position:absolute;top:591px;left:106px;white-space:nowrap" class="ft511">This&#160;medicine&#160;contains&#160;322.6&#160;mg&#160;sorbitol&#160;in each vial.&#160;&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft511">Sorbitol&#160;is a&#160;source of&#160;fructose. If&#160;you&#160;have hereditary&#160;fructose intolerance (HFI),&#160;a&#160;rare genetic&#160;</p>
<p style="position:absolute;top:648px;left:106px;white-space:nowrap" class="ft511">disorder, you&#160;must&#160;not&#160;receive&#160;this medicine.&#160;Patients&#160;with HFI&#160;cannot&#160;break down fructose, which&#160;</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft511">may&#160;cause serious side&#160;effects.&#160;&#160;</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft511">You must&#160;tell&#160;your&#160;doctor&#160;before&#160;receiving this&#160;medicine if&#160;you&#160;have&#160;HFI&#160;or&#160;if&#160;you&#160;can no&#160;longer&#160;take&#160;</p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft511">sweet&#160;foods or&#160;drinks&#160;because&#160;you&#160;feel&#160;sick,&#160;vomit&#160;or&#160;get&#160;unpleasant&#160;effects such as bloating, stomach&#160;</p>
<p style="position:absolute;top:723px;left:106px;white-space:nowrap" class="ft511">cramps&#160;or&#160;diarrhoea.&#160;</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft511">Ogivri&#160;contains&#160;less than 1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;dose,&#160;that&#160;is to&#160;say&#160;essentially&#160;‘sodium&#160;free’.&#160;</p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft512"><b>3.&#160;</b></p>
<p style="position:absolute;top:818px;left:149px;white-space:nowrap" class="ft512"><b>How&#160;Ogivri&#160;is given&#160;</b></p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft511">Before&#160;starting&#160;the&#160;treatment&#160;your&#160;doctor&#160;will&#160;determine&#160;the&#160;amount&#160;of&#160;HER2&#160;in&#160;your&#160;tumour.&#160;Only&#160;</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft511">patients&#160;with&#160;a&#160;large&#160;amount&#160;of&#160;HER2&#160;will&#160;be&#160;treated&#160;with&#160;Ogivri.&#160;Ogivri&#160;should&#160;only&#160;be&#160;given&#160;by&#160;a&#160;</p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft511">doctor&#160;or&#160;nurse.&#160;Your&#160;doctor&#160;will&#160;prescribe&#160;a&#160;dose&#160;and&#160;treatment&#160;regimen&#160;that&#160;is&#160;right&#160;for&#160;you.&#160;The&#160;</p>
<p style="position:absolute;top:915px;left:106px;white-space:nowrap" class="ft511">dose&#160;of&#160;Ogivri&#160;depends&#160;on&#160;your&#160;body&#160;weight.&#160;</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft511">The&#160;first&#160;dose&#160;of&#160;your&#160;treatment&#160;is&#160;given&#160;over&#160;90&#160;minutes&#160;and&#160;you&#160;will&#160;be&#160;observed&#160;by a health&#160;</p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft511">professional&#160;while&#160;it&#160;is&#160;being&#160;given&#160;in&#160;case&#160;you&#160;have&#160;any&#160;side&#160;effects.&#160;If&#160;the&#160;first&#160;dose&#160;is&#160;well&#160;tolerated&#160;</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft511">the&#160;next&#160;doses&#160;may&#160;be&#160;given&#160;over&#160;30&#160;minutes&#160;(see&#160;section&#160;2&#160;under&#160;“Warnings&#160;and&#160;precautions”).&#160;The&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft511">number&#160;of&#160;infusions&#160;you&#160;receive&#160;will&#160;depend&#160;on&#160;how&#160;you&#160;respond&#160;to the&#160;treatment.&#160;Your&#160;doctor&#160;will&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft5129">discuss&#160;this&#160;with&#160;you.&#160;<br/>&#160;</p>
<p style="position:absolute;top:1050px;left:109px;white-space:nowrap" class="ft5113">&#160;</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft511">Ogivri&#160;is&#160;given&#160;as&#160;an&#160;infusion&#160;into&#160;a vein&#160;(intravenous&#160;infusion, drip),&#160;this&#160;intravenous&#160;formulation&#160;is&#160;</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft511">not&#160;for&#160;subcutaneous&#160;use&#160;and&#160;should&#160;be&#160;given&#160;as&#160;an&#160;intravenous&#160;infusion&#160;only.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft5113">&#160;</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page52-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft520">52&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft521">For&#160;early&#160;breast&#160;cancer,&#160;metastatic breast&#160;cancer&#160;and&#160;metastatic&#160;gastric&#160;cancer,&#160;Ogivri&#160;is&#160;given every&#160;3&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft521">weeks.&#160;Ogivri&#160;may&#160;also&#160;be&#160;given&#160;once&#160;a week&#160;for&#160;metastatic&#160;breast&#160;cancer.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft521">In&#160;order&#160;to&#160;prevent&#160;medication&#160;errors&#160;it&#160;is&#160;important&#160;to&#160;check&#160;the&#160;vial&#160;labels&#160;to&#160;ensure&#160;that&#160;the&#160;medicine&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft521">being&#160;prepared&#160;and&#160;given&#160;is&#160;Ogivri&#160;(trastuzumab)&#160;and&#160;not&#160;another&#160;trastuzumab-containing&#160;product&#160;(e.g.&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft521">trastuzumab&#160;emtansine&#160;or&#160;trastuzumab deruxtecan).&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft522"><b>If&#160;you&#160;stop&#160;using&#160;Ogivri&#160;</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft521">Do&#160;not&#160;stop&#160;using&#160;this&#160;medicine&#160;without&#160;talking&#160;to&#160;your&#160;doctor&#160;first.&#160;All&#160;doses&#160;should&#160;be&#160;taken&#160;at&#160;the&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft521">right&#160;time every&#160;week&#160;or&#160;every&#160;three&#160;weeks&#160;(depending&#160;on&#160;your&#160;dosing&#160;schedule).&#160;This&#160;helps&#160;your&#160;</p>
<p style="position:absolute;top:293px;left:106px;white-space:nowrap" class="ft521">medicine&#160;work&#160;as&#160;well&#160;as&#160;it&#160;can.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:331px;left:106px;white-space:nowrap" class="ft521">It&#160;may&#160;take&#160;up&#160;to&#160;7&#160;months&#160;for&#160;Ogivri&#160;to&#160;be&#160;removed&#160;from&#160;your&#160;body.&#160;Therefore,&#160;your&#160;doctor&#160;may&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft521">decide&#160;to&#160;continue&#160;to&#160;check&#160;your&#160;heart&#160;functions,&#160;even&#160;after&#160;you&#160;finish&#160;treatment.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft521">If&#160;you&#160;have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine,&#160;ask&#160;your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse.&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft522"><b>4.&#160;</b></p>
<p style="position:absolute;top:446px;left:149px;white-space:nowrap" class="ft522"><b>Possible&#160;side&#160;effects&#160;</b></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft521">Like&#160;all&#160;medicines,&#160;this&#160;medicine&#160;can&#160;cause&#160;side&#160;effects,&#160;although&#160;not&#160;everybody&#160;gets&#160;them.&#160;&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft521">Some&#160;of&#160;these side&#160;effects&#160;may&#160;be&#160;serious&#160;and&#160;may&#160;lead&#160;to&#160;hospitalisation.&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft521">During&#160;an&#160;Ogivri&#160;infusion,&#160;chills,&#160;fever&#160;and&#160;other&#160;flu&#160;like&#160;symptoms&#160;may&#160;occur.&#160;These&#160;are&#160;very&#160;</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft521">common&#160;(may&#160;affect&#160;more&#160;than&#160;1&#160;in&#160;10&#160;people).&#160;&#160;</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft521">Other&#160;infusion-related&#160;symptoms&#160;are:&#160;feeling&#160;sick&#160;(nausea),&#160;vomiting,&#160;pain,&#160;increased&#160;muscle&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft521">tension&#160;and&#160;shaking,&#160;headache,&#160;dizziness,&#160;breathing difficulties,&#160;high&#160;or&#160;low&#160;blood&#160;pressure,&#160;heart&#160;</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft521">rhythm&#160;disturbances&#160;(palpitations,&#160;heart&#160;fluttering&#160;or&#160;irregular&#160;heart&#160;beat),&#160;swelling&#160;of&#160;the&#160;face and&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft521">lips,&#160;rash&#160;and&#160;feeling&#160;tired.&#160;&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft521">Some&#160;of&#160;these&#160;symptoms&#160;can&#160;be&#160;serious&#160;and&#160;some&#160;patients&#160;have&#160;died&#160;(see&#160;section&#160;2&#160;under&#160;</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft521">“Warnings&#160;and precautions”).&#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft521">These&#160;effects&#160;mainly&#160;occur&#160;with&#160;the&#160;first&#160;intravenous&#160;infusion&#160;(“drip”&#160;into&#160;your&#160;vein)&#160;and&#160;during&#160;the&#160;</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft521">first&#160;few&#160;hours&#160;after&#160;the&#160;start&#160;of&#160;the&#160;infusion.&#160;They&#160;are&#160;usually&#160;temporary.&#160;You&#160;will&#160;be&#160;observed&#160;by a&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft521">health&#160;care&#160;professional&#160;during&#160;the&#160;infusion&#160;and&#160;for&#160;at&#160;least&#160;six&#160;hours&#160;after&#160;the&#160;start&#160;of&#160;the&#160;first&#160;infusion&#160;</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft521">and&#160;for&#160;two&#160;hours&#160;after&#160;the&#160;start&#160;of&#160;other&#160;infusions.&#160;If&#160;you&#160;develop&#160;a reaction,&#160;they&#160;will&#160;slow&#160;down&#160;or&#160;</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft521">stop&#160;the&#160;infusion&#160;and&#160;may&#160;give&#160;you&#160;treatment&#160;to&#160;counteract&#160;the&#160;side&#160;effects.&#160;The&#160;infusion&#160;may&#160;be&#160;</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft521">continued&#160;after&#160;the&#160;symptoms&#160;improve.&#160;</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft521">Occasionally,&#160;symptoms&#160;start&#160;later&#160;than&#160;six&#160;hours&#160;after&#160;the&#160;infusion&#160;begins.&#160;If&#160;this&#160;happens&#160;to&#160;you,&#160;</p>
<p style="position:absolute;top:893px;left:106px;white-space:nowrap" class="ft521">contact&#160;your&#160;doctor&#160;immediately.&#160;Sometimes,&#160;symptoms&#160;may&#160;improve&#160;and&#160;then&#160;get&#160;worse&#160;later.&#160;</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:931px;left:106px;white-space:nowrap" class="ft522"><b>Serious side effects</b></p>
<p style="position:absolute;top:929px;left:239px;white-space:nowrap" class="ft5213">&#160;</p>
<p style="position:absolute;top:950px;left:106px;white-space:nowrap" class="ft521">Other&#160;side&#160;effects&#160;can&#160;occur&#160;at&#160;any&#160;time&#160;during&#160;treatment&#160;with&#160;Ogivri,&#160;not&#160;just&#160;related&#160;to&#160;an&#160;infusion.&#160;</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft522"><b>Tell&#160;a&#160;doctor or nurse straight&#160;away, if&#160;you notice&#160;any of the following&#160;side&#160;effects:&#160;&#160;</b></p>
<p style="position:absolute;top:990px;left:106px;white-space:nowrap" class="ft528">•&#160;</p>
<p style="position:absolute;top:989px;left:149px;white-space:nowrap" class="ft521">Heart&#160;problems&#160;can&#160;sometimes&#160;occur&#160;during&#160;treatment&#160;and&#160;occasionally&#160;after&#160;treatment&#160;has&#160;</p>
<p style="position:absolute;top:1008px;left:149px;white-space:nowrap" class="ft521">stopped&#160;and&#160;can&#160;be&#160;serious.&#160;They&#160;include&#160;weakening&#160;of&#160;the&#160;heart&#160;muscle&#160;possibly&#160;leading&#160;to&#160;heart&#160;</p>
<p style="position:absolute;top:1027px;left:149px;white-space:nowrap" class="ft521">failure,&#160;inflammation&#160;of&#160;the&#160;lining&#160;around&#160;the&#160;heart&#160;and&#160;heart&#160;rhythm&#160;disturbances.&#160;This&#160;can&#160;lead&#160;</p>
<p style="position:absolute;top:1046px;left:149px;white-space:nowrap" class="ft521">to&#160;symptoms&#160;such&#160;as&#160;breathlessness&#160;(including&#160;breathlessness&#160;at&#160;night),&#160;cough,&#160;fluid&#160;retention&#160;</p>
<p style="position:absolute;top:1065px;left:149px;white-space:nowrap" class="ft521">(swelling)&#160;in&#160;the&#160;legs&#160;or&#160;arms,&#160;palpitations&#160;(heart&#160;fluttering&#160;or&#160;irregular&#160;heart&#160;beat)&#160;(see&#160;section&#160;2.&#160;</p>
<p style="position:absolute;top:1084px;left:149px;white-space:nowrap" class="ft521">Heart&#160;checks).&#160;</p>
<p style="position:absolute;top:1103px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft530">53&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft531">Your&#160;doctor&#160;will&#160;monitor&#160;your&#160;heart&#160;regularly&#160;during&#160;and&#160;after&#160;treatment&#160;but&#160;you&#160;should&#160;tell&#160;your&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft531">doctor&#160;immediately&#160;if&#160;you&#160;notice&#160;any&#160;of&#160;the&#160;above&#160;symptoms.&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:144px;left:149px;white-space:nowrap" class="ft531">Tumour&#160;lysis syndrome&#160;(a&#160;group of&#160;metabolic&#160;complications occurring after&#160;cancer&#160;treatment&#160;</p>
<p style="position:absolute;top:162px;left:149px;white-space:nowrap" class="ft531">characterised by high blood&#160;levels of&#160;potassium&#160;and phosphate, and low&#160;blood levels of&#160;</p>
<p style="position:absolute;top:182px;left:149px;white-space:nowrap" class="ft531">calcium). Symptoms&#160;may&#160;include kidney problems&#160;(weakness, shortness&#160;of&#160;breath,&#160;fatigue and&#160;</p>
<p style="position:absolute;top:200px;left:149px;white-space:nowrap" class="ft531">confusion), heart&#160;problems&#160;(fluttering&#160;of&#160;the heart&#160;or&#160;a&#160;faster&#160;or&#160;slower&#160;heartbeat),&#160;seizures,&#160;</p>
<p style="position:absolute;top:219px;left:149px;white-space:nowrap" class="ft531">vomiting or&#160;diarrhoea and&#160;tingling&#160;in&#160;the&#160;mouth, hands&#160;or&#160;feet.&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft531">If&#160;you&#160;experience&#160;any&#160;of&#160;the&#160;above&#160;symptoms&#160;when&#160;your&#160;treatment&#160;with&#160;Ogivri&#160;has&#160;finished,&#160;you&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft531">should&#160;see&#160;your&#160;doctor&#160;and&#160;tell&#160;them&#160;that&#160;you&#160;have&#160;previously&#160;been&#160;treated&#160;with&#160;Ogivri.&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft532"><b>Very&#160;common side effects:</b>&#160;may&#160;affect&#160;more&#160;than&#160;1&#160;in&#160;10&#160;people&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:335px;left:149px;white-space:nowrap" class="ft531">infections&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:355px;left:149px;white-space:nowrap" class="ft531">diarrhoea&#160;</p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:375px;left:149px;white-space:nowrap" class="ft531">constipation&#160;</p>
<p style="position:absolute;top:396px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:395px;left:149px;white-space:nowrap" class="ft531">heartburn (dyspepsia)&#160;</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:415px;left:149px;white-space:nowrap" class="ft531">fatigue&#160;</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:435px;left:149px;white-space:nowrap" class="ft531">skin&#160;rashes&#160;</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:456px;left:149px;white-space:nowrap" class="ft531">chest&#160;pain&#160;</p>
<p style="position:absolute;top:476px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:476px;left:149px;white-space:nowrap" class="ft531">abdominal&#160;(stomach)&#160;pain&#160;</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:496px;left:149px;white-space:nowrap" class="ft531">joint&#160;pain&#160;</p>
<p style="position:absolute;top:517px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:516px;left:149px;white-space:nowrap" class="ft531">low&#160;counts of&#160;red blood&#160;cells and white blood&#160;cells&#160;(which help&#160;fight&#160;infection)&#160;sometimes&#160;with&#160;</p>
<p style="position:absolute;top:535px;left:149px;white-space:nowrap" class="ft531">fever&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:555px;left:149px;white-space:nowrap" class="ft531">muscle&#160;pain&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:575px;left:149px;white-space:nowrap" class="ft531">conjunctivitis&#160;(discharge with itching of&#160;the eyes&#160;and crusty&#160;eyelids)&#160;</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft531">watery eyes&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:616px;left:149px;white-space:nowrap" class="ft531">nose&#160;bleeds&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:636px;left:149px;white-space:nowrap" class="ft531">runny nose&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:656px;left:149px;white-space:nowrap" class="ft531">hair&#160;loss&#160;</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:676px;left:149px;white-space:nowrap" class="ft531">tremor&#160;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft531">hot&#160;flush&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:716px;left:149px;white-space:nowrap" class="ft531">dizziness&#160;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:737px;left:149px;white-space:nowrap" class="ft531">nail&#160;disorders&#160;</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:757px;left:149px;white-space:nowrap" class="ft531">weight&#160;loss&#160;</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:777px;left:149px;white-space:nowrap" class="ft531">loss&#160;of&#160;appetite&#160;</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:797px;left:149px;white-space:nowrap" class="ft531">inability&#160;to&#160;sleep&#160;(insomnia)&#160;</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:817px;left:149px;white-space:nowrap" class="ft531">altered taste&#160;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:837px;left:149px;white-space:nowrap" class="ft531">low&#160;platelet&#160;count&#160;</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:858px;left:149px;white-space:nowrap" class="ft531">bruising&#160;</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:878px;left:149px;white-space:nowrap" class="ft531">numbness&#160;or&#160;tingling of&#160;the&#160;fingers and&#160;toes, which occasionally&#160;may&#160;extend&#160;to the&#160;rest&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:897px;left:149px;white-space:nowrap" class="ft531">limb&#160;</p>
<p style="position:absolute;top:917px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:917px;left:149px;white-space:nowrap" class="ft531">redness,&#160;swelling or&#160;sores&#160;in your&#160;mouth and/or&#160;throat&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:937px;left:149px;white-space:nowrap" class="ft531">pain,&#160;swelling, redness&#160;or&#160;tingling of&#160;hands and/or&#160;feet&#160;</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:957px;left:149px;white-space:nowrap" class="ft531">breathlessness&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:977px;left:149px;white-space:nowrap" class="ft531">headache&#160;</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:997px;left:149px;white-space:nowrap" class="ft531">cough&#160;</p>
<p style="position:absolute;top:1018px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:1018px;left:149px;white-space:nowrap" class="ft531">vomiting&#160;</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:1038px;left:149px;white-space:nowrap" class="ft531">nausea&#160;(feeling&#160;sick)&#160;</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft532"><b>Common&#160;side effects:&#160;</b>may&#160;affect&#160;up&#160;to&#160;1&#160;in&#160;10&#160;people&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:1096px;left:133px;white-space:nowrap" class="ft531">allergic&#160;reactions&#160;</p>
<p style="position:absolute;top:1096px;left:457px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:1117px;left:106px;white-space:nowrap" class="ft538">•&#160;</p>
<p style="position:absolute;top:1116px;left:133px;white-space:nowrap" class="ft531">dry&#160;mouth and&#160;skin&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft540">54&#160;</p>
<p style="position:absolute;top:106px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:106px;left:133px;white-space:nowrap" class="ft541">throat&#160;infections&#160;</p>
<p style="position:absolute;top:106px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:126px;left:133px;white-space:nowrap" class="ft541">dry eyes&#160;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:146px;left:133px;white-space:nowrap" class="ft541">bladder&#160;and skin&#160;infections&#160;</p>
<p style="position:absolute;top:146px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:167px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:166px;left:133px;white-space:nowrap" class="ft541">sweating&#160;</p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:186px;left:133px;white-space:nowrap" class="ft541">feeling&#160;weak&#160;and unwell&#160;</p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:206px;left:133px;white-space:nowrap" class="ft541">inflammation of&#160;the breast&#160;</p>
<p style="position:absolute;top:206px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:227px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:227px;left:133px;white-space:nowrap" class="ft541">anxiety&#160;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:247px;left:133px;white-space:nowrap" class="ft541">inflammation of&#160;the&#160;liver&#160;</p>
<p style="position:absolute;top:247px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:267px;left:133px;white-space:nowrap" class="ft541">depression&#160;</p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:287px;left:133px;white-space:nowrap" class="ft541">kidney&#160;disorders&#160;</p>
<p style="position:absolute;top:287px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:308px;left:103px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:307px;left:133px;white-space:nowrap" class="ft541">increased&#160;muscle&#160;tone or&#160;tension&#160;(hypertonia)&#160;&#160;&#160;</p>
<p style="position:absolute;top:328px;left:103px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:327px;left:133px;white-space:nowrap" class="ft541">asthma&#160;</p>
<p style="position:absolute;top:348px;left:103px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:347px;left:133px;white-space:nowrap" class="ft541">infection of&#160;lungs&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:368px;left:133px;white-space:nowrap" class="ft541">pain&#160;in&#160;the arms and/or&#160;legs&#160;</p>
<p style="position:absolute;top:368px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:388px;left:133px;white-space:nowrap" class="ft541">lung disorders&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:408px;left:133px;white-space:nowrap" class="ft541">itchy rash&#160;</p>
<p style="position:absolute;top:408px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:428px;left:133px;white-space:nowrap" class="ft541">back pain&#160;</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:448px;left:133px;white-space:nowrap" class="ft541">sleepiness&#160;(somnolence)&#160;</p>
<p style="position:absolute;top:448px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:468px;left:133px;white-space:nowrap" class="ft541">neck pain&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:489px;left:133px;white-space:nowrap" class="ft541">haemorrhoids (swelling of&#160;blood vessels around&#160;the back passage)&#160;&#160;&#160;</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:509px;left:133px;white-space:nowrap" class="ft541">bone pain&#160;</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:529px;left:133px;white-space:nowrap" class="ft541">itchiness&#160;</p>
<p style="position:absolute;top:529px;left:457px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:549px;left:133px;white-space:nowrap" class="ft541">acne&#160;</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:569px;left:133px;white-space:nowrap" class="ft541">leg cramps&#160;</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft542"><b>Uncommon side effects:&#160;</b>may&#160;affect&#160;up&#160;to&#160;1&#160;in&#160;100&#160;people&#160;</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:627px;left:133px;white-space:nowrap" class="ft541">deafness&#160;</p>
<p style="position:absolute;top:648px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:648px;left:133px;white-space:nowrap" class="ft541">bumpy&#160;rash&#160;</p>
<p style="position:absolute;top:668px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:668px;left:133px;white-space:nowrap" class="ft541">wheezing&#160;</p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:688px;left:133px;white-space:nowrap" class="ft541">inflammation or&#160;scarring of&#160;the&#160;lungs&#160;</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft542"><b>Rare&#160;side effects:&#160;</b>may&#160;affect&#160;up&#160;to&#160;1&#160;in&#160;1000&#160;people&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:746px;left:133px;white-space:nowrap" class="ft541">jaundice&#160;(yellowing&#160;of&#160;the&#160;skin and the whites&#160;of&#160;the&#160;eyes)&#160;</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:766px;left:133px;white-space:nowrap" class="ft541">anaphylactic reactions&#160;(serious sudden allergic&#160;reaction with&#160;symptoms&#160;such&#160;as&#160;rash, itchy&#160;skin,&#160;</p>
<p style="position:absolute;top:785px;left:133px;white-space:nowrap" class="ft541">difficulty breathing or&#160;feeling dizzy or&#160;faint)&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft542"><b>Side effects of&#160;not&#160;known&#160;frequency:</b>&#160;&#160;frequency&#160;cannot&#160;be&#160;estimated&#160;from&#160;the&#160;available&#160;data&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:843px;left:133px;white-space:nowrap" class="ft541">abnormal&#160;or&#160;impaired blood clotting&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:863px;left:133px;white-space:nowrap" class="ft541">high potassium&#160;levels&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:884px;left:133px;white-space:nowrap" class="ft541">swelling&#160;or&#160;bleeding&#160;at&#160;the&#160;back of&#160;the eyes&#160;</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:904px;left:133px;white-space:nowrap" class="ft541">shock&#160;(a dangerous&#160;decrease of&#160;blood&#160;pressure causing&#160;symptoms&#160;like rapid, shallow&#160;breathing,&#160;</p>
<p style="position:absolute;top:923px;left:133px;white-space:nowrap" class="ft541">cold,&#160;clammy skin,&#160;a rapid,&#160;weak pulse, dizziness, weakness&#160;and&#160;fainting)&#160;</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:943px;left:133px;white-space:nowrap" class="ft541">abnormal&#160;heart&#160;rhythm&#160;</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:963px;left:133px;white-space:nowrap" class="ft541">respiratory distress&#160;</p>
<p style="position:absolute;top:984px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:983px;left:133px;white-space:nowrap" class="ft541">respiratory failure&#160;</p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1003px;left:133px;white-space:nowrap" class="ft541">acute accumulation of&#160;fluid&#160;in&#160;the lungs&#160;</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1024px;left:133px;white-space:nowrap" class="ft541">acute narrowing of&#160;the airways&#160;</p>
<p style="position:absolute;top:1044px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1044px;left:133px;white-space:nowrap" class="ft541">abnormally&#160;low&#160;oxygen&#160;levels&#160;in&#160;the blood&#160;</p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1064px;left:133px;white-space:nowrap" class="ft541">difficulty in breathing when lying flat&#160;</p>
<p style="position:absolute;top:1085px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1084px;left:133px;white-space:nowrap" class="ft541">liver&#160;damage&#160;</p>
<p style="position:absolute;top:1105px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1104px;left:133px;white-space:nowrap" class="ft541">swelling&#160;of&#160;the&#160;face, lips&#160;and throat&#160;</p>
<p style="position:absolute;top:1125px;left:106px;white-space:nowrap" class="ft548">•&#160;</p>
<p style="position:absolute;top:1124px;left:133px;white-space:nowrap" class="ft541">kidney&#160;failure&#160;</p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft5530{font-size:17px;font-family:CourierNewPSMT;color:#000000;}
-->
</style>
<div id="page55-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft550">55&#160;</p>
<p style="position:absolute;top:106px;left:106px;white-space:nowrap" class="ft558">•&#160;</p>
<p style="position:absolute;top:106px;left:133px;white-space:nowrap" class="ft551">abnormally&#160;low&#160;levels&#160;of&#160;fluid around&#160;baby&#160;in womb&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft558">•&#160;</p>
<p style="position:absolute;top:126px;left:133px;white-space:nowrap" class="ft551">failure of&#160;lungs&#160;to develop in the womb&#160;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft558">•&#160;</p>
<p style="position:absolute;top:146px;left:133px;white-space:nowrap" class="ft551">abnormal&#160;kidney&#160;development&#160;in the womb&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft551">Some&#160;of&#160;the&#160;side-effects&#160;you&#160;experience&#160;may&#160;be&#160;due&#160;to&#160;your&#160;underlying&#160;breast&#160;cancer.&#160;If&#160;you&#160;receive&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft551">Ogivri&#160;in&#160;combination&#160;with&#160;chemotherapy,&#160;some&#160;of&#160;them&#160;may&#160;also&#160;be&#160;due&#160;to&#160;the&#160;chemotherapy.&#160;&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft552"><b>Reporting&#160;of&#160;side&#160;effects</b>&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft551">If&#160;you&#160;get&#160;any&#160;side&#160;effects,&#160;talk&#160;to&#160;your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse.&#160;This&#160;includes&#160;any&#160;possible&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft551">side&#160;effects&#160;not&#160;listed&#160;in&#160;this&#160;leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side&#160;effects&#160;directly&#160;via&#160;the&#160;national&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft551">reporting&#160;system&#160;listed&#160;in<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">&#160;Appendix&#160;V.&#160;</a>By&#160;reporting&#160;side&#160;effects&#160;you&#160;can&#160;help&#160;provide&#160;more&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft551">information&#160;on&#160;the&#160;safety&#160;of&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:371px;left:106px;white-space:nowrap" class="ft552"><b>5.&#160;</b></p>
<p style="position:absolute;top:371px;left:149px;white-space:nowrap" class="ft552"><b>How&#160;to&#160;store&#160;Ogivri&#160;</b></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft551">Keep this&#160;medicine&#160;out&#160;of&#160;the sight&#160;and&#160;reach of&#160;children.&#160;</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft551">Do not&#160;use this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date which is&#160;stated on the outer&#160;carton&#160;and on the vial&#160;label&#160;</p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft551">after&#160;EXP. The expiry date&#160;refers&#160;to&#160;the&#160;last&#160;day of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft551">Store&#160;in&#160;a refrigerator&#160;(2°C&#160;–&#160;8°C).&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft551">Infusion&#160;solutions&#160;should be used&#160;immediately&#160;after&#160;dilution. Do not&#160;use&#160;Ogivri&#160;if&#160;you notice any&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft551">particulate&#160;matter&#160;or&#160;discoloration&#160;prior&#160;to administration.&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft551">Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household waste. Ask your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft551">throw&#160;away&#160;medicines&#160;you&#160;no longer&#160;use. These&#160;measures&#160;will&#160;help protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft552"><b>6.&#160;&#160;Contents of&#160;the pack and&#160;other&#160;information&#160;</b></p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft552"><b>What&#160;Ogivri&#160;contains&#160;&#160;</b></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft552"><b>&#160;</b></p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft551">-&#160;</p>
<p style="position:absolute;top:750px;left:149px;white-space:nowrap" class="ft551">The active substance&#160;is&#160;trastuzumab. Each&#160;vial&#160;contains&#160;either;&#160;</p>
<p style="position:absolute;top:776px;left:160px;white-space:nowrap" class="ft5530">o</p>
<p style="position:absolute;top:775px;left:170px;white-space:nowrap" class="ft554">&#160;</p>
<p style="position:absolute;top:769px;left:187px;white-space:nowrap" class="ft551">150&#160;mg&#160;trastuzumab&#160;that&#160;has to be dissolved&#160;in 7.2 mL&#160;of&#160;water&#160;for&#160;injections, or&#160;</p>
<p style="position:absolute;top:795px;left:160px;white-space:nowrap" class="ft5530">o</p>
<p style="position:absolute;top:794px;left:170px;white-space:nowrap" class="ft554">&#160;</p>
<p style="position:absolute;top:788px;left:187px;white-space:nowrap" class="ft551">420 mg&#160;trastuzumab&#160;that&#160;has to be dissolved&#160;in&#160;20&#160;mL&#160;of&#160;water&#160;for&#160;injections.&#160;&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft551">-&#160;</p>
<p style="position:absolute;top:807px;left:149px;white-space:nowrap" class="ft551">The resulting solution&#160;contains&#160;approximately&#160;21&#160;mg/mL trastuzumab.&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft551">-&#160;</p>
<p style="position:absolute;top:826px;left:149px;white-space:nowrap" class="ft551">The other&#160;ingredient(s)&#160;are&#160;L-histidine hydrochloride,&#160;L-histidine,&#160;sorbitol&#160;(E420&#160;(see&#160;section 2&#160;</p>
<p style="position:absolute;top:845px;left:149px;white-space:nowrap" class="ft551">“Ogivri&#160;contains sorbitol&#160;(E420)&#160;and sodium.”)),&#160;macrogol&#160;3350,&#160;hydrochloric&#160;acid&#160;and&#160;sodium&#160;</p>
<p style="position:absolute;top:864px;left:149px;white-space:nowrap" class="ft551">hydroxide&#160;(for&#160;pH&#160;adjustment).&#160;</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft552"><b>What&#160;Ogivri&#160;looks like and contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft551">Ogivri&#160;is a&#160;powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;intravenous&#160;infusion, which&#160;is supplied&#160;in&#160;a glass&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft551">vial&#160;with a&#160;rubber&#160;stopper&#160;containing&#160;either&#160;150&#160;mg&#160;or&#160;420 mg&#160;of&#160;trastuzumab. The powder&#160;is&#160;a white&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft551">to pale yellow&#160;pellet. Each&#160;carton contains 1 vial&#160;of&#160;powder.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft552"><b>Marketing&#160;Authorisation&#160;Holder&#160;&#160;</b></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft551">Viatris&#160;Limited&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft551">Damastown Industrial&#160;Park&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft551">Mulhuddart&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft551">Dublin&#160;15&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft551">DUBLIN&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft551">Ireland&#160;</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft560">56&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft562"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft561">McDermott&#160;Laboratories&#160;Limited T/A&#160;Mylan Dublin Biologics&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft561">Newenham&#160;Court&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft561">Northern Cross&#160;</p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft561">Malahide Road&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft561">Dublin&#160;17&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft561">Ireland&#160;</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft561">Mylan Germany GmbH&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft561">Zweigniederlassung Bad Homburg v. d.&#160;Hoehe, Benzstrasse&#160;1&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft561">Bad Homburg v.&#160;d. Hoehe&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft561">Hessen,&#160;61352,&#160;&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft561">Germany&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft561">For any&#160;information about&#160;this&#160;medicine, please&#160;contact&#160;the local&#160;representative of&#160;the&#160;Marketing&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft561">Authorisation Holder:&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:446px;left:132px;white-space:nowrap" class="ft562"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:468px;left:132px;white-space:nowrap" class="ft561">Mylan&#160;EPD&#160;bvba/sprl</p>
<p style="position:absolute;top:468px;left:276px;white-space:nowrap" class="ft562"><b>&#160;</b></p>
<p style="position:absolute;top:490px;left:132px;white-space:nowrap" class="ft561">Tél/Tel:&#160;+ 32 (0)2 658&#160;61 00&#160;</p>
<p style="position:absolute;top:512px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:446px;left:451px;white-space:nowrap" class="ft562"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:468px;left:451px;white-space:nowrap" class="ft561">Mylan Healthcare UAB&#160;</p>
<p style="position:absolute;top:490px;left:451px;white-space:nowrap" class="ft561">Tel:&#160;+370 5&#160;205 1288&#160;</p>
<p style="position:absolute;top:512px;left:451px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:533px;left:132px;white-space:nowrap" class="ft562"><b>България&#160;</b></p>
<p style="position:absolute;top:555px;left:132px;white-space:nowrap" class="ft561">Майлан ЕООД&#160;</p>
<p style="position:absolute;top:577px;left:132px;white-space:nowrap" class="ft561">Teл.:&#160;+359 2&#160;44 55 400&#160;</p>
<p style="position:absolute;top:599px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:533px;left:451px;white-space:nowrap" class="ft562"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:555px;left:451px;white-space:nowrap" class="ft561">Mylan EPD&#160;bvba/sprl&#160;</p>
<p style="position:absolute;top:577px;left:451px;white-space:nowrap" class="ft561">Tel:&#160;+ 32&#160;(0)2 658 61&#160;00&#160;</p>
<p style="position:absolute;top:599px;left:451px;white-space:nowrap" class="ft561">(Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:621px;left:451px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:642px;left:132px;white-space:nowrap" class="ft562"><b>Česká republika&#160;</b></p>
<p style="position:absolute;top:664px;left:132px;white-space:nowrap" class="ft561">Viatris&#160;CZ s.r.o.&#160;</p>
<p style="position:absolute;top:686px;left:132px;white-space:nowrap" class="ft561">Tel:&#160;+420&#160;222&#160;004&#160;400&#160;</p>
<p style="position:absolute;top:708px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:642px;left:451px;white-space:nowrap" class="ft562"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:664px;left:451px;white-space:nowrap" class="ft561">Mylan EPD&#160;Kft&#160;</p>
<p style="position:absolute;top:686px;left:451px;white-space:nowrap" class="ft561">Tel:&#160;+ 36 1&#160;465 2100&#160;</p>
<p style="position:absolute;top:692px;left:451px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:730px;left:132px;white-space:nowrap" class="ft562"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:752px;left:132px;white-space:nowrap" class="ft561">Viatris&#160;ApS&#160;</p>
<p style="position:absolute;top:773px;left:132px;white-space:nowrap" class="ft561">Tlf:&#160;+45 28&#160;11&#160;69&#160;32&#160;</p>
<p style="position:absolute;top:795px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:730px;left:451px;white-space:nowrap" class="ft562"><b>Malta&#160;</b></p>
<p style="position:absolute;top:752px;left:451px;white-space:nowrap" class="ft561">V.J. Salomone Pharma Ltd&#160;</p>
<p style="position:absolute;top:773px;left:451px;white-space:nowrap" class="ft561">Tel:&#160;+ 356&#160;21 22 01 74&#160;</p>
<p style="position:absolute;top:795px;left:451px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:817px;left:132px;white-space:nowrap" class="ft562"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:839px;left:132px;white-space:nowrap" class="ft561">Viatris&#160;Healthcare GmbH&#160;&#160;</p>
<p style="position:absolute;top:861px;left:132px;white-space:nowrap" class="ft561">Tel:&#160;+49 800 0700&#160;800&#160;</p>
<p style="position:absolute;top:883px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:817px;left:451px;white-space:nowrap" class="ft562"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:839px;left:451px;white-space:nowrap" class="ft561">Mylan&#160;Healthcare&#160;B.V.&#160;</p>
<p style="position:absolute;top:861px;left:451px;white-space:nowrap" class="ft561">Tel:&#160;+31&#160;(0)20 426 3300&#160;</p>
<p style="position:absolute;top:904px;left:132px;white-space:nowrap" class="ft562"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:926px;left:132px;white-space:nowrap" class="ft561">BGP Products Switzerland&#160;GmbH&#160;Eesti&#160;</p>
<p style="position:absolute;top:948px;left:132px;white-space:nowrap" class="ft561">filiaal&#160;</p>
<p style="position:absolute;top:970px;left:132px;white-space:nowrap" class="ft561">Tel:&#160;+ 372&#160;6363 052&#160;</p>
<p style="position:absolute;top:992px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:904px;left:451px;white-space:nowrap" class="ft562"><b>Norge&#160;</b></p>
<p style="position:absolute;top:926px;left:451px;white-space:nowrap" class="ft561">Viatris&#160;AS&#160;</p>
<p style="position:absolute;top:948px;left:451px;white-space:nowrap" class="ft561">Tlf:&#160;+ 47&#160;66 75 33 00&#160;</p>
<p style="position:absolute;top:970px;left:451px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:1013px;left:132px;white-space:nowrap" class="ft562"><b>Ελλάδα&#160;</b>&#160;</p>
<p style="position:absolute;top:1035px;left:132px;white-space:nowrap" class="ft561">BGP ΠΡΟΪΟΝΤΑ&#160;Μ.Ε.Π.Ε.&#160;&#160;</p>
<p style="position:absolute;top:1057px;left:132px;white-space:nowrap" class="ft561">Τηλ:&#160;&#160;+30 210 9891 777&#160;</p>
<p style="position:absolute;top:1079px;left:132px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:1013px;left:451px;white-space:nowrap" class="ft562"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:1035px;left:451px;white-space:nowrap" class="ft561">Mylan Österreich GmbH&#160;</p>
<p style="position:absolute;top:1057px;left:451px;white-space:nowrap" class="ft561">Tel:&#160;+43 1&#160;86390&#160;</p>
<p style="position:absolute;top:1079px;left:451px;white-space:nowrap" class="ft561">&#160;</p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft570">57&#160;</p>
<p style="position:absolute;top:104px;left:132px;white-space:nowrap" class="ft572"><b>España&#160;</b></p>
<p style="position:absolute;top:126px;left:132px;white-space:nowrap" class="ft571">Viatris&#160;Pharmaceuticals, S.L.U.&#160;</p>
<p style="position:absolute;top:148px;left:132px;white-space:nowrap" class="ft571">Tel:&#160;+34 900 102 712&#160;</p>
<p style="position:absolute;top:170px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:104px;left:451px;white-space:nowrap" class="ft572"><b>Polska</b>&#160;</p>
<p style="position:absolute;top:126px;left:451px;white-space:nowrap" class="ft571">Mylan&#160;Healthcare&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:148px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+ 48 22 546 64 00&#160;</p>
<p style="position:absolute;top:170px;left:451px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:192px;left:132px;white-space:nowrap" class="ft572"><b>France&#160;</b></p>
<p style="position:absolute;top:214px;left:132px;white-space:nowrap" class="ft571">Mylan Medical&#160;SAS&#160;</p>
<p style="position:absolute;top:236px;left:132px;white-space:nowrap" class="ft571">Tel:&#160;+33&#160;1&#160;56 64 10 70&#160;</p>
<p style="position:absolute;top:257px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:192px;left:451px;white-space:nowrap" class="ft572"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:214px;left:451px;white-space:nowrap" class="ft571">Mylan, Lda.&#160;</p>
<p style="position:absolute;top:236px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+ 351&#160;214&#160;127&#160;200&#160;</p>
<p style="position:absolute;top:257px;left:451px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:279px;left:132px;white-space:nowrap" class="ft572"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:301px;left:132px;white-space:nowrap" class="ft571">Mylan Hrvatska d.o.o. &#160;&#160;</p>
<p style="position:absolute;top:323px;left:132px;white-space:nowrap" class="ft571">Tel:&#160;+385 1&#160;23 50&#160;599&#160;</p>
<p style="position:absolute;top:345px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:279px;left:451px;white-space:nowrap" class="ft572"><b>România&#160;</b></p>
<p style="position:absolute;top:301px;left:451px;white-space:nowrap" class="ft571">BGP Products SRL&#160;</p>
<p style="position:absolute;top:323px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+ 40 372 579&#160;000&#160;</p>
<p style="position:absolute;top:345px;left:451px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:366px;left:132px;white-space:nowrap" class="ft572"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:388px;left:132px;white-space:nowrap" class="ft571">Mylan Ireland Limited&#160;</p>
<p style="position:absolute;top:407px;left:132px;white-space:nowrap" class="ft571">Tel:&#160;+353 1&#160;8711600&#160;</p>
<p style="position:absolute;top:411px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:366px;left:451px;white-space:nowrap" class="ft572"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:388px;left:451px;white-space:nowrap" class="ft571">Viatris&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:407px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+ 386&#160;1 23 63&#160;180&#160;</p>
<p style="position:absolute;top:426px;left:451px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:445px;left:132px;white-space:nowrap" class="ft572"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:467px;left:132px;white-space:nowrap" class="ft571">Icepharma hf.&#160;</p>
<p style="position:absolute;top:489px;left:132px;white-space:nowrap" class="ft571">Sími:&#160;+354 540 8000&#160;</p>
<p style="position:absolute;top:511px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:445px;left:451px;white-space:nowrap" class="ft572"><b>Slovenská republika&#160;</b></p>
<p style="position:absolute;top:467px;left:451px;white-space:nowrap" class="ft571">Viatris&#160;Slovakia&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:489px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+421&#160;2&#160;32 199&#160;100&#160;</p>
<p style="position:absolute;top:495px;left:451px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:532px;left:132px;white-space:nowrap" class="ft572"><b>Italia&#160;</b></p>
<p style="position:absolute;top:554px;left:132px;white-space:nowrap" class="ft571">Mylan Italia&#160;SRL&#160;</p>
<p style="position:absolute;top:576px;left:132px;white-space:nowrap" class="ft571">Tel:&#160;+ 39 02 612 46921&#160;</p>
<p style="position:absolute;top:598px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:532px;left:451px;white-space:nowrap" class="ft572"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:554px;left:451px;white-space:nowrap" class="ft571">Viatris&#160;OY&#160;</p>
<p style="position:absolute;top:573px;left:451px;white-space:nowrap" class="ft571">Puh/Tel:&#160;+ 358 20 720 9555&#160;</p>
<p style="position:absolute;top:620px;left:132px;white-space:nowrap" class="ft572"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:641px;left:132px;white-space:nowrap" class="ft571">Varnavas&#160;Hadjipanayis&#160;Ltd.&#160;</p>
<p style="position:absolute;top:661px;left:132px;white-space:nowrap" class="ft571">Τηλ:&#160;+ 357&#160;2220 7723&#160;</p>
<p style="position:absolute;top:682px;left:132px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:620px;left:451px;white-space:nowrap" class="ft572"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:641px;left:451px;white-space:nowrap" class="ft571">Viatris&#160;AB&#160;&#160;</p>
<p style="position:absolute;top:663px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+46&#160;(0)&#160;8 630 19&#160;00&#160;&#160;</p>
<p style="position:absolute;top:685px;left:451px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:707px;left:132px;white-space:nowrap" class="ft572"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:729px;left:132px;white-space:nowrap" class="ft571">Mylan&#160;Healthcare&#160;SIA&#160;&#160;</p>
<p style="position:absolute;top:751px;left:132px;white-space:nowrap" class="ft571">Tel:&#160;+371 676 055&#160;80&#160;</p>
<p style="position:absolute;top:707px;left:451px;white-space:nowrap" class="ft572"><b>United&#160;Kingdom&#160;(Northern Ireland)&#160;</b></p>
<p style="position:absolute;top:729px;left:451px;white-space:nowrap" class="ft571">Mylan IRE Healthcare Limited&#160;</p>
<p style="position:absolute;top:751px;left:451px;white-space:nowrap" class="ft571">Tel:&#160;+353 18711600&#160;</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft572"><b>&#160;</b></p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft572"><b>This&#160;leaflet&#160;was&#160;last&#160;revised in&#160;&#160;</b></p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft572"><b>&#160;</b></p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft571">Detailed&#160;information on&#160;this medicine&#160;is&#160;available on&#160;the European&#160;Medicines Agency web&#160;site:&#160;</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft5714">http://www.ema.europa.eu.&#160;</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft5713">&#160;</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft571">---------------------------------------------------------------------------------------------------------------------------&#160;&#160;</p>
<p style="position:absolute;top:923px;left:106px;white-space:nowrap" class="ft5713">&#160;</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft580">58&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft582"><b>The&#160;following&#160;information&#160;is&#160;intended&#160;for&#160;healthcare&#160;professionals&#160;only&#160;</b></p>
<p style="position:absolute;top:122px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft581">In order&#160;to prevent&#160;medication errors it&#160;is important&#160;to&#160;check&#160;the vial&#160;labels&#160;to ensure that&#160;the&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft581">medicine being&#160;prepared and given&#160;is Ogivri&#160;(trastuzumab)&#160;and&#160;not&#160;another&#160;trastuzumab-containing&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft581">product&#160;(e.g.&#160;trastuzumab&#160;emtansine or&#160;trastuzumab deruxtecan).&#160;&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft581">Always&#160;keep&#160;this&#160;medicine&#160;in&#160;the&#160;closed&#160;original&#160;pack&#160;at&#160;a&#160;temperature&#160;of&#160;2ºC&#160;–&#160;8&#160;ºC&#160;in&#160;a refrigerator.&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft581">A&#160;vial&#160;of&#160;Ogivri&#160;reconstituted&#160;with&#160;water&#160;for&#160;injections&#160;(not&#160;supplied)&#160;is&#160;stable&#160;for&#160;10&#160;days&#160;at&#160;2ºC&#160;–&#160;8ºC&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft581">after&#160;reconstitution&#160;and&#160;must&#160;not&#160;be&#160;frozen.&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft581">Ogivri&#160;should&#160;be&#160;&#160;carefully&#160;handled&#160;during&#160;reconstitution.&#160;Causing&#160;excessive&#160;foaming&#160;during&#160;</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft581">reconstitution&#160;or&#160;shaking&#160;the&#160;reconstituted&#160;Ogivri&#160;may&#160;result&#160;in&#160;problems&#160;with&#160;the&#160;amount&#160;of&#160;</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft581">Ogivri&#160;that&#160;can&#160;be&#160;withdrawn&#160;from&#160;the&#160;vial.&#160;</p>
<p style="position:absolute;top:357px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft581">Ogivri&#160;150&#160;mg&#160;powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:396px;left:106px;white-space:nowrap" class="ft581">Appropriate&#160;aseptic&#160;technique&#160;should&#160;be&#160;used.&#160;Each&#160;150&#160;mg&#160;vial&#160;of&#160;Ogivri&#160;is&#160;reconstituted&#160;with&#160;</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft581">7.2&#160;mL&#160;of&#160;sterile&#160;water&#160;for&#160;injections&#160;(not&#160;supplied). Use of&#160;other&#160;reconstitution solvents&#160;should be&#160;</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft581">avoided. This yields a&#160;7.4&#160;mL&#160;solution&#160;for&#160;single-dose&#160;use,&#160;containing&#160;approximately&#160;21&#160;mg/mL&#160;</p>
<p style="position:absolute;top:454px;left:106px;white-space:nowrap" class="ft581">trastuzumab.&#160;A&#160;volume overage&#160;of&#160;4&#160;%&#160;ensures&#160;that&#160;the&#160;labelled&#160;dose&#160;of&#160;150&#160;mg&#160;can&#160;be&#160;withdrawn&#160;</p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft581">from&#160;each&#160;vial.&#160;</p>
<p style="position:absolute;top:491px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft581">Ogivri&#160;420&#160;mg powder&#160;for&#160;concentrate for&#160;solution&#160;for&#160;infusion&#160;</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft581">Appropriate aseptic technique should be used. Each&#160;420 mg&#160;vial&#160;of&#160;Ogivri&#160;is&#160;reconstituted with&#160;20&#160;mL&#160;</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft581">of&#160;sterile water&#160;for&#160;injections&#160;(not&#160;supplied). Use&#160;of&#160;other&#160;reconstitution solvents&#160;should be avoided.&#160;</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft581">This&#160;yields&#160;a&#160;21&#160;mL solution&#160;for&#160;single-dose&#160;use, containing approximately 21&#160;mg/mL trastuzumab. A&#160;</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft581">volume overage&#160;of&#160;4.8&#160;%&#160;ensures that&#160;the&#160;labelled&#160;dose of&#160;420&#160;mg can&#160;be withdrawn from&#160;each vial.&#160;</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:627px;left:122px;white-space:nowrap" class="ft581">Ogivri&#160;vial&#160;</p>
<p style="position:absolute;top:627px;left:287px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:627px;left:317px;white-space:nowrap" class="ft581">Volume of&#160;sterile&#160;water&#160;for&#160;</p>
<p style="position:absolute;top:646px;left:317px;white-space:nowrap" class="ft581">injections&#160;</p>
<p style="position:absolute;top:627px;left:553px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:627px;left:582px;white-space:nowrap" class="ft581">Final&#160;concentration&#160;</p>
<p style="position:absolute;top:666px;left:122px;white-space:nowrap" class="ft581">150 mg&#160;vial&#160;</p>
<p style="position:absolute;top:666px;left:282px;white-space:nowrap" class="ft581">+&#160;&#160;7.2 mL&#160;</p>
<p style="position:absolute;top:666px;left:548px;white-space:nowrap" class="ft581">=&#160;&#160;21 mg/mL&#160;</p>
<p style="position:absolute;top:685px;left:122px;white-space:nowrap" class="ft581">420 mg&#160;vial&#160;</p>
<p style="position:absolute;top:685px;left:282px;white-space:nowrap" class="ft581">+&#160;&#160;20 mL&#160;</p>
<p style="position:absolute;top:685px;left:548px;white-space:nowrap" class="ft581">=&#160;&#160;21 mg/mL&#160;</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft581">Instructions&#160;for&#160;reconstitution&#160;</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft581">1)&#160;Using&#160;a sterile&#160;syringe,&#160;slowly&#160;inject&#160;the appropriate&#160;volume&#160;(as&#160;noted above)&#160;of&#160;water&#160;for&#160;</p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft581">injections&#160;in&#160;the&#160;vial&#160;containing&#160;the&#160;lyophilised&#160;Ogivri,&#160;directing&#160;the&#160;stream&#160;into&#160;the&#160;lyophilised&#160;</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft581">cake.&#160;</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft581">2)&#160;Swirl&#160;vial&#160;gently&#160;to&#160;aid&#160;reconstitution.&#160;DO&#160;NOT&#160;SHAKE!&#160;</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft581">Slight&#160;foaming&#160;of&#160;the&#160;product&#160;upon&#160;reconstitution&#160;is&#160;not&#160;unusual.&#160;Allow&#160;the&#160;vial&#160;to stand&#160;undisturbed&#160;</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft581">for&#160;approximately&#160;5&#160;minutes.&#160;The&#160;reconstituted&#160;Ogivri&#160;results&#160;in&#160;a&#160;colourless&#160;to&#160;pale&#160;yellow&#160;</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft581">transparent&#160;solution&#160;and&#160;should&#160;be&#160;essentially&#160;free&#160;of&#160;visible&#160;particulates.&#160;</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft581">Determine&#160;the&#160;volume&#160;of&#160;the&#160;solution&#160;required:&#160;</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft581">•&#160;</p>
<p style="position:absolute;top:969px;left:149px;white-space:nowrap" class="ft581">based&#160;on&#160;a&#160;loading&#160;dose&#160;of&#160;4&#160;mg&#160;trastuzumab/kg&#160;body&#160;weight,&#160;or&#160;a&#160;subsequent&#160;weekly&#160;dose&#160;of&#160;</p>
<p style="position:absolute;top:989px;left:106px;white-space:nowrap" class="ft581">2&#160;mg&#160;trastuzumab/kg&#160;body&#160;weight:&#160;</p>
<p style="position:absolute;top:1007px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft582"><b>Volume&#160;</b>(mL)&#160;=&#160;<b>Body&#160;weight&#160;</b>(kg)&#160;x&#160;<b>dose&#160;</b>(<b>4&#160;</b>mg/kg&#160;for&#160;loading&#160;or&#160;<b>2&#160;</b>mg/kg&#160;for&#160;maintenance)&#160;</p>
<p style="position:absolute;top:1047px;left:187px;white-space:nowrap" class="ft582"><b>21&#160;</b>(mg/mL,&#160;concentration&#160;of&#160;reconstituted&#160;solution)&#160;</p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft5828">&#160;</p>
<p style="position:absolute;top:1086px;left:106px;white-space:nowrap" class="ft581">•&#160;</p>
<p style="position:absolute;top:1086px;left:149px;white-space:nowrap" class="ft581">based&#160;on&#160;a&#160;loading&#160;dose&#160;of&#160;8&#160;mg&#160;trastuzumab/kg&#160;body&#160;weight,&#160;or&#160;a&#160;subsequent&#160;3-weekly&#160;dose&#160;of&#160;</p>
<p style="position:absolute;top:1104px;left:106px;white-space:nowrap" class="ft581">6&#160;mg&#160;trastuzumab/kg&#160;body&#160;weight:&#160;</p>
<p style="position:absolute;top:1121px;left:106px;white-space:nowrap" class="ft5813">&#160;</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft590">59&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft5913">&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft592"><b>Volume&#160;</b>(mL)&#160;=&#160;<b>Body&#160;weight&#160;</b>(kg)&#160;x&#160;<b>dose&#160;</b>(<b>8&#160;</b>mg/kg&#160;for&#160;loading&#160;or&#160;<b>6&#160;</b>mg/kg&#160;for&#160;maintenance)&#160;</p>
<p style="position:absolute;top:142px;left:187px;white-space:nowrap" class="ft592"><b>21&#160;</b>(mg/mL,&#160;concentration&#160;of&#160;reconstituted&#160;solution)&#160;</p>
<p style="position:absolute;top:160px;left:106px;white-space:nowrap" class="ft5913">&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft591">The&#160;appropriate&#160;amount&#160;of&#160;solution&#160;should&#160;be&#160;withdrawn&#160;from&#160;the&#160;vial&#160;using a&#160;sterile needle and&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft591">syringe&#160;and&#160;added&#160;to&#160;a polyvinylchloride,&#160;polyethylene&#160;or&#160;polypropylene&#160;infusion&#160;bag&#160;containing&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft591">250&#160;mL&#160;of&#160;sodium&#160;chloride&#160;9 mg/mL&#160;(0.9%)&#160;solution&#160;for&#160;injection.&#160;Do&#160;not&#160;use&#160;with&#160;glucose-</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft591">containing&#160;solutions.&#160;The&#160;bag&#160;should&#160;be&#160;gently&#160;inverted&#160;to&#160;mix&#160;the&#160;solution&#160;in&#160;order&#160;to&#160;avoid&#160;</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft591">foaming.&#160;Parenteral&#160;solutions&#160;should&#160;be&#160;inspected&#160;visually&#160;for&#160;particulates&#160;and&#160;discoloration&#160;prior&#160;to&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft591">administration.&#160;Once&#160;the&#160;infusion&#160;is&#160;prepared&#160;it&#160;should&#160;be administered&#160;immediately.&#160;If&#160;diluted&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft591">aseptically,&#160;it&#160;may&#160;be&#160;stored&#160;for&#160;up&#160;to&#160;90&#160;days&#160;at&#160;2°C&#160;–&#160;8°C&#160;and&#160;24&#160;hours&#160;at&#160;temperatures&#160;not&#160;</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft591">exceeding&#160;30°C.&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft591">&#160;</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="ogivri-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="ogivri-epar-product-information_en.html#36">A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="ogivri-epar-product-information_en.html#36">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="ogivri-epar-product-information_en.html#36">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="ogivri-epar-product-information_en.html#36">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="ogivri-epar-product-information_en.html#39">A. LABELLING</a></li>
<li><a href="ogivri-epar-product-information_en.html#48">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
